

Standard-dose versus high-dose conformal radiotherapy with or without consolidation carboplatin plus paclitaxel with or without thoracic lymph node irradiation in stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a phase 3 study

Lancet Oncology, The

16, 187-199

DOI: [10.1016/s1470-2045\(14\)71207-0](https://doi.org/10.1016/s1470-2045(14)71207-0)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Integrating immunotherapy into chemoradiation regimens for medically inoperable locally advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2007, 6, 113-118.	1.3	13
2	Clinical Trials Integrating Immunotherapy and Radiation for Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1685-1693.	0.5	62
3	Simultaneously modulated accelerated radiation therapy reduces severe oesophageal toxicity in concomitant chemoradiotherapy of locally advanced non-small-cell lung cancer. <i>British Journal of Radiology</i> , 2015, 88, 20150311.	1.0	7
4	é,éf”ç™Œã«ã³/4ã™ã,ã½žã³/4µè¥²æ€šæ²»ç™,ã®æ—°ã±•é—ã€•æ”³/4ã°,çšæ²»ç™,â€. <i>Journal of Otolaryngology of Japan</i> , 2015, 118, 1204-1211.	0.1	0
5	Title is missing!. <i>Journal of Otolaryngology of Japan</i> , 2015, 118, 1204-1211.	0.1	0
6	Patients Selected for Definitive Concurrent Chemoradiation at High-volume Facilities Achieve Improved Survival in Stage III Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015, 10, 937-943.	0.5	66
7	PET-based dose painting in non-small cell lung cancer: Comparing uniform dose escalation with boosting hypoxic and metabolically active sub-volumes. <i>Radiotherapy and Oncology</i> , 2015, 116, 281-286.	0.3	64
8	SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015. <i>Clinical and Translational Oncology</i> , 2015, 17, 1020-1029.	1.2	43
9	Normal tissue complication models for clinically relevant acute esophagitis (ã%¥ grade 2) in patients treated with dose differentiated accelerated radiotherapy (DART-bid). <i>Radiation Oncology</i> , 2015, 10, 121.	1.2	15
10	An update on current standards and clinical trials in systemic therapy for stage III NSCLC. <i>Lung Cancer Management</i> , 2015, 4, 289-297.	1.5	0
11	Current Standards and Clinical Trials in Systemic Therapy for Stage III Lung Cancer: What Is New?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e442-e447.	1.8	7
12	Esophagus and Contralateral Lung-Sparing IMRT for Locally Advanced Lung Cancer in the Community Hospital Setting. <i>Frontiers in Oncology</i> , 2015, 5, 127.	1.3	7
13	Editorial: Image-Guided Radiotherapy for Effective Radiotherapy Delivery. <i>Frontiers in Oncology</i> , 2015, 5, 253.	1.3	3
14	Preliminary Results of Proton-Beam Therapy for Stage iii Non-Small-Cell Lung Cancer. <i>Current Oncology</i> , 2015, 22, 370-375.	0.9	8
15	Proton Beam Therapy for Non-Small Cell Lung Cancer: Current Clinical Evidence and Future Directions. <i>Cancers</i> , 2015, 7, 1178-1190.	1.7	37
16	Immunotherapy for non-small-cell lung cancer: the past 10 years. <i>Future Oncology</i> , 2015, 11, 2681-2695.	1.1	6
17	Radiotherapy combined with immune checkpoint blockade immunotherapy: Achievements and challenges. <i>Cancer Letters</i> , 2015, 365, 23-29.	3.2	84
18	Exploring Spatial Overlap of High-Uptake Regions Derived From Dual Tracer Positron Emission Tomography-Computer Tomography Imaging Using 18F-Fluorodeoxyglucose and 18F-Fluorodeoxythymidine in Nonsmall Cell Lung Cancer Patients. <i>Medicine (United States)</i> , 2015, 94, e678.	0.4	7

#	ARTICLE	IF	CITATIONS
19	Comparison of once daily radiotherapy to 60%Gy and twice daily radiotherapy to 45%Gy for limited stage small cell lung cancer. <i>Thoracic Cancer</i> , 2015, 6, 643-648.	0.8	16
20	Reply to D.A. Palma et al and A. Addeo et al. <i>Journal of Clinical Oncology</i> , 2015, 33, 2929-2930.	0.8	2
21	Induction chemotherapy with cetuximab, vinorelbine+ cisplatin followed by thoracic radiotherapy and concurrent cetuximab, vinorelbine+ cisplatin in patients with unresectable stage III non-small cell lung cancer. <i>Lung Cancer</i> , 2015, 89, 249-254.	0.9	8
22	Which radiation therapy schedule in combination with chemotherapy for locally advanced NSCLC?. <i>Lung Cancer Management</i> , 2015, 4, 271-278.	1.5	0
24	Gemcitabine and Oxaliplatin, but Not Sorafenib or Paclitaxel, Have a Synergistic Effect with Yttrium-90 in Reducing Hepatocellular Carcinoma and Cholangiocarcinoma Cell Line Viability. <i>Journal of Vascular and Interventional Radiology</i> , 2015, 26, 1874-1878.e2.	0.2	5
25	EGFR targeted therapies and radiation: Optimizing efficacy by appropriate drug scheduling and patient selection. , 2015, 154, 67-77.		41
26	Higher Versus Standard Preoperative Radiation in the Trimodality Treatment of Stage IIIa Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2015, 100, 207-214.	0.7	14
27	Long-term outcomes after proton therapy, with concurrent chemotherapy, for stage II-III inoperable non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2015, 115, 367-372.	0.3	82
28	Curing Non-Small Cell Lung Cancer With Radiotherapy: No Longer an Oxymoron. <i>Seminars in Radiation Oncology</i> , 2015, 25, 65-66.	1.0	2
29	Computed Tomography-Guided Interstitial High-Dose-Rate Brachytherapy in Combination With Regional Positive Lymph Node Intensity-Modulated Radiation Therapy in Locally Advanced Peripheral Non-Small Cell Lung Cancer: A Phase 1 Clinical Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 1027-1034.	0.4	15
30	A Validated Prediction Model for Overall Survival From Stage III Non-Small Cell Lung Cancer: Toward Survival Prediction for Individual Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 935-944.	0.4	83
31	Superiority of Concomitant Chemoradiation Over Sequential Chemoradiation in Inoperable, Locally Advanced Non-Small Cell Lung Cancer: Challenges in the Selection of Appropriate Chemotherapy. <i>Seminars in Radiation Oncology</i> , 2015, 25, 122-132.	1.0	7
32	2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer. <i>Annals of Oncology</i> , 2015, 26, 1573-1588.	0.6	308
33	Radiotherapy dose and fractionation for stage III NSCLC. <i>Lancet Oncology</i> , The, 2015, 16, e156-e157.	5.1	14
34	The Slippery Slope of Broadening Treatment Eligibility and Weak End Points. <i>JAMA Oncology</i> , 2015, 1, 1219.	3.4	4
36	Precision Hypofractionated Radiation Therapy in Poor Performing Patients With Non-Small Cell Lung Cancer: Phase 1 Dose Escalation Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 72-81.	0.4	62
37	Radiation Therapy Intensification for Solid Tumors: A Systematic Review of Randomized Trials. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 737-745.	0.4	42
38	Adaptation requirements due to anatomical changes in free-breathing and deep-inspiration breath-hold for standard and dose-escalated radiotherapy of lung cancer patients. <i>Acta Oncologica</i> , 2015, 54, 1453-1460.	0.8	12

#	ARTICLE	IF	CITATIONS
39	â€œError Barsâ€ in Medical Imaging: Stealth and Treacherous. <i>Radiology</i> , 2015, 277, 318-328.	3.6	3
40	Clinical outcome of image-guided adaptive radiotherapy in the treatment of lung cancer patients. <i>Acta OncolÃ³gica</i> , 2015, 54, 1430-1437.	0.8	39
41	Radiotherapy of non-small-cell lung cancer in the era of <i>EGFR</i> gene mutations and EGF receptor tyrosine kinase inhibitors. <i>Future Oncology</i> , 2015, 11, 2329-2342.	1.1	15
42	Regional Lymph Node Uptake of [18F]Fluorodeoxyglucose After Definitive Chemoradiation Therapy Predicts Local-Regional Failure of Locally Advanced Non-Small Cell Lung Cancer: Results of ACRIN 6668/RTOG 0235. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 597-605.	0.4	19
43	Use a survival model to correlate single-nucleotide polymorphisms of DNA repair genes with radiation doseâ€™response in patients with non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2015, 117, 77-82.	0.3	15
45	Locally Advanced Non-Small Cell Lung Cancer: Optimal Chemotherapeutic Agents and Duration. <i>Current Treatment Options in Oncology</i> , 2015, 16, 47.	1.3	6
46	Inclusion of functional information from perfusion SPECT improves predictive value of doseâ€™volume parameters in lung toxicity outcome after radiotherapy for non-small cell lung cancer: A prospective study. <i>Radiotherapy and Oncology</i> , 2015, 117, 9-16.	0.3	58
47	New dose constraint reduces radiation-induced fatal pneumonitis in locally advanced non-small cell lung cancer patients treated with intensity-modulated radiotherapy. <i>Acta OncolÃ³gica</i> , 2015, 54, 1343-1349.	0.8	61
48	Applications of Fluorodeoxyglucose PET/Computed Tomography in the Assessment and Prediction of Radiation Therapyâ€™related Complications. <i>PET Clinics</i> , 2015, 10, 555-571.	1.5	12
49	Definitive chemotherapy and radiotherapy in patients with stage II non-small cell lung cancer: A population-based outcomes study. <i>Lung Cancer</i> , 2015, 90, 61-64.	0.9	6
50	Dose and Fractionation in Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer: Lessons Learned and Where Do We Go Next?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 765-768.	0.4	11
51	Phase I Dose Escalation Study of Accelerated Radiation Therapy With Concurrent Chemotherapy for Locally Advanced Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 997-1004.	0.4	9
52	Progress in lung cancer: ASCO 2015. <i>Surgical Oncology</i> , 2015, 24, 367-368.	0.8	2
53	Tomotherapy improves local control and changes failure patterns in locally advanced malignant pleural mesothelioma. <i>Practical Radiation Oncology</i> , 2015, 5, 366-373.	1.1	11
54	Is a Clinical Target Volume (CTV) Necessary in the Treatment of Lung Cancer in the Modern Era Combining 4-D Imaging and Image-guided Radiotherapy (IGRT)? <i>Cureus</i> , 2016, 8, e466.	0.2	12
55	Combined Modality Therapy for Thoracic and head and Neck Cancers: A Review of Updated Literature Based on a Consensus Meeting. <i>Tumori</i> , 2016, 102, 459-471.	0.6	11
56	Limiting the risk of cardiac toxicity with esophageal-sparing intensity modulated radiotherapy for locally advanced lung cancers. <i>Journal of Thoracic Disease</i> , 2016, 8, 942-949.	0.6	11
57	Savior or not: ADAM17 inhibitors overcome radiotherapy-resistance in non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2016, 8, E813-E813.	0.6	19

#	ARTICLE	IF	CITATIONS
58	Non-small cell lung cancer (NSCLC) and central nervous system (CNS) metastases: role of tyrosine kinase inhibitors (TKIs) and evidence in favor or against their use with concurrent cranial radiotherapy. <i>Translational Lung Cancer Research</i> , 2016, 5, 588-598.	1.3	28
59	Did dose escalated radiotherapy in stage III non-small cell lung cancer improve overall survival?. <i>Journal of Thoracic Disease</i> , 2016, 8, 3338-3342.	0.6	3
60	Feasibility and efficacy of helical intensity-modulated radiotherapy for stage III non-small cell lung cancer in comparison with conventionally fractionated 3D-CRT. <i>Journal of Thoracic Disease</i> , 2016, 8, 862-871.	0.6	12
61	Cons: concurrent chemo-radiotherapy remains the ideal treatment in fit patients with inoperable large volume stage III non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2016, 5, 195-197.	1.3	1
62	Improving survival of patients with locally advanced non-small-cell cancer remains a challenge: comment to PROCLAIM. <i>Journal of Thoracic Disease</i> , 2016, 8, E607-E610.	0.6	2
63	Rebuttal from Prof. Kong and Dr. Rabatic. <i>Translational Lung Cancer Research</i> , 2016, 5, 198-200.	1.3	0
64	Pros: concurrent chemo-radiotherapy remains the ideal treatment in fit patients with large volume unresectable stage III non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2016, 5, 190-194.	1.3	3
65	Phase 3 Randomized Low-Dose Paclitaxel Chemoradiotherapy Study for Locally Advanced Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2016, 6, 260.	1.3	8
66	Radiation-induced esophagitis in lung cancer. <i>Lung Cancer: Targets and Therapy</i> , 2016, Volume 7, 119-127.	1.3	32
67	Involved-field Radiation Therapy for Patients with Stage III Non-small-cell Lung Cancer: Early Results of Hypofractionated Involved-field Radiation Therapy. <i>Japanese Journal of Lung Cancer</i> , 2016, 56, 1003-1011.	0.0	1
68	Preclinical Rationale and Clinical Considerations for Radiotherapy Plus Immunotherapy. <i>Cancer Journal (Sudbury, Mass)</i> , 2016, 22, 130-137.	1.0	37
69	Lung cancer radiation therapy in Australia and New Zealand: Patterns of practice. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2016, 60, 677-685.	0.9	7
70	Chemoradiotherapy of locally advanced nonsmall cell lung cancer. <i>Current Opinion in Oncology</i> , 2016, 28, 104-109.	1.1	16
71	Can the probability of radiation esophagitis be reduced without compromising lung tumor control: A radiobiological modeling study. <i>Acta Oncologica</i> , 2016, 55, 926-930.	0.8	3
73	Institutional Enrollment and Survival Among NSCLC Patients Receiving Chemoradiation: NRG Oncology Radiation Therapy Oncology Group (RTOG) 0617. <i>Journal of the National Cancer Institute</i> , 2016, 108, .	3.0	92
74	Repression of the autophagic response sensitises lung cancer cells to radiation and chemotherapy. <i>British Journal of Cancer</i> , 2016, 115, 312-321.	2.9	28
75	Neoadjuvant combination chemotherapy for unresectable stage III non-small cell lung cancer. <i>Cancer</i> , 2016, 122, 674-675.	2.0	0
76	A systematic review of the cost and cost-effectiveness studies of proton radiotherapy. <i>Cancer</i> , 2016, 122, 1483-1501.	2.0	162

#	ARTICLE	IF	CITATIONS
77	Should regional ventilation function be considered during radiation treatment planning to prevent radiation-induced complications?. <i>Medical Physics</i> , 2016, 43, 5072-5079.	1.6	13
78	The Challenges Faced in Developing Novel Drug Radiation Combinations in Non-small Cell Lung Cancer. <i>Clinical Oncology</i> , 2016, 28, 720-725.	0.6	6
79	Protocol for the isotoxic intensity modulated radiotherapy (IMRT) in stage III non-small cell lung cancer (NSCLC): a feasibility study. <i>BMJ Open</i> , 2016, 6, e010457.	0.8	24
80	Robust Intratumor Partitioning to Identify High-Risk Subregions in Lung Cancer: A Pilot Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 1504-1512.	0.4	71
81	The State of Lung Cancer Research: A Global Analysis. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1040-1050.	0.5	166
83	Salvage surgery for locoregional recurrence or persistent tumor after high dose chemoradiotherapy for locally advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2016, 94, 108-113.	0.9	51
84	Concurrent chemoradiotherapy with cisplatin and S-1 or vinorelbine for patients with stage III unresectable non-small cell lung cancer: A retrospective study. <i>Respiratory Investigation</i> , 2016, 54, 334-340.	0.9	4
85	Evaluating Intensity-Modulated Radiation Therapy in Locally Advanced Non-Small-Cell Lung Cancer: Results From the National Cancer Data Base. <i>Clinical Lung Cancer</i> , 2016, 17, 398-405.	1.1	44
86	Circulating miR-29a and miR-150 correlate with delivered dose during thoracic radiation therapy for non-small cell lung cancer. <i>Radiation Oncology</i> , 2016, 11, 61.	1.2	97
87	A Phase 2 Trial of Concurrent Chemotherapy and Proton Therapy for Stage III Non-Small Cell Lung Cancer: Results and Reflections Following Early Closure of a Single-Institution Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 517-522.	0.4	49
88	An Analysis of Plan Robustness for Esophageal Tumors: Comparing Volumetric Modulated Arc Therapy Plans and Spot Scanning Proton Planning. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 199-207.	0.4	28
89	Adaptive planning using positron emission tomography for locally advanced lung cancer: A feasibility study. <i>Practical Radiation Oncology</i> , 2016, 6, 96-104.	1.1	15
90	Radio(chemo)therapy in locally advanced nonsmall cell lung cancer. <i>European Respiratory Review</i> , 2016, 25, 65-70.	3.0	24
91	Potential Use of 18F-fluorodeoxyglucose Positron Emission Tomography-Based Quantitative Imaging Features for Guiding Dose Escalation in Stage III Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 368-376.	0.4	13
92	PET imaging of epidermal growth factor receptor expression in tumours using 89Zr-labelled ZEGFR:2377 affibody molecules. <i>International Journal of Oncology</i> , 2016, 48, 1325-1332.	1.4	50
93	Modern Radiotherapy Techniques in Lung Cancer. , 2016, , 13-38.		0
94	Secretome Signature Identifies ADAM17 as Novel Target for Radiosensitization of Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 4428-4439.	3.2	39
95	PET-Based Thoracic Radiation Oncology. <i>PET Clinics</i> , 2016, 11, 319-332.	1.5	24

#	ARTICLE	IF	CITATIONS
96	Impact of heart and lung dose on early survival in patients with non-small cell lung cancer treated with chemoradiation. <i>Radiotherapy and Oncology</i> , 2016, 119, 495-500.	0.3	75
97	Learning From Trials on Radiation Dose in Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 748-750.	0.4	2
98	Outcome after PORT in ypN2 or R1/R2 versus no PORT in ypN0 Stage III-N2 NSCLC after Induction Chemotherapy and Resection. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1940-1953.	0.5	23
99	Translation of Targeted Radiation Sensitizers into Clinical Trials. <i>Seminars in Radiation Oncology</i> , 2016, 26, 261-270.	1.0	16
100	Role of surgery in clinical N2 non-small-cell lung cancer: a pro and con debate; the "con" viewpoint: Table 1.. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 1022-1025.	0.6	1
101	A critical review of recent developments in radiotherapy for non-small cell lung cancer. <i>Radiation Oncology</i> , 2016, 11, 115.	1.2	112
104	Adaptive Dose Escalation using Serial Four-dimensional Positron Emission Tomography/Computed Tomography Scans during Radiotherapy for Locally Advanced Non-small Cell Lung Cancer. <i>Clinical Oncology</i> , 2016, 28, e199-e205.	0.6	14
105	Longstanding Challenges in Lung Cancer: Are We Meeting Them?. <i>Clinical Oncology</i> , 2016, 28, 669-671.	0.6	3
106	Cardiac and respiration induced motion of mediastinal lymph node targets in lung cancer patients throughout the radiotherapy treatment course. <i>Radiotherapy and Oncology</i> , 2016, 121, 52-58.	0.3	23
107	Patient preferences regarding prophylactic cranial irradiation: A discrete choice experiment. <i>Radiotherapy and Oncology</i> , 2016, 121, 225-231.	0.3	9
108	Australia and New Zealand Faculty of Radiation Oncology Lung Interest Cooperative: 2015 consensus guidelines for the use of advanced technologies in the radiation therapy treatment of locally advanced non-small cell lung cancer. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2016, 60, 686-692.	0.9	1
109	Dose and Fractionation in Radiation Therapy of Curative Intent for Non-Small Cell Lung Cancer: Meta-Analysis of Randomized Trials. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 736-747.	0.4	78
111	Stage III Non-Small Cell Lung Cancer in the elderly: Patient characteristics predictive for tolerance and survival of chemoradiation in daily clinical practice. <i>Radiotherapy and Oncology</i> , 2016, 121, 26-31.	0.3	46
112	Meta-analysis of the incidence and risk of arterial and venous thromboembolic events associated with anti-EGFR agents in non-small-cell lung cancer patients. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 1389-1395.	1.3	0
113	Management of Stage IIIA (N2) Non-Small Cell Lung Cancer. <i>Thoracic Surgery Clinics</i> , 2016, 26, 271-285.	0.4	21
114	Dose escalation study of proton beam therapy with concurrent chemotherapy for stage III non-small cell lung cancer. <i>Cancer Science</i> , 2016, 107, 1018-1021.	1.7	13
115	Inhibition on Numb/Notch signal pathway enhances radiosensitivity of lung cancer cell line H358. <i>Tumor Biology</i> , 2016, 37, 13705-13719.	0.8	9
116	Dosimetric comparison of carbon ion and X-ray radiotherapy for Stage IIIA non-small cell lung cancer. <i>Journal of Radiation Research</i> , 2016, 57, 548-554.	0.8	27

#	ARTICLE	IF	CITATIONS
117	Patterns of Locoregional Relapses in Patients with Contemporarily Staged Stage III-N2 NSCLC Treated with Induction Chemotherapy and Resection: Implications for Postoperative Radiotherapy Target Volumes. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1538-1549.	0.5	22
118	Improved survival with dose-escalated radiotherapy in stage III non-small-cell lung cancer: analysis of the National Cancer Database. <i>Annals of Oncology</i> , 2016, 27, 1887-1894.	0.6	28
119	Treatment: Radiation Therapy. <i>Cancer Treatment and Research</i> , 2016, 170, 105-118.	0.2	24
120	Multimodality Therapy for NSCLC. <i>Cancer Treatment and Research</i> , 2016, 170, 151-163.	0.2	6
121	Proton beam therapy in Japan: current and future status. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 885-892.	0.6	38
122	Limited Impact of Setup and Range Uncertainties, Breathing Motion, and Interplay Effects in Robustly Optimized Intensity Modulated Proton Therapy for Stage III Non-small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 661-669.	0.4	59
123	Randomized phase III PITCAP trial and meta-analysis of induction chemotherapy followed by thoracic irradiation with or without concurrent taxane-based chemotherapy in locally advanced NSCLC. <i>Lung Cancer</i> , 2016, 100, 30-37.	0.9	3
124	The impact of epidermal growth factor receptor mutations on patterns of disease recurrence after chemoradiotherapy for locally advanced non-small cell lung cancer: a literature review and pooled analysis. <i>Journal of Radiation Research</i> , 2016, 57, 449-459.	0.8	13
125	Dosimetric comparison between proton beam therapy and photon radiation therapy for locally advanced non-small cell lung cancer. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 1008-1014.	0.6	9
126	Is selective nodal irradiation in non-small cell lung cancer still safe when using IMRT? Results of a prospective cohort study. <i>Radiotherapy and Oncology</i> , 2016, 121, 322-327.	0.3	12
127	Stereotactic Body Radiation Therapy Boost After Concurrent Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer: A Phase 1 Dose Escalation Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 1021-1027.	0.4	36
128	Update in Lung Cancer 2015. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 661-671.	2.5	13
129	Deep inspiration breath-hold volumetric modulated arc radiotherapy decreases dose to mediastinal structures in locally advanced lung cancer. <i>Acta Oncologica</i> , 2016, 55, 1053-1056.	0.8	14
130	In Reply to Sun et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 1545-1546.	0.4	1
131	Treatment of Stage IIIA Non-Small-Cell Lung Cancer: A Concise Review for the Practicing Oncologist. <i>Journal of Oncology Practice</i> , 2016, 12, 601-606.	2.5	13
132	Adaptive radiotherapy for advanced lung cancer ensures target coverage and decreases lung dose. <i>Radiotherapy and Oncology</i> , 2016, 121, 32-38.	0.3	79
133	Feasibility and efficacy of salvage lung resection after definitive chemoradiation therapy for Stage III non-small-cell lung cancer. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2016, 23, 895-901.	0.5	30
134	Feasibility of imaging of epidermal growth factor receptor expression with ZEGFR:2377 affibody molecule labeled with ^{99m} Tc using a peptide-based cysteine-containing chelator. <i>International Journal of Oncology</i> , 2016, 49, 2285-2293.	1.4	27

#	ARTICLE	IF	CITATIONS
135	Targeting the PD-1/PD-L1 axis in the treatment of lung cancer. <i>Forum of Clinical Oncology</i> , 2016, 7, 17-27.	0.1	0
136	Role of multimodality therapy in cIIIA-N2 non-small cell lung cancer: perspective. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 1174-1178.	0.6	4
137	Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize. <i>Nature Communications</i> , 2016, 7, 13019.	5.8	51
138	PRONTOX proton therapy to reduce acute normal tissue toxicity in locally advanced non-small-cell lung carcinomas (NSCLC): study protocol for a randomised controlled trial. <i>Trials</i> , 2016, 17, 543.	0.7	20
140	Radiation-induced heart disease in lung cancer radiotherapy. <i>Medicine (United States)</i> , 2016, 95, e5051.	0.4	29
141	Concomitant etoposide and cisplatin provided improved survival compared with docetaxel and cisplatin in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy. <i>Medicine (United States)</i> , 2016, 95, e4280.	0.4	12
142	Accelerated hypofractionated three-dimensional conformal radiation therapy (3 Gy/fraction) combined with concurrent chemotherapy for patients with unresectable stage III non-small cell lung cancer: preliminary results of an early terminated phase II trial. <i>BMC Cancer</i> , 2016, 16, 288.	1.1	17
143	Superior sulcus non-small cell lung carcinoma: A comparison of IMRT and 3D-RT dosimetry. <i>Reports of Practical Oncology and Radiotherapy</i> , 2016, 21, 427-434.	0.3	6
144	Small-Cell Lung Cancer: New Directions for Systemic Therapy. <i>Journal of Oncology Practice</i> , 2016, 12, 119-120.	2.5	5
145	Necitumumab in squamous non-small-cell lung cancer: how to move forward?. <i>Annals of Oncology</i> , 2016, 27, 1374-1376.	0.6	0
146	Standardized Uptake Decrease on [18F]-Fluorodeoxyglucose Positron Emission Tomography After Neoadjuvant Chemotherapy Is a Prognostic Classifier for Long-Term Outcome After Multimodality Treatment: Secondary Analysis of a Randomized Trial for Resectable Stage IIIA/B Non-small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 2526-2533.	0.8	40
147	Toxicity of definitive and post-operative radiation following ipilimumab in non-small cell lung cancer. <i>Lung Cancer</i> , 2016, 98, 76-78.	0.9	27
150	Prior cancer does not adversely affect survival in locally advanced lung cancer: A national SEER-medicare analysis. <i>Lung Cancer</i> , 2016, 98, 106-113.	0.9	45
151	The advantage of deep-inspiration breath-hold and cone-beam CT based soft-tissue registration for locally advanced lung cancer radiotherapy. <i>Radiotherapy and Oncology</i> , 2016, 119, 432-437.	0.3	17
152	IDEAL-CRT: A Phase 1/2 Trial of Isotoxic Dose-Escalated Radiation Therapy and Concurrent Chemotherapy in Patients With Stage II/III Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 1367-1377.	0.4	41
153	Continuous hyperfractionated accelerated radiotherapy Escalated dose (CHART-ED): A phase I study. <i>Radiotherapy and Oncology</i> , 2016, 118, 471-477.	0.3	13
154	Prospective study of proton beam radiation therapy for adjuvant and definitive treatment of thymoma and thymic carcinoma: Early response and toxicity assessment. <i>Radiotherapy and Oncology</i> , 2016, 118, 504-509.	0.3	41
155	Establishing the feasibility of the dosimetric compliance criteria of RTOG 1308: phase III randomized trial comparing overall survival after photon versus proton radiochemotherapy for inoperable stage II-IIIB NSCLC. <i>Radiation Oncology</i> , 2016, 11, 66.	1.2	80

#	ARTICLE	IF	CITATIONS
156	Clinical and research priorities for combined modality therapy in stage III NSCLC. <i>Lung Cancer Management</i> , 2016, 5, 43-50.	1.5	0
157	kV x-ray dual digital tomosynthesis for image guided lung SBRT. , 2016, , .		2
158	Hsp90 Inhibitor Ganetespib Sensitizes Non-“Small Cell Lung Cancer to Radiation but Has Variable Effects with Chemoradiation. <i>Clinical Cancer Research</i> , 2016, 22, 5876-5886.	3.2	25
159	Consensus Statement on Proton Therapy in Early-Stage and Locally Advanced Non-“Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 505-516.	0.4	125
160	The Importance of Quality of Life Assessment. <i>JAMA Oncology</i> , 2016, 2, 367.	3.4	3
161	PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-“Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 953-962.	0.8	365
162	Improving Therapeutic Outcomes in Non-small Cell Lung Cancer not Suitable for Curative Intent Therapy – A Review of the Role of Radiation Therapy in an Era of Increasing Systemic Therapy Options. <i>Clinical Oncology</i> , 2016, 28, 327-333.	0.6	4
163	What is changing in radiotherapy for the treatment of locally advanced nonsmall cell lung cancer patients? A review. <i>Cancer Investigation</i> , 2016, 34, 80-93.	0.6	9
164	Squamous-cell carcinoma of the anus: progress in radiotherapy treatment. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 447-459.	12.5	32
165	Emerging Role of MRI for Radiation Treatment Planning in Lung Cancer. <i>Technology in Cancer Research and Treatment</i> , 2016, 15, NP47-NP60.	0.8	12
166	Proton beams in cancer treatments: Clinical outcomes and dosimetric comparisons with photon therapy. <i>Cancer Treatment Reviews</i> , 2016, 43, 104-112.	3.4	69
167	Population-Based Patterns of Surgical Care for Stage IIIA NSCLC in the Netherlands between 2010 and 2013. <i>Journal of Thoracic Oncology</i> , 2016, 11, 566-572.	0.5	28
168	Candidates for Intensive Local Treatment in cIIIA-N2 Non-Small Cell Lung Cancer: Deciphering the Heterogeneity. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 155-162.	0.4	8
169	Cone-beam CT-guided radiotherapy in the management of lung cancer. <i>Strahlentherapie Und Onkologie</i> , 2016, 192, 83-91.	1.0	31
170	Improved progression free survival for patients with diabetes and locally advanced non-small cell lung cancer (NSCLC) using metformin during concurrent chemoradiotherapy. <i>Radiotherapy and Oncology</i> , 2016, 118, 453-459.	0.3	68
171	Long-term follow-up of patients with locally advanced non-small cell lung cancer receiving concurrent hypofractionated chemoradiotherapy with or without cetuximab. <i>Radiotherapy and Oncology</i> , 2016, 118, 442-446.	0.3	59
172	Phase II Study of Concurrent Pemetrexed, Cisplatin, and Radiation Therapy for Stage IIIA/B Unresectable Non-“Small Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2016, 17, 133-141.	1.1	10
173	Multi-criteria optimization achieves superior normal tissue sparing in a planning study of intensity-modulated radiation therapy for RTOG 1308-eligible non-small cell lung cancer patients. <i>Radiotherapy and Oncology</i> , 2016, 118, 515-520.	0.3	28

#	ARTICLE	IF	CITATIONS
174	The Quest for Evidence for Proton Therapy: Model-Based Approach and Precision Medicine. International Journal of Radiation Oncology Biology Physics, 2016, 95, 30-36.	0.4	105
175	GILTâ€”A randomised phaseâ€”III study of oral vinorelbine and cisplatin with concomitant radiotherapy followed by either consolidation therapy with oral vinorelbine and cisplatin or best supportive care alone in stageâ€”III non-small cell lung cancer. Strahlentherapie Und Onkologie, 2016, 192, 216-222.	1.0	66
176	Factors Associated With Early Mortality in Patients Treated With Concurrent Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2016, 94, 612-620.	0.4	49
177	Deep Inspiration Breath Holdâ€”Based Radiation Therapy: A Clinical Review. International Journal of Radiation Oncology Biology Physics, 2016, 94, 478-492.	0.4	184
178	Pretreatment ¹⁸ F-FDG PET Textural Features in Locally Advanced Nonâ€”Small Cell Lung Cancer: Secondary Analysis of ACRIN 6668/RTOG 0235. Journal of Nuclear Medicine, 2016, 57, 842-848.	2.8	75
179	Validity of Current Stereotactic Body Radiation Therapy Dose Constraints for Aorta and Major Vessels. Seminars in Radiation Oncology, 2016, 26, 135-139.	1.0	30
180	The Optimal Local Treatment of Stage IIIA-N2 NSCLC: Is the Issue Finally Settled?. Journal of Thoracic Oncology, 2016, 11, 284-286.	0.5	9
181	Thoracic Vertebral Body Irradiation Contributes to Acute Hematologic Toxicity During Chemoradiation Therapy for Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2016, 94, 147-154.	0.4	44
182	Pathways to improving combined modality therapy for stage III nonsmall-cell lung cancer. Annals of Oncology, 2016, 27, 590-599.	0.6	35
183	Pitfalls and Challenges to Consider before Setting up a Lung Cancer Intensity-modulated Radiotherapy Service: A Review of the Reported Clinical Experience. Clinical Oncology, 2016, 28, 185-197.	0.6	5
184	Quality of Life Analysis of a Radiation Doseâ€”Escalation Study of Patients With Nonâ€”Small-Cell Lung Cancer. JAMA Oncology, 2016, 2, 359.	3.4	145
185	Dose Escalation in Stage III Nonâ€”Small-Cell Lung Cancer. JAMA Oncology, 2016, 2, 368.	3.4	1
186	No Role For Trimodality Therapy and Consolidation Chemotherapy Compared With Concurrent Radiochemotherapy Alone in Stage III Nonâ€”Small-Cell Lung Cancer. Journal of Clinical Oncology, 2016, 34, 196-197.	0.8	5
187	Breast cancer therapy-associated cardiovascular disease. Nature Reviews Clinical Oncology, 2016, 13, 172-184.	12.5	121
188	Management of Lung Cancer in the Elderly. Clinics in Geriatric Medicine, 2016, 32, 81-95.	1.0	17
189	IMRT and 3D conformal radiotherapy with or without elective nodal irradiation in locally advanced NSCLC. Strahlentherapie Und Onkologie, 2016, 192, 75-82.	1.0	18
190	Comparison of Toxicity Between Intensity-Modulated Radiotherapy and 3-Dimensional Conformal Radiotherapy for Locally Advanced Nonâ€”small-cell Lung Cancer. Clinical Lung Cancer, 2016, 17, 18-23.	1.1	24
191	Integrating chemoradiation and molecularly targeted therapy. Advanced Drug Delivery Reviews, 2017, 109, 74-83.	6.6	22

#	ARTICLE	IF	CITATIONS
192	Targeted therapy combined with radiotherapy in non-small-cell lung cancer: a review of the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society). <i>Clinical and Translational Oncology</i> , 2017, 19, 31-43.	1.2	19
193	Matched-Pair Analysis of High Dose Versus Standard Dose Definitive Chemoradiation for Locally Advanced Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2017, 18, 149-155.	1.1	13
194	Significance of Co-expression of Epidermal Growth Factor Receptor and Ki67 on Clinical Outcome in Patients With Anal Cancer Treated With Chemoradiotherapy: An Analysis of NRG Oncology RTOG 9811. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 554-562.	0.4	14
195	First Clinical Report of Proton Beam Therapy for Postoperative Radiotherapy for Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2017, 18, 364-371.	1.1	38
196	NLRP3 inflammasome activation mediates radiation-induced pyroptosis in bone marrow-derived macrophages. <i>Cell Death and Disease</i> , 2017, 8, e2579-e2579.	2.7	122
197	Long-Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non-Small Cell Lung Cancer: NCCTG N0028 (Alliance). <i>Journal of Thoracic Oncology</i> , 2017, 12, 697-703.	0.5	16
198	Biology and patterns of response to EGFR-inhibition in squamous cell cancers of the lung and head & neck. <i>Cancer Treatment Reviews</i> , 2017, 54, 43-57.	3.4	28
199	Cardiac Toxicity After Radiotherapy for Stage III Non-Small-Cell Lung Cancer: Pooled Analysis of Dose-Escalation Trials Delivering 70 to 90 Gy. <i>Journal of Clinical Oncology</i> , 2017, 35, 1387-1394.	0.8	318
200	DART-bid for loco-regionally advanced NSCLC. <i>Strahlentherapie Und Onkologie</i> , 2017, 193, 315-323.	1.0	9
201	Dosimetric advantages of intensity modulated radiation therapy in locally advanced lung cancer. <i>Advances in Radiation Oncology</i> , 2017, 2, 6-11.	0.6	24
202	Lung and Heart Dose Variability During Radiation Therapy of Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 683-690.	0.4	12
203	Antagonism of EGFR and Notch limits resistance to EGFR inhibitors and radiation by decreasing tumor-initiating cell frequency. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	62
204	New Era in Radiation Oncology for Lung Cancer: Recognizing the Importance of Cardiac Irradiation. <i>Journal of Clinical Oncology</i> , 2017, 35, 1381-1383.	0.8	22
205	Radical hypo-fractionated radiotherapy with volumetric modulated arc therapy in lung cancer. <i>Strahlentherapie Und Onkologie</i> , 2017, 193, 385-391.	1.0	7
206	Evolution of [¹⁸ F]fluorodeoxyglucose and [¹⁸ F]fluoroazomycin arabinoside PET uptake distributions in lung tumours during radiation therapy. <i>Acta Oncologica</i> , 2017, 56, 516-524.	0.8	17
207	Definitive Radiotherapy for Local Recurrence of NSCLC After Surgery. <i>Clinical Lung Cancer</i> , 2017, 18, e161-e168.	1.1	17
208	Long-term Outcomes of Induction Carboplatin and Gemcitabine Followed by Concurrent Radiotherapy With Low-dose Paclitaxel and Gemcitabine for Stage III Non-small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2017, 18, 565-571.	1.1	9
209	Precision radiation oncology: Achievements and challenges. <i>Precision Radiation Oncology</i> , 2017, 1, 4-6.	0.4	2

#	ARTICLE	IF	CITATIONS
210	Long-Term Outcomes of Salvage Stereotactic Ablative Radiotherapy for Isolated Lung Recurrence of Non-Small Cell Lung Cancer: A Phase II Clinical Trial. <i>Journal of Thoracic Oncology</i> , 2017, 12, 983-992.	0.5	51
211	Concurrent chemoradiation with cisplatin and vinorelbine followed by consolidation with oral vinorelbine in locally advanced non-small cell lung cancer (NSCLC): the phase II CONCAVE study. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, 137-144.	0.7	5
212	The effect of induction chemotherapy in patients with locally advanced nonsmall cell lung cancer who received chemoradiotherapy. <i>Medicine (United States)</i> , 2017, 96, e6165.	0.4	16
213	Local Control and Toxicity of Adaptive Radiotherapy Using Weekly CT Imaging: Results from the LARTIA Trial in Stage III NSCLC. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1122-1130.	0.5	48
214	Reirradiation of recurrent node-positive non-small cell lung cancer after previous stereotactic radiotherapy for stage I disease. <i>Strahlentherapie Und Onkologie</i> , 2017, 193, 515-524.	1.0	13
215	A randomized phase II trial of concurrent chemoradiation with two doses of radiotherapy, 60 Gy and 66 Gy, concomitant with a fixed dose of oral vinorelbine in locally advanced NSCLC. <i>Radiotherapy and Oncology</i> , 2017, 123, 276-281.	0.3	20
216	The use of dose-escalated radiation for locally advanced non-small cell lung cancer in the U.S., 2004-2013. <i>Radiation Oncology</i> , 2017, 12, 19.	1.2	0
218	Radiation Treatment Time and Overall Survival in Locally Advanced Non-small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 1142-1152.	0.4	87
222	Functional lung avoidance and response-adaptive escalation (FLARE) RT: Multimodality plan dosimetry of a precision radiation oncology strategy. <i>Medical Physics</i> , 2017, 44, 3418-3429.	1.6	55
223	Biomarkers and Radiotherapy. <i>Cancer Treatment and Research</i> , 2017, , 223-238.	0.2	0
224	Heart Dosimetry is Correlated With Risk of Radiation Pneumonitis After Lung-Sparing Hemithoracic Pleural Intensity Modulated Radiation Therapy for Malignant Pleural Mesothelioma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 61-69.	0.4	19
225	The Impact of Cardiac Radiation Dosimetry on Survival After Radiation Therapy for Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 51-60.	0.4	75
226	Dose to heart substructures is associated with non-cancer death after SBRT in stage I-II NSCLC patients. <i>Radiotherapy and Oncology</i> , 2017, 123, 370-375.	0.3	115
227	Autophagy enhanced the radioresistance of non-small cell lung cancer by regulating ROS level under hypoxia condition. <i>International Journal of Radiation Biology</i> , 2017, 93, 764-770.	1.0	44
228	Early cardiac perfusion defects after left-sided radiation therapy for breast cancer: is there a volume response?. <i>Breast Cancer Research and Treatment</i> , 2017, 164, 253-262.	1.1	25
229	Developing and Validating a Survival Prediction Model for NSCLC Patients Through Distributed Learning Across 3 Countries. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 344-352.	0.4	102
230	Potential for adaptive dose escalation in radiotherapy for patients with locally advanced non-small-cell lung cancer in a low mid income setting. <i>British Journal of Radiology</i> , 2017, 90, 20140234.	1.0	7
231	Treatment of Locally Advanced Non-Small Cell Lung Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2017, 31, 45-57.	0.9	9

#	ARTICLE	IF	CITATIONS
232	Proton therapy – Present and future. <i>Advanced Drug Delivery Reviews</i> , 2017, 109, 26-44.	6.6	303
233	Time and Effort Required for Tissue Acquisition and Submission in Lung Cancer Clinical Trials. <i>Clinical Lung Cancer</i> , 2017, 18, 626-630.	1.1	7
234	Management of Stage I Lung Cancer with Stereotactic Ablative Radiation Therapy. <i>Surgical Oncology Clinics of North America</i> , 2017, 26, 393-403.	0.6	1
236	Do protons have a role in the treatment of locally advanced NSCLC with radiotherapy?. <i>Lung Cancer</i> , 2017, 110, 71-73.	0.9	1
237	Incidence and Predictors of Pericardial Effusion After Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 70-79.	0.4	52
238	Outcome and toxicity of intensity modulated radiotherapy with simultaneous integrated boost in locally advanced non-small cell lung cancer patients. <i>Clinical and Translational Oncology</i> , 2017, 19, 1469-1477.	1.2	9
239	Effect of Midtreatment PET/CT-Adapted Radiation Therapy With Concurrent Chemotherapy in Patients With Locally Advanced Non-Small-Cell Lung Cancer. <i>JAMA Oncology</i> , 2017, 3, 1358.	3.4	177
240	Dose Escalation Optimization in Patients With Locally Advanced Non-Small-Cell Lung Cancer. <i>JAMA Oncology</i> , 2017, 3, 1365.	3.4	2
241	Scientific Advances in Thoracic Oncology 2016. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1183-1209.	0.5	40
242	The Role of Radiotherapy in Localized Esophageal and Gastric Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2017, 31, 453-468.	0.9	17
243	Reproducibility of the EGFR immunohistochemistry scores for tumor samples from patients with advanced non-small cell lung cancer. <i>Oncology Letters</i> , 2017, 13, 912-920.	0.8	16
244	The relationship between cardiac radiation dose and mediastinal lymph node involvement in stage III non-small cell lung cancer patients. <i>Advances in Radiation Oncology</i> , 2017, 2, 192-196.	0.6	12
245	Enrollment of Elderly Patients With Locally Advanced Non-Small Cell Lung Cancer in Multi-institutional Trials of Proton Beam Radiation Therapy. <i>Clinical Lung Cancer</i> , 2017, 18, 441-443.	1.1	12
246	Superior Sulcus Tumors: Early Detection Is the Key. <i>Journal for Nurse Practitioners</i> , 2017, 13, 271-276.	0.4	0
247	Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial. <i>Annals of Oncology</i> , 2017, 28, 777-783.	0.6	155
248	Heart dose exposure as prognostic marker after radiotherapy for resectable stage IIIA/B non-small-cell lung cancer: secondary analysis of a randomized trial. <i>Annals of Oncology</i> , 2017, 28, 1084-1089.	0.6	38
249	Risk of major cardiac events following adjuvant proton versus photon radiation therapy for patients with thymic malignancies. <i>Acta Oncologica</i> , 2017, 56, 1060-1064.	0.8	13
250	Effect of accurate heart delineation on cardiac dose during the CONVERT trial. <i>British Journal of Radiology</i> , 2017, 90, 20170036.	1.0	8

#	ARTICLE	IF	CITATIONS
251	Phase II Study of a Radiotherapy Total Dose Increase in Hypoxic Lesions Identified by ¹⁸ F-Misonidazole PET/CT in Patients with Non-Small Cell Lung Carcinoma (RTEP5 Study). Journal of Nuclear Medicine, 2017, 58, 1045-1053.	2.8	70
252	Lower Incidence of Esophagitis in the Elderly Undergoing Definitive Radiation Therapy for Lung Cancer. Journal of Thoracic Oncology, 2017, 12, 539-546.	0.5	12
253	Charged-particle therapy in cancer: clinical uses and future perspectives. Nature Reviews Clinical Oncology, 2017, 14, 483-495.	12.5	317
254	Lung Cancer and Other Thoracic Malignancies. Medical Radiology, 2017, , 45-80.	0.0	0
255	Three-Arm Randomized Trial of Sodium Alginate for Preventing Radiation-Induced Esophagitis in Locally Advanced Non-Small Cell Lung Cancer Receiving Concurrent Chemoradiotherapy: The OLCSG1401 Study Protocol. Clinical Lung Cancer, 2017, 18, 245-249.	1.1	8
256	Cardiac Dose and Survival After Stereotactic Body Radiotherapy for Early-stage Non-Small-cell Lung Cancer. Clinical Lung Cancer, 2017, 18, 293-298.	1.1	20
257	Treatment Design and Rationale for a Randomized Trial of Cisplatin and Etoposide Plus Thoracic Radiotherapy Followed by Nivolumab or Placebo for Locally Advanced Non-Small-Cell Lung Cancer (RTOG 3505). Clinical Lung Cancer, 2017, 18, 333-339.	1.1	47
258	Cardiac atlas development and validation for automatic segmentation of cardiac substructures. Radiotherapy and Oncology, 2017, 122, 66-71.	0.3	76
259	Receptor Tyrosine Kinases as Targets for Enhancing Tumor Radiosensitivity. Cancer Drug Discovery and Development, 2017, , 35-55.	0.2	1
260	Adaptation is mandatory for intensity modulated proton therapy of advanced lung cancer to ensure target coverage. Radiotherapy and Oncology, 2017, 122, 400-405.	0.3	54
261	Concurrent Chemotherapy and Radiation Therapy for Inoperable Locally Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 2017, 35, 6-10.	0.8	36
262	From chemotherapy to target therapies associated with radiation in the treatment of NSCLC: a durable marriage?. Expert Review of Anticancer Therapy, 2017, 17, 157-165.	1.1	0
263	Comparison of Concurrent Use of Thoracic Radiation With Either Carboplatin-Paclitaxel or Cisplatin-Etoposide for Patients With Stage III Non-Small-Cell Lung Cancer. JAMA Oncology, 2017, 3, 1120.	3.4	93
264	A geometric atlas to predict lung tumor shrinkage for radiotherapy treatment planning. Physics in Medicine and Biology, 2017, 62, 702-714.	1.6	15
265	Melanoma: Last call for radiotherapy. Critical Reviews in Oncology/Hematology, 2017, 110, 13-19.	2.0	39
266	Heart dose associated with overall survival in locally advanced NSCLC patients treated with hypofractionated chemoradiotherapy. Radiotherapy and Oncology, 2017, 125, 62-65.	0.3	37
267	Treating locally advanced lung cancer with a 1.5 T MR-Linac – Effects of the magnetic field and irradiation geometry on conventionally fractionated and isotoxic dose-escalated radiotherapy. Radiotherapy and Oncology, 2017, 125, 280-285.	0.3	52
268	Deep reinforcement learning for automated radiation adaptation in lung cancer. Medical Physics, 2017, 44, 6690-6705.	1.6	161

#	ARTICLE	IF	CITATIONS
269	Heart dosimetric analysis of three types of cardiac toxicity in patients treated on dose-escalation trials for Stage III non-small-cell lung cancer. <i>Radiotherapy and Oncology</i> , 2017, 125, 293-300.	0.3	91
270	Patterns and correlates of treatment failure in relation to isodose distribution in non-small cell lung cancer: An analysis of 1522 patients in the modern era. <i>Radiotherapy and Oncology</i> , 2017, 125, 325-330.	0.3	0
271	Feasibility of stereotactic body radiotherapy for locally-advanced non-small cell lung cancer. <i>Clinical and Translational Radiation Oncology</i> , 2017, 6, 21-24.	0.9	2
272	Prediction of Treatment Response for Combined Chemo- and Radiation Therapy for Non-Small Cell Lung Cancer Patients Using a Bio-Mathematical Model. <i>Scientific Reports</i> , 2017, 7, 13542.	1.6	56
273	Mid-radiotherapy PET/CT for prognostication and detection of early progression in patients with stage III non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2017, 125, 338-343.	0.3	29
274	Standard of care in high-dose radiotherapy for localized non-small cell lung cancer. <i>Acta Oncologica</i> , 2017, 56, 1610-1613.	0.8	2
275	Adaptive radiotherapy for locally advanced non-small cell lung cancer: dosimetric gain and treatment outcome prediction. <i>Acta Oncologica</i> , 2017, 56, 1656-1659.	0.8	16
276	Lung Cancer. <i>Journal of Thoracic Imaging</i> , 2017, 32, 288-299.	0.8	3
277	Dosimetric comparison to the heart and cardiac substructure in a large cohort of esophageal cancer patients treated with proton beam therapy or Intensity-modulated radiation therapy. <i>Radiotherapy and Oncology</i> , 2017, 125, 48-54.	0.3	69
278	Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2017, 377, 1919-1929.	13.9	3,261
279	Difference in target definition using three different methods to include respiratory motion in radiotherapy of lung cancer. <i>Acta Oncologica</i> , 2017, 56, 1604-1609.	0.8	9
281	Radiation dose to heart base linked with poorer survival in lung cancer patients. <i>European Journal of Cancer</i> , 2017, 85, 106-113.	1.3	136
282	Does Motion Assessment With 4-Dimensional Computed Tomographic Imaging for Non-Small Cell Lung Cancer Radiotherapy Improve Target Volume Coverage?. <i>Clinical Medicine Insights: Oncology</i> , 2017, 11, 117955491769846.	0.6	10
283	Prophylactic Cranial Irradiation (PCI) versus Active MRI Surveillance for Small Cell Lung Cancer: The Case for Equipoise. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1746-1754.	0.5	48
284	Alteration of PD-L1 expression and its prognostic impact after concurrent chemoradiation therapy in non-small cell lung cancer patients. <i>Scientific Reports</i> , 2017, 7, 11373.	1.6	70
285	Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling. <i>Cancer Discovery</i> , 2017, 7, 1394-1403.	7.7	701
286	Prognostic Value of Primary Tumor Volume Changes on kV-CBCT during Definitive Chemoradiotherapy for Stage III Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1779-1787.	0.5	24
287	Loss of Nrf2 promotes alveolar type 2 cell loss in irradiated, fibrotic lung. <i>Free Radical Biology and Medicine</i> , 2017, 112, 578-586.	1.3	24

#	ARTICLE	IF	CITATIONS
288	Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non-â€“Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2017, 3, e172032.	3.4	119
289	Correlation analysis of [¹⁸ F]fluorodeoxyglucose and [¹⁸ F]fluoroazomycin arabinoside uptake distributions in lung tumours during radiation therapy. <i>Acta OncolÃ³gica</i> , 2017, 56, 1181-1188.	0.8	17
290	Survival advantage for etoposide/cisplatin over paclitaxel/carboplatin concurrent chemoradiation in patients with inoperable stage III NSCLC: a subgroup analysis for ECOG 2 patients would be of great interest. <i>Annals of Oncology</i> , 2017, 28, 2319-2320.	0.6	5
291	An individualized radiation dose escalation trial in non-small cell lung cancer based on FDG-PET imaging. <i>Strahlentherapie Und Onkologie</i> , 2017, 193, 812-822.	1.0	14
292	Potential of Proton Therapy to Reduce Acute Hematologic Toxicity in Concurrent Chemoradiation Therapy for Esophageal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 729-737.	0.4	21
293	Impact of field number and beam angle on functional image-guided lung cancer radiotherapy planning. <i>Physics in Medicine and Biology</i> , 2017, 62, 7114-7130.	1.6	8
294	Clinical outcomes of black vs. non-black patients with locally advanced non-â€“small cell lung cancer. <i>Lung Cancer</i> , 2017, 114, 44-49.	0.9	6
295	Rethink radiotherapy â€“ BIGART 2017. <i>Acta OncolÃ³gica</i> , 2017, 56, 1341-1352.	0.8	6
296	Immunotherapy for Unresectable Stage III Non-â€“Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2017, 377, 1986-1988.	13.9	40
297	Dosimetric comparison of the helical tomotherapy, volumetric-modulated arc therapy and fixed-field intensity-modulated radiotherapy for stage IIB-IIIB non-small cell lung cancer. <i>Scientific Reports</i> , 2017, 7, 14863.	1.6	13
298	Concomitant Chemotherapy and Radiotherapy with SBRT Boost for Unresectable Stage III Non-â€“Small Cell Lung Cancer: A Phase I Study. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1687-1695.	0.5	47
299	Management of stage III non-â€“small cell lung cancer. <i>Seminars in Oncology</i> , 2017, 44, 163-177.	0.8	40
300	Randomized Phase II Study of Preoperative Chemoradiotherapy Â± Panitumumab Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIa, N2+) Non-â€“Small Cell Lung Cancer: NRG Oncology RTOG 0839. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1413-1420.	0.5	22
301	Standardization of radiation therapy dose for locally advanced non-small cell lung cancer through changes to a lung cancer clinical pathway in a large, integrated comprehensive cancer center network. <i>Practical Radiation Oncology</i> , 2017, 7, e551-e557.	1.1	3
302	Heterogeneous FDG-guided dose-escalation for locally advanced NSCLC (the NARLAL2 trial): Design and early dosimetric results of a randomized, multi-centre phase-III study. <i>Radiotherapy and Oncology</i> , 2017, 124, 311-317.	0.3	24
303	Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2017, 28, iv1-iv21.	0.6	1,456
304	Radiation injury to cardiac arteries and myocardium is reduced by soy isoflavones. <i>Journal of Radiation Oncology</i> , 2017, 6, 307-315.	0.7	8
306	Is pulmonary artery a dose-limiting organ at risk in non-small cell lung cancer patients treated with definitive radiotherapy?. <i>Radiation Oncology</i> , 2017, 12, 34.	1.2	24

#	ARTICLE	IF	CITATIONS
307	Prognostic analysis of radiation pneumonitis: carbon-ion radiotherapy in patients with locally advanced lung cancer. <i>Radiation Oncology</i> , 2017, 12, 91.	1.2	16
308	Pulmonary Function Changes After Radiotherapy for Lung or Esophageal Cancer: A Systematic Review Focusing on Dose-Volume Parameters. <i>Oncologist</i> , 2017, 22, 1257-1264.	1.9	29
310	Multi-Institutional Prospective Study of Reirradiation with Proton Beam Radiotherapy for Locoregionally Recurrent Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 281-292.	0.5	82
311	National Cancer Database Analysis of Proton Versus Photon Radiation Therapy in Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 128-137.	0.4	105
312	Heart Dose Is an Independent Dosimetric Predictor of Overall Survival in Locally Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 293-301.	0.5	207
313	Radiation Oncology in India: Challenges and Opportunities. <i>Seminars in Radiation Oncology</i> , 2017, 27, 158-163.	1.0	19
314	Metabolic tumor volume predicts overall survival and local control in patients with stage III non-small cell lung cancer treated in ACRIN 6668/RTOG 0235. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 17-24.	3.3	98
315	¹⁸ F-Fluorodeoxyglucose/Positron Emission Tomography Predicts Patterns of Failure After Definitive Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 372-380.	0.4	19
316	Reassessing the Time Course for Radiation-Induced Cardiac Mortality in Patients With Breast Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 303-305.	0.4	10
317	Lung cancer: current therapies and new targeted treatments. <i>Lancet, The</i> , 2017, 389, 299-311.	6.3	2,267
318	Does Peer Review of Radiation Plans Affect Clinical Care? A Systematic Review of the Literature. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 27-34.	0.4	56
319	Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 56-62.	0.8	557
320	Influence of Surveillance PET/CT on Detection of Early Recurrence After Definitive Radiation in Stage III Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2017, 18, 141-148.	1.1	12
321	The world's first single-room proton therapy facility: Two-year experience. <i>Practical Radiation Oncology</i> , 2017, 7, e71-e76.	1.1	21
322	Carbon-ion radiotherapy for patients with advanced stage non-small-cell lung cancer at multicenters. <i>Journal of Radiation Research</i> , 2017, 58, 761-764.	0.8	16
323	Les nouvelles techniques de radiothérapie. <i>Revue Des Maladies Respiratoires Actualites</i> , 2017, 9, 181-189.	0.0	0
325	Study on orally delivered paclitaxel nanocrystals: modification, characterization and activity in the gastrointestinal tract. <i>Royal Society Open Science</i> , 2017, 4, 170753.	1.1	3
326	Consuming a Ketogenic Diet while Receiving Radiation and Chemotherapy for Locally Advanced Lung Cancer and Pancreatic Cancer: The University of Iowa Experience of Two Phase 1 Clinical Trials. <i>Radiation Research</i> , 2017, 187, 743-754.	0.7	100

#	ARTICLE	IF	CITATIONS
327	Intensity-modulated versus 3-dimensional conformal radiotherapy in the definitive treatment of esophageal cancer: comparison of outcomes and acute toxicity. <i>Radiation Oncology</i> , 2017, 12, 131.	1.2	29
328	Radiation Therapy with a Simultaneous Integrated Boost. , 0, , .		4
329	Targeting metabolism and AMP-activated kinase with metformin to sensitize non-small cell lung cancer (NSCLC) to cytotoxic therapy: translational biology and rationale for current clinical trials. <i>Oncotarget</i> , 2017, 8, 57733-57754.	0.8	35
330	Acute and Late Toxicities of Concurrent Chemoradiotherapy for Locally-Advanced Non-Small Cell Lung Cancer. <i>Cancers</i> , 2017, 9, 120.	1.7	55
331	Results of a Single Institution Experience with Dose-Escalated Chemoradiation for Locally Advanced Unresectable Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2017, 7, 1.	1.3	48
332	Emerging Therapies for Stage III Non-Small Cell Lung Cancer: Stereotactic Body Radiation Therapy and Immunotherapy. <i>Frontiers in Oncology</i> , 2017, 7, 197.	1.3	18
333	The Potential of Heavy-Ion Therapy to Improve Outcomes for Locally Advanced Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2017, 7, 201.	1.3	5
334	Radiotherapy Dosing for Locally Advanced Non-Small Cell Lung Carcinoma: "MTD" or "ALARA"? <i>Frontiers in Oncology</i> , 2017, 7, 205.	1.3	9
335	Treatment for non-small-cell lung cancer and circulating tumor cells. <i>Lung Cancer Management</i> , 2017, 6, 129-139.	1.5	13
336	Nitric Oxide Donors Sensitize Resistant Cancer Cells to Apoptosis Induced by Chemotherapy: Molecular Mechanisms of Sensitization. , 2017, , 15-34.		2
337	Thoracic Radiation Normal Tissue Injury. <i>Seminars in Radiation Oncology</i> , 2017, 27, 370-377.	1.0	105
338	The evolution of proton beam therapy: Current and future status (Review). <i>Molecular and Clinical Oncology</i> , 2018, 8, 15-21.	0.4	49
339	Comparison of photon volumetric modulated arc therapy, intensity-modulated proton therapy, and intensity-modulated carbon ion therapy for delivery of hypo-fractionated thoracic radiotherapy. <i>Radiation Oncology</i> , 2017, 12, 132.	1.2	5
340	Five-fraction SBRT for ultra-central NSCLC in-field recurrences following high-dose conventional radiation. <i>Radiation Oncology</i> , 2017, 12, 162.	1.2	15
341	Temporal and spatial dose distribution of radiation pneumonitis after concurrent radiochemotherapy in stage III non-small cell cancer patients. <i>Radiation Oncology</i> , 2017, 12, 165.	1.2	5
343	Meta-analysis Exploring the Effectiveness of S-1-Based Chemotherapy for Advanced Non-Small Cell Lung Cancer. <i>Tohoku Journal of Experimental Medicine</i> , 2017, 241, 1-11.	0.5	2
344	Highlights from the eCancer Future Horizons in Lung Cancer conference, 1"2 September 2016: Focusing on the future of treatment for NSCLC and SCLC. <i>Ecancermedicalscience</i> , 2017, 11, 729.	0.6	2
345	A Dosimetric Comparison of Dose Escalation with Simultaneous Integrated Boost for Locally Advanced Non-Small-Cell Lung Cancer. <i>BioMed Research International</i> , 2017, 2017, 1-7.	0.9	5

#	ARTICLE	IF	CITATIONS
346	The Future of Altered Fractionation. <i>Medical Radiology</i> , 2017, , 41-63.	0.0	0
347	Reply to D. Ball et al. <i>Journal of Clinical Oncology</i> , 2017, 35, 1493-1494.	0.8	1
348	Cardiac Events After Radiation Therapy: Combined Analysis of Prospective Multicenter Trials for Locally Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 1395-1402.	0.8	283
349	Reply to J.P. Gross et al. <i>Journal of Clinical Oncology</i> , 2017, 35, 2216-2217.	0.8	4
350	Routine Use of Intensity-Modulated Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer Is Neither Choosing Wisely Nor Personalized Medicine. <i>Journal of Clinical Oncology</i> , 2017, 35, 1492-1493.	0.8	6
351	Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies. <i>Journal of Clinical Oncology</i> , 2017, 35, 2885-2892.	0.8	68
352	Therapeutic management options for stage III non-small cell lung cancer. <i>World Journal of Clinical Oncology</i> , 2017, 8, 1.	0.9	188
353	Management of non-small cell lung cancer with EGFR mutation: the role of radiotherapy in the era of tyrosine kinase inhibitor therapy—opportunities and challenges. <i>Journal of Thoracic Disease</i> , 2017, 9, 3385-3393.	0.6	13
354	Is a clinical target volume (CTV) necessary for locally advanced non-small cell lung cancer treated with intensity-modulated radiotherapy?—a dosimetric evaluation of three different treatment plans. <i>Journal of Thoracic Disease</i> , 2017, 9, 5194-5202.	0.6	10
355	Radiomics in precision medicine for lung cancer. <i>Translational Lung Cancer Research</i> , 2017, 6, 635-647.	1.3	26
356	Research in imaging/biomarkers for precision medicine in lung cancer: National Cancer Institute funding opportunities. <i>Translational Lung Cancer Research</i> , 2017, 6, 615-616..	1.3	0
357	Blood-based biomarkers for precision medicine in lung cancer: precision radiation therapy. <i>Translational Lung Cancer Research</i> , 2017, 6, 661-669.	1.3	10
358	Comments on the trial of cisplatin and etoposide plus thoracic radiotherapy followed by nivolumab or placebo for locally advanced non-small cell lung cancer (RTOG 3505). <i>Journal of Thoracic Disease</i> , 2017, 9, 3525-3528.	0.6	0
359	Locally advanced non-small cell lung cancer treatment: another step forward. <i>Journal of Thoracic Disease</i> , 2017, 9, 4908-4911.	0.6	4
360	Advances in radiotherapy techniques and delivery for non-small cell lung cancer: benefits of intensity-modulated radiation therapy, proton therapy, and stereotactic body radiation therapy. <i>Translational Lung Cancer Research</i> , 2017, 6, 131-147.	1.3	48
361	Magnetic resonance imaging in precision radiation therapy for lung cancer. <i>Translational Lung Cancer Research</i> , 2017, 6, 689-707.	1.3	56
362	ECCO essential requirements for quality cancer care: Melanoma. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 122, 164-178.	2.0	41
363	Natural Disasters and the Importance of Minimizing Subsequent Radiation Therapy Interruptions for Locally Advanced Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 836-837.	0.4	10

#	ARTICLE	IF	CITATIONS
364	Durvalumab in Stage III Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2018, 378, 868-870.	13.9	33
365	Implications of Pathologic Complete Response Beyond Mediastinal Nodal Clearance With High-Dose Neoadjuvant Chemoradiation Therapy in Locally Advanced, Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 445-452.	0.4	16
366	Combination of post-operative radiotherapy and cetuximab for high-risk cutaneous squamous cell cancer of the head and neck: A propensity score analysis. <i>Oral Oncology</i> , 2018, 78, 102-107.	0.8	23
367	Progress in the Management of Early-Stage Non-Small Cell Lung Cancer in 2017. <i>Journal of Thoracic Oncology</i> , 2018, 13, 767-778.	0.5	24
368	Lung Cancer. <i>Radiologic Clinics of North America</i> , 2018, 56, 471-483.	0.9	7
369	Association between radiation heart dosimetric parameters, myocardial infarct and overall survival in stage 3 non-small cell lung cancer treated with definitive thoracic radiotherapy. <i>Lung Cancer</i> , 2018, 120, 54-59.	0.9	7
370	Is tumor volume reduction during radiotherapy prognostic relevant in patients with stage III non-small cell lung cancer?. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1165-1171.	1.2	16
371	Consolidation systemic treatment after radiochemotherapy for unresectable stage III non-small cell lung cancer. <i>Cancer Treatment Reviews</i> , 2018, 66, 114-121.	3.4	28
372	Stereotactic ablative radiotherapy after concomitant chemoradiotherapy in non-small cell lung cancer: A TITE-CRM phase 1 trial. <i>Radiotherapy and Oncology</i> , 2018, 127, 239-245.	0.3	5
373	Metformin for non-small cell lung cancer patients: Opportunities and pitfalls. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 125, 41-47.	2.0	32
374	NF- κ B inhibition by dimethylaminoparthenolide radiosensitizes non-small-cell lung carcinoma by blocking DNA double-strand break repair. <i>Cell Death Discovery</i> , 2018, 4, 10.	2.0	15
375	A phase III randomised study comparing concomitant radiochemotherapy with cisplatin and docetaxel as induction versus consolidation treatment in patients with locally advanced unresectable non-small cell lung cancer. <i>Lung Cancer</i> , 2018, 117, 32-37.	0.9	13
376	Is heterogeneity in stage 3 non-small cell lung cancer obscuring the potential benefits of dose-escalated concurrent chemo-radiotherapy in clinical trials?. <i>Lung Cancer</i> , 2018, 118, 139-147.	0.9	10
377	Out of the darkness and into the light: New strategies for improving treatments for locally advanced non-small cell lung cancer. <i>Cancer Letters</i> , 2018, 421, 59-62.	3.2	8
378	Beyond Concurrent Chemoradiation: The Emerging Role of PD-1/PD-L1 Inhibitors in Stage III Lung Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 1271-1276.	3.2	32
379	Local failure after radical radiotherapy of non-small cell lung cancer in relation to the planning FDG-PET/CT. <i>Acta Oncologica</i> , 2018, 57, 813-819.	0.8	7
380	Resolution of atelectasis during radiochemotherapy of lung cancer with serious implications for further treatment. A case report. <i>Clinical and Translational Radiation Oncology</i> , 2018, 9, 1-4.	0.9	3
381	Radiation Dose to the Thoracic Vertebral Bodies Is Associated With Acute Hematologic Toxicities in Patients Receiving Concurrent Chemoradiation for Lung Cancer: Results of a Single-Center Retrospective Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 748-755.	0.4	24

#	ARTICLE	IF	CITATIONS
382	PD-1 Modulates Radiation-Induced Cardiac Toxicity through Cytotoxic T Lymphocytes. <i>Journal of Thoracic Oncology</i> , 2018, 13, 510-520.	0.5	77
383	Thoracic reirradiation with SBRT for residual/recurrent and new primary NSCLC within or immediately adjacent to a prior high-dose radiation field. <i>Practical Radiation Oncology</i> , 2018, 8, e117-e123.	1.1	22
384	Prediction of Radiation Esophagitis in Non-Small Cell Lung Cancer Using Clinical Factors, Dosimetric Parameters, and Pretreatment Cytokine Levels. <i>Translational Oncology</i> , 2018, 11, 102-108.	1.7	10
386	Simultaneous Integrated Boost for Radiation Dose Escalation to the Gross Tumor Volume With Intensity Modulated (Photon) Radiation Therapy or Intensity Modulated Proton Therapy and Concurrent Chemotherapy for Stage II to III Non-Small Cell Lung Cancer: A Phase 1 Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 730-737.	0.4	27
387	Serial 4DCT/4DPET imaging to predict and monitor response for locally-advanced non-small cell lung cancer chemo-radiotherapy. <i>Radiotherapy and Oncology</i> , 2018, 126, 347-354.	0.3	13
388	Benefit of using motion compensated reconstructions for reducing inter-observer and intra-observer contouring variation for organs at risk in lung cancer patients. <i>Radiotherapy and Oncology</i> , 2018, 126, 333-338.	0.3	6
389	Continuous Hyperfractionated Accelerated Radiotherapy (CHART) for Non-small Cell Lung Cancer (NSCLC): 7 Years' Experience From Nine UK Centres. <i>Clinical Oncology</i> , 2018, 30, 144-150.	0.6	10
390	Risk of fatigue in cancer patients receiving anti-EGFR monoclonal antibodies: results from a systematic review and meta-analysis of randomized controlled trial. <i>International Journal of Clinical Oncology</i> , 2018, 23, 389-399.	1.0	1
391	Health care disparities among octogenarians and nonagenarians with stage III lung cancer. <i>Cancer</i> , 2018, 124, 775-784.	2.0	24
392	Improve dosimetric outcome in stage III non-small-cell lung cancer treatment using spot-scanning proton arc (SPArc) therapy. <i>Radiation Oncology</i> , 2018, 13, 35.	1.2	45
393	A secondary analysis of FDG spatio-temporal consistency in the randomized phase II PET-boost trial in stage II-III NSCLC. <i>Radiotherapy and Oncology</i> , 2018, 127, 259-266.	0.3	4
394	Does Proton Therapy Offer Demonstrable Clinical Advantages for Treating Thoracic Tumors?. <i>Seminars in Radiation Oncology</i> , 2018, 28, 114-124.	1.0	7
395	A quality control method for intensity-modulated radiation therapy planning based on generalized equivalent uniform dose. <i>Journal of Applied Clinical Medical Physics</i> , 2018, 19, 276-282.	0.8	3
396	Radiation Therapy Quality Assurance (RTQA) of Concurrent Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer in the PROCLAIM Phase 3 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 927-934.	0.4	23
397	Exploring Radiotherapy Targeting Strategy and Dose: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Stage III NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1171-1182.	0.5	17
398	Concurrent chemoradiation for locally advanced stage III non-small cell lung cancer with cisplatin, vinorelbine, and thoracic radiotherapy: a phase II study from the Galician Lung Cancer Group. <i>Clinical and Translational Oncology</i> , 2018, 20, 1467-1473.	1.2	2
399	High-Dose Radiotherapy as Neoadjuvant Treatment in Non-Small-Cell Lung Cancer. <i>Oncology</i> , 2018, 95, 13-19.	0.9	7
400	Cetuximab for treating non-small cell lung cancer. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 483-493.	1.4	44

#	ARTICLE	IF	CITATIONS
401	PD-(L)1 Inhibition and Cardiac Damage: A Relevant Toxicity?. <i>Journal of Thoracic Oncology</i> , 2018, 13, 478-479.	0.5	4
402	ESTRO ACROP guidelines for target volume definition in the treatment of locally advanced non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2018, 127, 1-5.	0.3	141
403	The effects of radiotherapy on the survival of patients with unresectable non-small cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 593-602.	1.1	18
404	Phase 1 Study of Accelerated Hypofractionated Radiation Therapy With Concurrent Chemotherapy for Stage III Non-Small Cell Lung Cancer: CALGB 31102 (Alliance). <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 177-185.	0.4	35
405	A Competing Risk Model of First Failure Site after Definitive Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 559-567.	0.5	16
406	Locally Advanced Lung Cancer: Is It Time to Take Cardiac Protection Seriously in Radiation Planning?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 1091-1094.	0.4	4
407	Treatment of locally advanced, unresectable or medically inoperable stage III non-small-cell lung cancer; the past, present and future of chemoradiotherapy. <i>Journal of Oncological Science</i> , 2018, 4, 49-52.	0.1	2
408	Pulmonary Resection for a Residual Tumor after Definitive Radiation in Locally Advanced Non-Small Cell Lung Cancer. <i>Thoracic and Cardiovascular Surgeon</i> , 2018, 66, 170-173.	0.4	0
409	Local Radiotherapy Intensification for Locally Advanced Non-small-cell Lung Cancer – A Call to Arms. <i>Clinical Lung Cancer</i> , 2018, 19, 17-26.	1.1	13
410	Quantitatively Excessive Normal Tissue Toxicity and Poor Target Coverage in Postoperative Lung Cancer Radiotherapy Meta-analysis. <i>Clinical Lung Cancer</i> , 2018, 19, e123-e130.	1.1	4
411	Prognostic Impact of Missed Chemotherapy Doses During Chemoradiation Therapy for Non-small Cell Lung Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 362-366.	0.6	15
412	Identifying the Optimal Radiation Dose in Locally Advanced Non-small-cell Lung Cancer Treated With Definitive Radiotherapy Without Concurrent Chemotherapy. <i>Clinical Lung Cancer</i> , 2018, 19, e131-e140.	1.1	10
413	The NARLAL2 dose escalation trial: dosimetric implications of inter-fractional changes in organs at risk. <i>Acta Oncologica</i> , 2018, 57, 473-479.	0.8	4
414	Dose Escalation Study of Concurrent Chemoradiotherapy With the Use of Involved-field Conformal Radiotherapy and Accelerated Hyperfractionation in Combination With Cisplatin and Vinorelbine Chemotherapy for Stage III Non-small Cell Lung Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 967-971.	0.6	0
415	Serum MicroRNA Signature Predicts Response to High-Dose Radiation Therapy in Locally Advanced Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 107-114.	0.4	28
416	Targeting Hypoxia to Improve Non-small Cell Lung Cancer Outcome. <i>Journal of the National Cancer Institute</i> , 2018, 110, 14-30.	3.0	177
417	Accelerated hypofractionated radiotherapy for advanced lung cancer. <i>Journal of Radiotherapy in Practice</i> , 2018, 17, 78-84.	0.2	0
418	Radiation Dose, Local Disease Progression, and Overall Survival in Patients With Inoperable Non-Small Cell Lung Cancer After Concurrent Chemoradiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 452-461.	0.4	11

#	ARTICLE	IF	CITATIONS
419	Trends in Cardiac Mortality in Patients With Locally Advanced Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 100, 470-477.	0.4	25
420	Positron Emission Tomography-Adjusted Intensity Modulated Radiation Therapy for Locally Advanced Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 102, 709-715.	0.4	14
421	Long-Term Survival after Salvage Surgery for Local Failure after Definitive Chemoradiation Therapy for Locally Advanced Non-small Cell Lung Cancer. Thoracic and Cardiovascular Surgeon, 2018, 66, 135-141.	0.4	22
422	Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer. JAMA Oncology, 2018, 4, e173501.	3.4	755
423	Technical Requirements for Lung Cancer Radiotherapy. , 2018, , 318-329.e2.		2
424	Radiobiology of Lung Cancer. , 2018, , 330-336.e2.		0
425	Radiotherapy for Locally Advanced Nonsmall Cell Lung Cancer Including Combined Modality. , 2018, , 363-373.e3.		0
426	Acute and Late Toxicities of Thoracic Radiotherapy. , 2018, , 393-408.e4.		1
427	Survival Impact of Cardiac Dose Following Lung Stereotactic Body Radiotherapy. Clinical Lung Cancer, 2018, 19, e241-e246.	1.1	28
428	The dosimetric effects of limited elective nodal irradiation in volumetric modulated arc therapy treatment planning for locally advanced non-small cell lung cancer. Journal of Radiation Oncology, 2018, 7, 45-51.	0.7	3
429	Treatment planning with intensity modulated particle therapy for multiple targets in stage IV non-small cell lung cancer. Physics in Medicine and Biology, 2018, 63, 025034.	1.6	6
430	Long term radiological features of radiation-induced lung damage. Radiotherapy and Oncology, 2018, 126, 300-306.	0.3	18
431	Cell Death, Inflammation, Tumor Burden, and Proliferation Blood Biomarkers Predict Lung Cancer Radiotherapy Response and Correlate With Tumor Volume and Proliferation Imaging. Clinical Lung Cancer, 2018, 19, 239-248.e7.	1.1	16
432	Patterns of locoregional failure in locally advanced non-small cell lung cancer treated with definitive conformal radiotherapy: Results from the Gating 2006 trial. Radiotherapy and Oncology, 2018, 126, 291-299.	0.3	17
433	Induction Therapies Plus Surgery Versus Exclusive Radiochemotherapy in Stage IIIA/N2 Non-Small Cell Lung Cancer (NSCLC). American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 267-273.	0.6	2
434	Analysis of primary tumor metabolic volume during chemoradiotherapy in locally advanced non-small cell lung cancer. Strahlentherapie Und Onkologie, 2018, 194, 107-115.	1.0	22
435	Continuous Infusion of Cilengitide Plus Chemoradiotherapy for Patients With Stage III Non-Small-cell Lung Cancer: A Phase I Study. Clinical Lung Cancer, 2018, 19, e277-e285.	1.1	19
436	A Phase II Toxicity End Point Trial (ICORG 99-09) of Accelerated Dose-escalated Hypofractionated Radiation in Non-small Cell Lung Cancer. Clinical Oncology, 2018, 30, 30-38.	0.6	8

#	ARTICLE	IF	CITATIONS
437	Dosimetric predictors for acute esophagitis during radiation therapy for lung cancer: Results of a large statewide observational study. <i>Practical Radiation Oncology</i> , 2018, 8, 167-173.	1.1	19
438	What Happens When Proton Meets Randomization: Is There a Future for Proton Therapy?. <i>Journal of Clinical Oncology</i> , 2018, 36, 1777-1779.	0.8	9
439	Challenge of Proving the Value of Proton Therapy in an Unselected Patient Population in the Era of Precision Oncology: The Fallacy of a One-Size-Fits-All Strategy in Radiotherapy for Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 2003-2004.	0.8	4
440	Comparison of IMRT and VMAT Plan for Advanced Stage Non-Small Cell Lung Cancer Treatment. <i>Annals of Behavioural Science</i> , 2018, 04, .	0.1	3
441	Stage III Non-Small-Cell Lung Cancer Treated With Concurrent Chemoradiation Followed or Not by Consolidation Chemotherapy: A Survival Analysis From a Brazilian Multicentric Cohort. <i>Journal of Global Oncology</i> , 2018, 4, 1-11.	0.5	3
442	Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 1813-1822.	0.8	243
444	Immunotherapy after chemoradiotherapy in stage III non-small cell lung cancer: a new standard of care?. <i>Journal of Thoracic Disease</i> , 2018, 10, 1198-1200.	0.6	6
445	Advanced radiation techniques for locally advanced non-small cell lung cancer: intensity-modulated radiation therapy and proton therapy. <i>Journal of Thoracic Disease</i> , 2018, 10, S2474-S2491.	0.6	24
446	The evolving role of radiotherapy in the management of small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, S2545-S2554.	0.6	6
447	Consolidation of immunotherapy becomes new standard of care in unresectable stage III non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, 1205-1206.	0.6	2
448	The current state of oligometastatic and oligoprogressive non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, S2537-S2544.	0.6	26
449	Neoadjuvant PD-1 blockade in non-small cell lung cancer: what else do we need to do?. <i>Journal of Thoracic Disease</i> , 2018, 10, S3162-S3165.	0.6	0
450	Locally-advanced non-small cell lung cancer: shall immunotherapy be a new chance?. <i>Journal of Thoracic Disease</i> , 2018, 10, S1461-S1467.	0.6	25
451	Breaking the dose ceiling: proton therapy for locally advanced non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, 130-134.	0.6	2
452	Neoadjuvant and consolidation immuno-oncology therapy in stage III non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, S451-S459.	0.6	34
453	A promising result of locoregional tumor control with biologically adaptive radiotherapy in patients with locally advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2018, 7, S111-S113.	1.3	2
454	Precision radiotherapy for patients with locally advanced non-small cell lung cancer in the era of immunotherapy and precision medicine. <i>Translational Lung Cancer Research</i> , 2018, 7, S146-S148.	1.3	2
455	Durvalumab for non-resectable stage IIIB non-small cell lung cancer—a small step or a big leap?. <i>Translational Lung Cancer Research</i> , 2018, 7, S153-S157.	1.3	1

#	ARTICLE	IF	CITATIONS
456	Proton therapy for small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2018, 7, 134-140.	1.3	8
457	Particle therapy in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2018, 7, 141-152.	1.3	16
458	Reirradiation for locoregionally recurrent non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, S2522-S2536.	0.6	20
459	Evaluation of combined anti-PD-1 immunotherapy and radiation therapy in a preclinical mouse model of pneumonitis and fibrosis. <i>Journal of Thoracic Disease</i> , 2018, 10, 6254-6260.	0.6	6
460	Optimizing radiation dose and fractionation for the definitive treatment of locally advanced non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, S2465-S2473.	0.6	32
461	Advances in the use of motion management and image guidance in radiation therapy treatment for lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, S2437-S2450.	0.6	40
462	Pacific trial: a new ocean or an abnormal wave?. <i>Journal of Thoracic Disease</i> , 2018, 10, 1225-1226.	0.6	1
463	Radiation pneumonitis in lung cancer treated with volumetric modulated arc therapy. <i>Journal of Thoracic Disease</i> , 2018, 10, 6531-6539.	0.6	14
464	Proton therapy for post-operative radiation therapy of non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2018, 7, 205-209.	1.3	4
465	Pitfalls in lung stereotactic body radiotherapy—a review of organ toxicities and dose constraints. <i>Journal of Xiangya Medicine</i> , 2018, 3, 36-36.	0.2	3
466	Combining stereotactic body radiation therapy with immunotherapy: current data and future directions. <i>Translational Lung Cancer Research</i> , 2018, 8, 107-115.	1.3	40
467	Combining immunotherapy with radiation therapy in thoracic oncology. <i>Journal of Thoracic Disease</i> , 2018, 10, S2492-S2507.	0.6	16
468	Curative Intent Treatment of Stage III Non-Small Cell Lung Cancer. , 2018, , 83-98.		1
469	Elderly patients with stage III NSCLC survive longer when chemotherapy is added to radiotherapy—fortune favours the bold. <i>Translational Lung Cancer Research</i> , 2018, 7, S388-S392.	1.3	4
470	Hypoxia imaging in upper gastrointestinal tumors and application to radiation therapy. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 1044-1053.	0.6	5
471	Serum microRNA guiding personalized radiation therapy in non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, S4108-S4112.	0.6	1
472	Impact of metformin use on survival outcomes in non-small cell lung cancer treated with platinum. <i>Medicine (United States)</i> , 2018, 97, e13652.	0.4	10
473	Heart Dose and Outcomes in Radiation Treatment for Esophageal Cancer. <i>Cureus</i> , 2018, 10, e2378.	0.2	10

#	ARTICLE	IF	CITATIONS
475	Phase I Study of Concurrent and Consolidation Cisplatin and Docetaxel Chemotherapy with Thoracic Radiotherapy in Non-Small Cell Lung Cancer. <i>Current Oncology</i> , 2018, 25, 22-31.	0.9	2
476	Hypo-fractionated boost in locally advanced non-small cell lung cancer: temporal distribution of boost fractions. <i>Physics in Medicine and Biology</i> , 2018, 63, 235018.	1.6	3
477	Radiotherapy dose escalation in locally advanced NSCLC – The limits of conventional radiochemotherapy. <i>Lung Cancer</i> , 2018, 126, 208-209.	0.9	0
479	Delineation of lung cancer with FDG PET/CT during radiation therapy. <i>Radiation Oncology</i> , 2018, 13, 219.	1.2	18
480	Noninvasive cardiac arrhythmia ablation with particle beams. <i>Medical Physics</i> , 2018, 45, e1024-e1035.	1.6	16
481	Functionally impaired follicular helper T cells induce regulatory B cells and CD 14 + human leukocyte antigen-DR ⁺ cell differentiation in non-small cell lung cancer. <i>Cancer Science</i> , 2018, 109, 3751-3761.	1.7	29
482	“Wisest Is He Who Knows What He Does Not Know.” <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 687-690.	0.4	2
483	A pilot study of stereotactic body radiation therapy (SBRT) after surgery for stage III non-small cell lung cancer. <i>BMC Cancer</i> , 2018, 18, 1183.	1.1	5
484	Comparison of proton therapy and intensity modulated photon radiotherapy for locally advanced non-small cell lung cancer: considerations for optimal trial design. <i>Journal of Thoracic Disease</i> , 2018, 10, S988-S990.	0.6	6
486	Quelles stratégies thérapeutiques pour les CBNPC de stade IIIB (T4N2/T1-T3N3) ?. <i>Revue Des Maladies Respiratoires Actualites</i> , 2018, 10, 319-325.	0.0	0
487	Proton Therapy in Non-small Cell Lung Cancer. <i>Current Treatment Options in Oncology</i> , 2018, 19, 76.	1.3	25
488	Identifying patterns of care for elderly patients with non-surgically treated stage III non-small cell lung cancer: an analysis of the national cancer database. <i>Radiation Oncology</i> , 2018, 13, 196.	1.2	20
489	External validation of an NTCP model for acute esophageal toxicity in locally advanced NSCLC patients treated with intensity-modulated (chemo-)radiotherapy. <i>Radiotherapy and Oncology</i> , 2018, 129, 249-256.	0.3	8
490	Radiation Dose Escalation in Accelerated Hyperfractionated Radiotherapy for Stage III Non-small-cell Lung Cancer. <i>Anticancer Research</i> , 2018, 38, 5951-5958.	0.5	9
492	Dosimetric Predictors of Symptomatic Cardiac Events After Conventional-Dose Chemoradiation Therapy for Inoperable NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1508-1518.	0.5	63
493	Fucoidan Inhibits Radiation-Induced Pneumonitis and Lung Fibrosis by Reducing Inflammatory Cytokine Expression in Lung Tissues. <i>Marine Drugs</i> , 2018, 16, 392.	2.2	46
494	Interim Analysis of a Two-Institution, Prospective Clinical Trial of 4DCT-Ventilation-based Functional Avoidance Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 1357-1365.	0.4	30
495	Radiation and the heart: systematic review of dosimetry and cardiac endpoints. <i>Expert Review of Cardiovascular Therapy</i> , 2018, 16, 931-950.	0.6	38

#	ARTICLE	IF	CITATIONS
496	FDG and FMISO PET-guided dose escalation with intensity-modulated radiotherapy in lung cancer. <i>Radiation Oncology</i> , 2018, 13, 208.	1.2	34
497	Enhancement of radiotherapeutic efficacy for esophageal cancer by paclitaxel-loaded red blood cell membrane nanoparticles modified by the recombinant protein anti-EGFR-iRGD. <i>Journal of Biomaterials Applications</i> , 2018, 33, 707-724.	1.2	11
498	Functional validation of miRNAs targeting genes of DNA double-strand break repair to radiosensitize non-small lung cancer cells. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2018, 1861, 1102-1118.	0.9	23
499	Salvage surgery for recurrent or persistent tumour after radical (chemo)radiotherapy for locally advanced non-small cell lung cancer: a systematic review. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591880415.	1.4	11
500	Use of PET and Other Functional Imaging to Guide Target Delineation in Radiation Oncology. <i>Seminars in Radiation Oncology</i> , 2018, 28, 171-177.	1.0	42
501	Proton therapy for thoracic reirradiation of non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2018, 7, 153-159.	1.3	5
502	Stereotactic radiotherapy boost after definite chemoradiation for non-responding locally advanced NSCLC based on early response monitoring 18F-FDG-PET/CT. <i>Physics and Imaging in Radiation Oncology</i> , 2018, 7, 16-22.	1.2	4
503	Novel CT-Based Objective Imaging Biomarkers of Long-Term Radiation-Induced Lung Damage. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 1287-1298.	0.4	7
504	A randomised phase II trial of S-1 plus cisplatin versus vinorelbine plus cisplatin with concurrent thoracic radiotherapy for unresectable, locally advanced non-small cell lung cancer: WJOG5008L. <i>British Journal of Cancer</i> , 2018, 119, 675-682.	2.9	32
505	Concurrent Daily Cisplatin and High-Dose Radiation Therapy in Patients With Stage III Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 543-551.	0.4	19
506	Durvalumab after chemoradiotherapy in stage III non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, S1032-S1036.	0.6	16
507	Twice-daily Thoracic Radiotherapy for Limited-stage Small-cell Lung Cancer Does Not Increase the Incidence of Acute Severe Esophagitis. <i>Clinical Lung Cancer</i> , 2018, 19, e885-e891.	1.1	4
508	Residual Setup Errors Towards the Heart After Image Guidance Linked With Poorer Survival in Lung Cancer Patients: Do We Need Stricter IGRT Protocols?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 434-442.	0.4	39
509	Radiation Therapy Is Associated With an Increased Incidence of Cardiac Events in Patients with Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 383-390.	0.4	15
510	Perspectives on potential research benefits from big data efforts in Radiation Oncology. <i>Medical Physics</i> , 2018, 45, e848-e849.	1.6	2
511	Practice-changing radiation therapy trials for the treatment of cancer: where are we 150 years after the birth of Marie Curie?. <i>British Journal of Cancer</i> , 2018, 119, 389-407.	2.9	92
512	A comprehensive analysis of clinical trials including both immunotherapy and radiation therapy. <i>Journal of Radiation Oncology</i> , 2018, 7, 223-232.	0.7	0
513	Non-small Cell Lung Cancer. , 2018, , 293-321.		1

#	ARTICLE	IF	CITATIONS
514	The Impact of Staging by Positron-Emission Tomography on Overall Survival and Progression-Free Survival in Patients With Locally Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1183-1188.	0.5	12
515	Anti-Epidermal Growth Factor Vaccine Antibodies Enhance the Efficacy of Tyrosine Kinase Inhibitors and Delay the Emergence of Resistance in EGFR Mutant Lung Cancer Cells. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1324-1337.	0.5	29
516	Immunotherapy in non-metastatic non-small cell lung cancer: Can the benefits of stage IV therapy be translated into earlier stages?. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591877281.	1.4	18
517	Cardiac dose is associated with immunosuppression and poor survival in locally advanced non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2018, 128, 498-504.	0.3	75
518	Lung IMRT planning with automatic determination of beam angle configurations. <i>Physics in Medicine and Biology</i> , 2018, 63, 135024.	1.6	10
519	Radiobiology of Proton Therapy: Results of an international expert workshop. <i>Radiotherapy and Oncology</i> , 2018, 128, 56-67.	0.3	85
521	The Integration of Radiotherapy with Immunotherapy for the Treatment of Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 5792-5806.	3.2	200
522	Dose escalation to 84 Gy with concurrent chemotherapy in stage III NSCLC appears excessively toxic: Results from a prematurely terminated randomized phase II trial. <i>Lung Cancer</i> , 2018, 122, 180-186.	0.9	14
523	Cardiac mortality in limited-stage small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2018, 128, 492-497.	0.3	10
524	Rationale and Protocol for a Canadian Multicenter Phase II Randomized Trial Assessing Selective Metabolically Adaptive Radiation Dose Escalation in Locally Advanced Non-small-cell Lung Cancer (NCT02788461). <i>Clinical Lung Cancer</i> , 2018, 19, e699-e703.	1.1	15
525	pH-Sensitive nanogels based on the electrostatic self-assembly of radionuclide ¹³¹ I labeled albumin and carboxymethyl cellulose for synergistic combined chemo-radioisotope therapy of cancer. <i>Journal of Materials Chemistry B</i> , 2018, 6, 4738-4746.	2.9	30
526	Immune Checkpoint Inhibitors in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer. <i>Current Treatment Options in Oncology</i> , 2018, 19, 39.	1.3	18
528	Feasibility of stereotactic radiotherapy for lung lesions and conventional radiotherapy for nodal areas in primary lung malignancies. <i>Radiation Oncology</i> , 2018, 13, 127.	1.2	3
529	Durvalumab: a potential maintenance therapy in surgery-ineligible non-small-cell lung cancer. <i>Cancer Management and Research</i> , 2018, Volume 10, 931-940.	0.9	10
530	Preoperative radiation may improve the outcomes of resectable IIIA/N2 non-small-cell lung cancer patients: A propensity score matching-based analysis from surveillance, epidemiology, and end results database. <i>Cancer Medicine</i> , 2018, 7, 4354-4360.	1.3	18
531	The role of radiation therapy in the treatment of metastatic cancer. <i>Clinical and Experimental Metastasis</i> , 2018, 35, 535-546.	1.7	2
532	Development of biocompatible and VEGF-targeted paclitaxel nanodrugs on albumin and graphene oxide dual-carrier for photothermal-triggered drug delivery in vitro and in vivo. <i>International Journal of Nanomedicine</i> , 2018, Volume 13, 439-453.	3.3	47
533	Tumor-penetrating peptide fused EGFR single domain antibody enhances radiation responses following EGFR inhibition in gastric cancer. <i>Oncology Reports</i> , 2018, 40, 1583-1591.	1.2	4

#	ARTICLE	IF	CITATIONS
534	Utility of polaprezinc in reducing toxicities during radiotherapy: a literature review. <i>Future Oncology</i> , 2018, 14, 1977-1988.	1.1	8
535	Ionizing Radiation Induces Endothelial Inflammation and Apoptosis via p90RSK-Mediated ERK5 S496 Phosphorylation. <i>Frontiers in Cardiovascular Medicine</i> , 2018, 5, 23.	1.1	17
536	Developing a Reliable Mouse Model for Cancer Therapy-Induced Cardiovascular Toxicity in Cancer Patients and Survivors. <i>Frontiers in Cardiovascular Medicine</i> , 2018, 5, 26.	1.1	7
537	Radiation Oncology in the 21st Century: Prospective Randomized Trials That Changed Practice or Didn't. <i>Frontiers in Oncology</i> , 2018, 8, 130.	1.3	4
538	Editorial: Controversies in the Local Management of Lung Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 233.	1.3	1
539	Skin toxicity with anti-EGFR monoclonal antibody in cancer patients: a meta-analysis of 65 randomized controlled trials. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 571-583.	1.1	13
540	Anticancer therapy and lung injury: molecular mechanisms. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 1041-1057.	1.1	30
541	Before or After: Evolving Neoadjuvant Approaches to Locally Advanced Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 5.	1.3	28
542	An esophagus-sparing technique to limit radiation esophagitis in locally advanced non-small cell lung cancer treated by simultaneous integrated boost intensity-modulated radiotherapy and concurrent chemotherapy. <i>Radiation Oncology</i> , 2018, 13, 130.	1.2	21
543	Cardiotoxicity associated with radiotherapy in breast cancer: A question-based review with current literatures. <i>Cancer Treatment Reviews</i> , 2018, 68, 9-15.	3.4	47
544	Variations in Initiation Dates of Chemotherapy and Radiation Therapy for Definitive Management of Inoperable Non-Small Cell Lung Cancer Are Associated With Decreases in Overall Survival. <i>Clinical Lung Cancer</i> , 2018, 19, e381-e390.	1.1	3
545	Salvage thoracic surgery in patients with lung cancer: potential indications and benefits. <i>Journal of Cardiothoracic Surgery</i> , 2018, 13, 13.	0.4	15
546	Surgically Treated Unsuspected N2-Positive NSCLC: Role of Extent and Location of Lymph Node Metastasis. <i>Clinical Lung Cancer</i> , 2018, 19, 418-425.	1.1	6
547	Long term safety and visibility of a novel liquid fiducial marker for use in image guided radiotherapy of non-small cell lung cancer. <i>Clinical and Translational Radiation Oncology</i> , 2018, 13, 24-28.	0.9	13
548	TUSC3 accelerates cancer growth and induces epithelial-mesenchymal transition by upregulating claudin-1 in non-small-cell lung cancer cells. <i>Experimental Cell Research</i> , 2018, 373, 44-56.	1.2	11
549	Advances in proton therapy in lung cancer. <i>Therapeutic Advances in Respiratory Disease</i> , 2018, 12, 175346661878387.	1.0	38
550	Optimized radiotherapy to improve clinical outcomes for locally advanced lung cancer. <i>Radiation Oncology</i> , 2018, 13, 147.	1.2	12
551	Preliminary Results about Application of Intensity-Modulated Radiotherapy to Reduce Prophylactic Radiation Dose in Limited-Stage Small Cell Lung Cancer. <i>Journal of Cancer</i> , 2018, 9, 2625-2630.	1.2	9

#	ARTICLE	IF	CITATIONS
552	Systemic Treatment of Chest Tumors: Highlighting Some Differences Between Eastern and Western Countries. <i>Current Cancer Therapy Reviews</i> , 2018, 14, 120-136.	0.2	0
553	Use of high and very high dose radiotherapy after radical prostatectomy for prostate cancer in the United States. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 584-593.	2.0	4
555	Mucositis with anti-EGFR monoclonal antibody in cancer patients: a meta-analysis of randomized controlled trials. <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 718-727.	0.6	4
556	Is immune checkpoint inhibition part of standard therapy for stage III non-small cell lung cancer?. <i>Cancer</i> , 2018, 124, 2878-2880.	2.0	0
557	How much primary tumor metabolic volume reduction is required to improve outcome in stage III NSCLC after chemoradiotherapy? A single-centre experience. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 2103-2109.	3.3	11
558	An overview on personalisation of radiotherapy prescriptions in locally advanced non-small cell lung cancer: Are we there yet?. <i>Radiotherapy and Oncology</i> , 2018, 128, 520-533.	0.3	4
560	Gallic acid-coated silver nanoparticle alters the expression of radiation-induced epithelial-mesenchymal transition in non-small lung cancer cells. <i>Toxicology in Vitro</i> , 2018, 52, 170-177.	1.1	37
561	EGFR-directed monoclonal antibodies in combination with chemotherapy for treatment of non-small-cell lung cancer: an updated review of clinical trials and new perspectives in biomarkers analysis. <i>Cancer Treatment Reviews</i> , 2019, 72, 15-27.	3.4	37
562	What ¹⁸ F-FDG PET Response-Assessment Method Best Predicts Survival After Curative-Intent Chemoradiation in Non-Small Cell Lung Cancer: EORTC, PERCIST, Peter Mac Criteria, or Deauville Criteria?. <i>Journal of Nuclear Medicine</i> , 2019, 60, 328-334.	2.8	24
563	Heart V5 predicts cardiac events in unresectable lung cancer patients undergoing chemoradiation. <i>Journal of Thoracic Disease</i> , 2019, 11, 2229-2239.	0.6	7
564	Prevention, Diagnosis, and Management of Radiation-Associated Cardiac Disease. <i>Journal of the American College of Cardiology</i> , 2019, 74, 905-927.	1.2	95
565	Clinical Outcomes of the HIV Protease Inhibitor Nelfinavir With Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2019, 5, 1464.	3.4	28
567	<p></p>Association of lung and heart dose with survival in patients with non-small cell lung cancer underwent volumetric modulated arc therapy</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 6091-6098.	0.9	4
568	Locally advanced inoperable primary or recurrent non-small cell lung cancer treated with 4-week hypofractionated radiation therapy (3ÂGy/fraction). <i>Radiologia Medica</i> , 2019, 124, 1324-1332.	4.7	6
569	Dosimetric Predictors of Cardiotoxicity in Thoracic Radiotherapy for Lung Cancer. <i>Clinical Lung Cancer</i> , 2019, 20, 435-441.	1.1	19
570	Lymphopenia as a predictor of survival in chemoradiation-treated stage III non-small-cell lung cancer (NSCLC): a multi-center retrospective analysis. <i>Journal of Radiation Oncology</i> , 2019, 8, 163-170.	0.7	1
571	The role of NLRP3 inflammasome activation in radiation damage. <i>Biomedicine and Pharmacotherapy</i> , 2019, 118, 109217.	2.5	50
572	Long-Term Benefits of Dose-Escalation in Localized Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 798-800.	0.4	6

#	ARTICLE	IF	CITATIONS
573	Impact of Radiation Dose to the Host Immune System on Tumor Control and Survival for Stage III Non-Small Cell Lung Cancer Treated with Definitive Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 346-355.	0.4	115
574	Patient-reported lung symptoms and quality of life before and after radiation therapy for non-small cell lung cancer: correlation with radiation pneumonitis and functional imaging. <i>Acta Oncol</i> , 2019, 58, 1523-1527.	0.8	8
575	Significance of overall concurrent chemoradiotherapy duration on survival outcomes of stage IIIB/C non-small-cell lung carcinoma patients: Analysis of 956 patients. <i>PLoS ONE</i> , 2019, 14, e0218627.	1.1	9
576	Surgery after Chemoradiotherapy in Patients with Stage III (n2 or N3, Excluding T4) Non-Small-Cell Lung Cancer: A Systematic Review. <i>Current Oncology</i> , 2019, 26, 398-404.	0.9	7
577	Optimising efficacy and reducing toxicity of anticancer radioimmunotherapy. <i>Lancet Oncology</i> , The, 2019, 20, e452-e463.	5.1	150
578	Synchronous Oligometastatic Non-small Cell Lung Cancer Managed With Curative-Intent Chemoradiation Therapy: Long-term Outcomes From a Single Institution. <i>Advances in Radiation Oncology</i> , 2019, 4, 541-550.	0.6	6
579	Accelerated hypofractionated radiotherapy plus chemotherapy for inoperable locally advanced non-small-cell lung cancer: final results of a prospective phase-II trial with a long-term follow-up. <i>Radiation Oncology</i> , 2019, 14, 112.	1.2	16
580	The radiation dose tolerance of the brachial plexus: A systematic review and meta-analysis. <i>Clinical and Translational Radiation Oncology</i> , 2019, 18, 23-31.	0.9	26
581	Vertebral body irradiation during chemoradiation therapy for esophageal cancer contributes to acute bone marrow toxicity. <i>Journal of Gastrointestinal Oncology</i> , 2019, 10, 513-522.	0.6	9
582	An investigative expansion of a competing risk model for first failure site in locally advanced non-small cell lung cancer. <i>Acta Oncol</i> , 2019, 58, 1386-1392.	0.8	6
583	EGFR Targeted Therapy. <i>Current Cancer Research</i> , 2019, , 1-30.	0.2	2
584	Dose to the cardio-pulmonary system and treatment-induced electrocardiogram abnormalities in locally advanced non-small cell lung cancer. <i>Clinical and Translational Radiation Oncology</i> , 2019, 19, 96-102.	0.9	16
585	The transformation of radiation oncology using real-time magnetic resonance guidance: A review. <i>European Journal of Cancer</i> , 2019, 122, 42-52.	1.3	136
587	Proton therapy for non-small cell lung cancer: the road ahead. <i>Translational Lung Cancer Research</i> , 2019, 8, S202-S212.	1.3	15
588	Is the Combination of Immunotherapy and Radiotherapy in Non-small Cell Lung Cancer a Feasible and Effective Approach?. <i>Frontiers in Medicine</i> , 2019, 6, 244.	1.2	31
589	Strengths and limitations of large databases in lung cancer radiation oncology research. <i>Translational Lung Cancer Research</i> , 2019, 8, S172-S183.	1.3	38
590	Management of locally advanced non-small cell lung cancer in the modern era: A national Italian survey on diagnosis, treatment and multidisciplinary approach. <i>PLoS ONE</i> , 2019, 14, e0224027.	1.1	5
591	Durvalumab for stage III non-small-cell lung cancer patients: clinical evidence and real-world experience. <i>Therapeutic Advances in Respiratory Disease</i> , 2019, 13, 175346661988553.	1.0	32

#	ARTICLE	IF	CITATIONS
592	Image-guided interstitial high-dose-rate brachytherapy for dose escalation in the radiotherapy treatment of locally advanced lung cancer: A single-institute experience. <i>Brachytherapy</i> , 2019, 18, 829-834.	0.2	6
593	Inclusiveness and ethical considerations for observational, translational, and clinical cancer health disparity research. <i>Cancer</i> , 2019, 125, 4452-4461.	2.0	17
594	Identification of FES as a novel radiosensitizing target in human cancers. <i>Clinical Cancer Research</i> , 2019, 26, clincanres.0610.2019.	3.2	3
595	PACIFIC: shifting tides in the treatment of locally advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2019, 8, S139-S146.	1.3	11
597	New frontiers in proton therapy: applications in cancers. <i>Cancer Communications</i> , 2019, 39, 1-7.	3.7	44
599	Immunotherapy in inoperable stage III non-small cell lung cancer: a review. <i>Drugs in Context</i> , 2019, 8, 1-6.	1.0	9
600	The Role of Additional Chemotherapy in Combination with Concurrent Chemoradiotherapy for Locally Advanced Inoperable Non-Small Cell Lung Cancer, a Systematic Review and Meta-Analysis of 12 Randomized Trials. <i>Cancer Investigation</i> , 2019, 37, 376-386.	0.6	6
601	Sparing Cardiac Substructures With Optimized Volumetric Modulated Arc Therapy and Intensity Modulated Proton Therapy in Thoracic Radiation for Locally Advanced Non-small Cell Lung Cancer. <i>Practical Radiation Oncology</i> , 2019, 9, e473-e481.	1.1	24
603	The evolving role of radiotherapy in non-small cell lung cancer. <i>British Journal of Radiology</i> , 2019, 92, 20190524.	1.0	88
604	Curative Radiotherapy for Non-small Cell Lung Cancer: Practice Changing and Changing Practice?. <i>Clinical Oncology</i> , 2019, 31, 678-680.	0.6	3
605	Daily Step Counts: A New Prognostic Factor in Locally Advanced Non-Small Cell Lung Cancer?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 745-751.	0.4	44
606	Dynamic Changes in Circulating Tumor DNA During Chemoradiation for Locally Advanced Lung Cancer. <i>Advances in Radiation Oncology</i> , 2019, 4, 748-752.	0.6	15
607	Changing equipoise in the landscape of radiation for oligometastatic lung cancer. <i>Translational Lung Cancer Research</i> , 2019, 8, S184-S191.	1.3	2
608	Organ sparing potential and inter-fraction robustness of adaptive intensity modulated proton therapy for lung cancer. <i>Acta Oncologica</i> , 2019, 58, 1775-1782.	0.8	11
609	PLK1 and EGFR targeted nanoparticle as a radiation sensitizer for non-small cell lung cancer. <i>Cancer Letters</i> , 2019, 467, 9-18.	3.2	50
611	Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib. <i>BMC Cancer</i> , 2019, 19, 901.	1.1	33
612	Treatment patterns and overall survival among patients with unresectable, stage III non-small-cell lung cancer. <i>Future Oncology</i> , 2019, 15, 3381-3393.	1.1	13
613	Impact of unfavorable factors on outcomes among inoperable stage II-IV Nonsmall cell lung cancer patients treated with proton therapy. <i>Acta Oncologica</i> , 2019, 58, 313-319.	0.8	2

#	ARTICLE	IF	CITATIONS
614	Is stereotactic body radiotherapy for ultra-central lung tumor a feasible option? A systemic review and meta-analysis. <i>International Journal of Radiation Biology</i> , 2019, 95, 329-337.	1.0	31
615	Unmet Clinical Need in the Management of Locally Advanced Unresectable Lung Cancer: Treatment Strategies to Improve Patient Outcomes. <i>Advances in Therapy</i> , 2019, 36, 563-578.	1.3	10
616	Developing a New qPCR-Based System for Screening Mutation. <i>Small</i> , 2019, 15, e1805285.	5.2	6
617	Real-world outcomes in patients with unresected stage III non-small cell lung cancer. <i>Medical Oncology</i> , 2019, 36, 24.	1.2	21
618	Daily Lisinopril vs Placebo for Prevention of Chemoradiation-Induced Pulmonary Distress in Patients With Lung Cancer (Alliance MC1221): A Pilot Double-Blind Randomized Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 686-696.	0.4	15
619	Incorporation of the SUVmax Measured From FDG PET and Neutrophil-to-lymphocyte Ratio Improves Prediction of Clinical Outcomes in Patients With Locally Advanced Non-small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2019, 20, 412-419.	1.1	17
620	Comparison of efficacy and safety between simultaneous integrated boost intensity-modulated radiotherapy and conventional intensity-modulated radiotherapy in locally advanced non-small-cell lung cancer: a retrospective study. <i>Radiation Oncology</i> , 2019, 14, 106.	1.2	22
621	Trends and Patterns of Disparities in Burden of Lung Cancer in the United States, 1974-2015. <i>Frontiers in Oncology</i> , 2019, 9, 404.	1.3	19
622	Cardiac Radiation Dose, Cardiac Disease, and Mortality in Patients With Lung Cancer. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2976-2987.	1.2	163
623	Real-World Treatment of Stage III NSCLC: The Role of Trimodality Treatment in the Era of Immunotherapy. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1430-1439.	0.5	17
624	Prognostic significance of lung radiation dose in patients with esophageal cancer treated with neoadjuvant chemoradiotherapy. <i>Radiation Oncology</i> , 2019, 14, 85.	1.2	13
625	Radiation Toxicity in Lung Cancer Patients: The Heart of the Problem?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 590-592.	0.4	8
626	Impact of Esophageal Motion on Dosimetry and Toxicity With Thoracic Radiation Therapy. <i>Technology in Cancer Research and Treatment</i> , 2019, 18, 153303381984907.	0.8	6
627	Prognostic value of TIM-1 expression in human non-small-cell lung cancer. <i>Journal of Translational Medicine</i> , 2019, 17, 178.	1.8	16
628	Treatment-duration is related to changes in peripheral lymphocyte counts during definitive radiotherapy for unresectable stage III NSCLC. <i>Radiation Oncology</i> , 2019, 14, 86.	1.2	30
629	A novel approach for salvage treatment of non-small-cell lung cancer: percutaneous CT fluoroscopy-guided permanent seed brachytherapy for salvage treatment of lung cancer: long-term results of a case series. <i>Journal of Contemporary Brachytherapy</i> , 2019, 11, 174-179.	0.4	8
630	Toward personalized dose-prescription in locally advanced non-small cell lung cancer: Validation of published normal tissue complication probability models. <i>Radiotherapy and Oncology</i> , 2019, 138, 45-51.	0.3	27
631	Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer. <i>Lung Cancer</i> , 2019, 134, 259-267.	0.9	28

#	ARTICLE	IF	CITATIONS
632	Intrafractional Displacement of Cardiac Substructures Among Patients With Mediastinal Lymphoma or Lung Cancer. <i>Advances in Radiation Oncology</i> , 2019, 4, 500-506.	0.6	11
633	The impact of epidermal growth factor receptor mutations on the efficacy of definitive chemoradiotherapy in patients with locally advanced unresectable stage III non-small cell lung cancer: a systematic review and meta-analysis. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 533-539.	1.1	11
634	A preliminary experience of moderate-intensity stereotactic body radiation therapy for ultra-central lung tumor. <i>International Journal of Radiation Biology</i> , 2019, 95, 1287-1294.	1.0	4
635	Stop hedging your bets: reasons for non-adherence to a tri-modality regimen in the treatment of esophageal cancer in a multidisciplinary setting. <i>Journal of Gastrointestinal Oncology</i> , 2019, 10, 387-390.	0.6	2
636	Locally Advanced Non Small Cell Lung Cancer: The Case for Radiation Dose De-escalation in the Management of the Mediastinum. <i>Frontiers in Oncology</i> , 2019, 9, 283.	1.3	1
637	Early Detection of Recurrence in Patients With Locally Advanced Non-Small-Cell Lung Cancer via Circulating Tumor Cell Analysis. <i>Clinical Lung Cancer</i> , 2019, 20, 384-390.e2.	1.1	20
638	Heart and lung doses are independent predictors of overall survival in esophageal cancer after chemoradiotherapy. <i>Clinical and Translational Radiation Oncology</i> , 2019, 17, 17-23.	0.9	24
639	Influence of tumour laterality on patient survival in non-small cell lung cancer after radiotherapy. <i>Radiotherapy and Oncology</i> , 2019, 137, 71-76.	0.3	9
640	Salvage surgery after definitive chemo-radiotherapy for patients with Non-Small Cell Lung Cancer. <i>Lung Cancer</i> , 2019, 133, 117-122.	0.9	23
641	Anatomical Adaptation—Early Clinical Evidence of Benefit and Future Needs in Lung Cancer. <i>Seminars in Radiation Oncology</i> , 2019, 29, 274-283.	1.0	17
642	Synergistic effect of immunotherapy and radiotherapy in non-small cell lung cancer: current clinical trials and prospective challenges. <i>Precision Clinical Medicine</i> , 2019, 2, 57-70.	1.3	24
643	Preoperative chemotherapy and radiotherapy concomitant to cetuximab in resectable stage IIIB NSCLC: a multicentre phase 2 trial (SAKK 16/08). <i>British Journal of Cancer</i> , 2019, 120, 968-974.	2.9	7
644	Pre-hydration in cisplatin-based CCRT: Effects on tumour concentrations and treatment outcome. <i>Radiotherapy and Oncology</i> , 2019, 134, 30-36.	0.3	5
645	Landmark Trials in Oncology. , 2019, , .		0
646	SABR versus conventional fractionation regimens in NSCLC — Authors' reply. <i>Lancet Oncology</i> , The, 2019, 20, e232.	5.1	1
647	Combined Chemoradiotherapy-induced Weight Loss Decreases Survival in Locally Advanced Non-small Cell Lung Cancer Patients. <i>In Vivo</i> , 2019, 33, 955-961.	0.6	3
648	MEDIastinal Irradiation and CARDio-Toxic Effects (MEDICATE): Exploring the Relationship between Cardiac Irradiation and High Sensitivity Troponins. <i>Clinical Oncology</i> , 2019, 31, 479-485.	0.6	6
649	Real-world treatment patterns among patients with unresected stage III non-small-cell lung cancer. <i>Future Oncology</i> , 2019, 15, 2943-2953.	1.1	26

#	ARTICLE	IF	CITATIONS
650	Perspectives on treatment advances for stage III locally advanced unresectable non-small-cell lung cancer. <i>Current Oncology</i> , 2019, 26, .	0.9	15
651	The single nucleotide variant rs2868371 associates with the risk of mortality in non-small cell lung cancer patients: A multicenter prospective validation. <i>Radiotherapy and Oncology</i> , 2019, 136, 29-36.	0.3	8
652	Clinical outcomes after intensity-modulated proton therapy with concurrent chemotherapy for inoperable non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2019, 136, 136-142.	0.3	21
653	Targeting the Immunomodulatory CD73/Adenosine System to Improve the Therapeutic Gain of Radiotherapy. <i>Frontiers in Immunology</i> , 2019, 10, 698.	2.2	64
654	Prognostic value of delta inflammatory biomarker-based nomograms in patients with inoperable locally advanced NSCLC. <i>International Immunopharmacology</i> , 2019, 72, 395-401.	1.7	28
655	Generation of virtual lung single-photon emission computed tomography/CT fusion images for functional avoidance radiotherapy planning using machine learning algorithms. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2019, 63, 229-235.	0.9	5
656	Management of Locally Advanced Lung Cancer. , 2019, , 57-86.		1
657	A new standard of care for patients with surgically unresectable stage III non-small cell lung cancer. <i>Cancer</i> , 2019, 125, 2148-2153.	2.0	1
658	Rethinking pulmonary toxicity in advanced non-small cell lung cancer in the era of combining anti-PD-1/PD-L1 therapy with thoracic radiotherapy. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2019, 1871, 323-330.	3.3	18
659	Incidence and risk factors of interstitial lung disease of patients with head and neck cancer treated with cetuximab. <i>Head and Neck</i> , 2019, 41, 2574-2580.	0.9	9
660	Radiotherapy boost in patients with hypoxic lesions identified by 18F-FMISO PET/CT in non-small-cell lung carcinoma: can we expect a better survival outcome without toxicity? [RTEP5 long-term follow-up]. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1448-1456.	3.3	40
661	Multi-Institutional Validation of a Knowledge-Based Planning Model for Patients Enrolled in RTOG 0617: Implications for Plan Quality Controls in Cooperative Group Trials. <i>Practical Radiation Oncology</i> , 2019, 9, e218-e227.	1.1	21
662	Targeted therapy combined with thoracic radiotherapy for non-small cell lung cancer. <i>Journal of Radiation Oncology</i> , 2019, 8, 1-12.	0.7	0
663	Retrospective comparison of stereotactic body radiotherapy versus intensity-modulated radiotherapy for stage III ultra-central squamous non-small-cell lung cancer. <i>Future Oncology</i> , 2019, 15, 1855-1862.	1.1	7
664	In Regard to Gagliardi et Aal. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 219-220.	0.4	0
665	Cost of Acute and Follow-Up Care in Patients With Pre-Existing Psychiatric Diagnoses Undergoing Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 748-755.	0.4	5
667	Circulating microRNAs as biomarkers of radiation-induced cardiac toxicity in non-small-cell lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1635-1643.	1.2	24
668	Impact of EGFR Mutation and ALK Translocation on Recurrence Pattern After Definitive Chemoradiotherapy for Inoperable Stage III Non-squamous Non-small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2019, 20, e256-e264.	1.1	22

#	ARTICLE	IF	CITATIONS
669	Clinical Outcomes of Patients With Recurrent Lung Cancer Reirradiated With Proton Therapy on the Proton Collaborative Group and University of Florida Proton Therapy Institute Prospective Registry Studies. <i>Practical Radiation Oncology</i> , 2019, 9, 280-288.	1.1	31
670	Comparative efficacy and safety for different chemotherapy regimens used concurrently with thoracic radiation for locally advanced non-small cell lung cancer: a systematic review and network meta-analysis. <i>Radiation Oncology</i> , 2019, 14, 55.	1.2	16
671	Re-irradiation in locally recurrent lung cancer patients. <i>Strahlentherapie Und Onkologie</i> , 2019, 195, 725-733.	1.0	17
672	Individualized accelerated isotoxic concurrent chemo-radiotherapy for stage III non-small cell lung cancer: 5-Year results of a prospective study. <i>Radiotherapy and Oncology</i> , 2019, 135, 141-146.	0.3	21
673	The impact of right ventricular function on prognosis in patients with stage III non-small cell lung cancer after concurrent chemoradiotherapy. <i>International Journal of Cardiovascular Imaging</i> , 2019, 35, 1009-1017.	0.7	21
674	Is the Importance of Heart Dose Overstated in the Treatment of Non-Small Cell Lung Cancer? A Systematic Review of the Literature. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 582-589.	0.4	57
675	Delineation of a Cardiac Planning Organ-At-Risk Volume Using Real-Time Magnetic Resonance Imaging for Cardiac Protection in Thoracic and Breast Radiation Therapy. <i>Practical Radiation Oncology</i> , 2019, 9, e298-e306.	1.1	4
676	Health-related quality of life analysis in stage III melanoma patients treated with adjuvant dendritic cell therapy. <i>Clinical and Translational Oncology</i> , 2019, 21, 774-780.	1.2	7
677	Preclinical Evaluation of Dose-Volume Effects and Lung Toxicity Occurring In and Out-of-Field. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 1231-1240.	0.4	17
678	Pathologic nodal clearance and complete response following neoadjuvant chemoradiation for clinical N2 non-small cell lung cancer: Predictors and long-term outcomes. <i>Lung Cancer</i> , 2019, 130, 93-100.	0.9	15
679	Safety assessment of anticancer drugs in association with radiotherapy in metastatic malignant melanoma: a real-life report. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 881-892.	1.1	5
680	Novel Genomic-Based Strategies to Personalize Lymph Node Radiation Therapy. <i>Seminars in Radiation Oncology</i> , 2019, 29, 111-125.	1.0	4
681	The role of tumour volume as a prognostic factor in non-small cell lung cancer (NSCLC) patients treated with definitive radiotherapy. <i>Journal of Radiotherapy in Practice</i> , 2019, 18, 218-224.	0.2	1
682	Survival Outcomes From Concurrent Chemoradiation for Lung Cancer in Indian Patients are Comparable With Reported UK Outcomes. <i>Clinical Oncology</i> , 2019, 31, 265.	0.6	2
683	Radiochemotherapy combined with NK cell transfer followed by second-line PD-1 inhibition in a patient with NSCLC stage IIIb inducing long-term tumor control: a case study. <i>Strahlentherapie Und Onkologie</i> , 2019, 195, 352-361.	1.0	32
684	Integrating Small Animal Irradiators with Functional Imaging for Advanced Preclinical Radiotherapy Research. <i>Cancers</i> , 2019, 11, 170.	1.7	20
685	Identifying Prognostic Groups Using Machine Learning Tools in Patients Undergoing Chemoradiation for Inoperable Locally Advanced Nonsmall Cell Lung Carcinoma. <i>Asian Journal of Oncology</i> , 0, 05, 056-063.	0.2	0
686	Accelerated, Dose escalated, Sequential Chemoradiotherapy in Non-small-cell lung cancer (ADSCaN): a protocol for a randomised phase II study. <i>BMJ Open</i> , 2019, 9, e019903.	0.8	9

#	ARTICLE	IF	CITATIONS
687	The utilization patterns and comparative effectiveness of systemic therapy with high-dose thoracic radiotherapy or low-dose thoracic radiotherapy versus systemic therapy alone in newly diagnosed metastatic non-small cell lung cancer patients. <i>Journal of Radiation Oncology</i> , 2019, 8, 425-438.	0.7	0
688	Stereotactic radiotherapy in previously treated lung cancers—what are the risks?. <i>Therapeutic Radiology and Oncology</i> , 0, 3, 11-11.	0.2	0
689	Dosimetric Comparison of Lung-Sparing Radiation Therapy between Volumetric Arc Therapy and Helical Tomotherapy for Unresectable Malignant Pleural Mesothelioma. <i>BioMed Research International</i> , 2019, 2019, 1-7.	0.9	3
690	Interdisciplinary multimodality management of stage III nonsmall cell lung cancer. <i>European Respiratory Review</i> , 2019, 28, 190024.	3.0	47
691	Cancers bronchiques localement avancés ou inopérables: rôle de l'oncologue. <i>Revue Des Maladies Respiratoires Actualites</i> , 2019, 11, 265-277.	0.0	0
692	Cancers bronchiques de stade III: rôle de l'onco-radiothérapeute. <i>Revue Des Maladies Respiratoires Actualites</i> , 2019, 11, 278-289.	0.0	0
693	Cardiotoxicity of mediastinal radiotherapy. <i>Reports of Practical Oncology and Radiotherapy</i> , 2019, 24, 629-643.	0.3	24
694	Survival score to characterize prognosis in inoperable stage III NSCLC after chemoradiotherapy. <i>Translational Lung Cancer Research</i> , 2019, 8, 593-604.	1.3	12
695	Biomarker-Driven Oncology Clinical Trials: Key Design Elements, Types, Features, and Practical Considerations. <i>JCO Precision Oncology</i> , 2019, 3, 1-12.	1.5	36
696	Inhibition of AIM2 inflammasome-mediated pyroptosis by Andrographolide contributes to amelioration of radiation-induced lung inflammation and fibrosis. <i>Cell Death and Disease</i> , 2019, 10, 957.	2.7	110
697	Risk factors of grade ≥ 2 radiation pneumonitis after gemcitabine induction chemotherapy for patients with non-small cell lung cancer. <i>Radiation Oncology</i> , 2019, 14, 229.	1.2	13
698	Immune Checkpoint Inhibition in Non-metastatic Non-small Cell Lung Cancer: Chance for Cure?. <i>Drugs</i> , 2019, 79, 1937-1945.	4.9	4
699	Applying Non-Homogeneous Dose Optimization to Improve Conventionally Fractionated Radiation Plan Quality in Patients with Non-Small Cell Lung Cancer. <i>Practical Radiation Oncology</i> , 2019, 9, e591-e598.	1.1	0
700	Epigenetic targeting of DNA repair in lung cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 22429-22431.	3.3	5
701	Proton Therapy. <i>Hematology/Oncology Clinics of North America</i> , 2019, 33, 989-1009.	0.9	28
702	Cardiac Toxicity in Operable Esophageal Cancer Patients Treated With or Without Chemoradiation. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 662-667.	0.6	15
703	Quantification of global lung inflammation using volumetric 18F-FDG PET/CT parameters in locally advanced non-small-cell lung cancer patients treated with concurrent chemoradiotherapy. <i>Nuclear Medicine Communications</i> , 2019, 40, 618-625.	0.5	7
704	Radiation Modifiers. <i>Hematology/Oncology Clinics of North America</i> , 2019, 33, 1041-1055.	0.9	9

#	ARTICLE	IF	CITATIONS
705	A phase II study of concurrent nab-paclitaxel/carboplatin combined with thoracic radiotherapy in locally advanced squamous cell lung cancer. <i>Journal of Thoracic Disease</i> , 2019, 11, 4529-4537.	0.6	8
706	Heart-sparing volumetric modulated arc therapy for whole lung irradiation. <i>Strahlentherapie Und Onkologie</i> , 2019, 195, 77-82.	1.0	5
707	Combining Radiotherapy and Immunotherapy in Lung Cancer: Can We Expect Limitations Due to Altered Normal Tissue Toxicity?. <i>International Journal of Molecular Sciences</i> , 2019, 20, 24.	1.8	100
708	Combination of novel systemic agents and radiotherapy for solid tumors – Part II: An AIRO (Italian) Tj ETQq1 1 0.784314 rgBT /Over Reviews in Oncology/Hematology, 2019, 134, 104-119.	2.0	10
709	Soy Isoflavones Protect Normal Tissues While Enhancing Radiation Responses. <i>Seminars in Radiation Oncology</i> , 2019, 29, 62-71.	1.0	11
710	HELPER study: A phase II trial of continuous infusion of endostar combined with concurrent etoposide plus cisplatin and radiotherapy for treatment of unresectable stage III non-small-cell lung cancer. <i>Radiotherapy and Oncology</i> , 2019, 131, 27-34.	0.3	29
711	Porous platinum nanoparticles as a high-Z and oxygen generating nanozyme for enhanced radiotherapy in vivo. <i>Biomaterials</i> , 2019, 197, 12-19.	5.7	152
712	SPECT V/Q in Lung Cancer Radiotherapy Planning. <i>Seminars in Nuclear Medicine</i> , 2019, 49, 31-36.	2.5	11
713	SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018). <i>Clinical and Translational Oncology</i> , 2019, 21, 3-17.	1.2	110
714	Toxicity Related to Radiotherapy Dose and Targeting Strategy: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Locally Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, 298-303.	0.5	13
715	Doses of radiation to the pericardium, instead of heart, are significant for survival in patients with non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2019, 133, 213-219.	0.3	29
716	Impact of modern radiotherapy techniques on survival outcomes for unselected patients with large volume non-small cell lung cancer. <i>British Journal of Radiology</i> , 2019, 92, 20180928.	1.0	4
717	The risk variant rs884225 within EGFR impairs miR-103a-3p's anti-tumourigenic function in non-small cell lung cancer. <i>Oncogene</i> , 2019, 38, 2291-2304.	2.6	19
718	Health Outcomes for Definite Concurrent Chemoradiation in Locally Advanced Non-Small Cell Lung Cancer: A Prospective Study. <i>Respiration</i> , 2019, 97, 310-318.	1.2	12
719	Clinical outcomes of carbon ion radiotherapy for locally advanced non-small cell lung cancer. <i>Cancer Science</i> , 2019, 110, 734-741.	1.7	24
720	Predictors of Acute Radiation Esophagitis in Non-small Cell Lung Cancer Patients Treated With Accelerated Hyperfractionated Chemoradiotherapy. <i>Anticancer Research</i> , 2019, 39, 491-497.	0.5	9
721	Esophageal carcinosarcoma that disappeared pathologically by palliative radiotherapy alone. <i>Clinical Journal of Gastroenterology</i> , 2019, 12, 247-253.	0.4	6
722	Predicting tumor responses and patient survival in chemoradiotherapy-treated patients with non-small-cell lung cancer using dynamic contrast-enhanced integrated magnetic resonance-positron-emission tomography. <i>Strahlentherapie Und Onkologie</i> , 2019, 195, 707-718.	1.0	10

#	ARTICLE	IF	CITATIONS
723	Role of immunotherapy in stage III nonsmall cell lung cancer. <i>Current Opinion in Oncology</i> , 2019, 31, 18-23.	1.1	12
724	Post-treatment mortality after definitive chemoradiotherapy versus trimodality therapy for locally advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2019, 127, 76-83.	0.9	7
725	Phantom Verification of AAA and Acuros Dose Calculations for Lung Cancer: Do Tumor Size and Regression Matter?. <i>Practical Radiation Oncology</i> , 2019, 9, 29-37.	1.1	13
726	Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP). <i>Annals of Oncology</i> , 2019, 30, 161-165.	0.6	60
727	Cardio-oncology - strategies for management of cancer-therapy related cardiovascular disease. <i>International Journal of Cardiology</i> , 2019, 280, 163-175.	0.8	138
728	Targeting DNA Double-Strand Break Repair Pathways to Improve Radiotherapy Response. <i>Genes</i> , 2019, 10, 25.	1.0	111
729	Prognostic and Added Value of Echocardiographic Strain for Prediction of Adverse Outcomes in Patients with Locally Advanced Non-Small Cell Lung Cancer after Radiotherapy. <i>Ultrasound in Medicine and Biology</i> , 2019, 45, 98-107.	0.7	12
730	Low- vs. High-Dose Neoadjuvant Radiation in Trimodality Treatment of Locally Advanced Esophageal Cancer. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 885-894.	0.9	21
731	Development and validation of a decision support tool to select IMRT as radiotherapy treatment planning modality for patients with locoregionally advanced non-small cell lung cancers (NSCLC). <i>British Journal of Radiology</i> , 2019, 92, 20180431.	1.0	1
732	Automatic segmentation of cardiac substructures from noncontrast CT images: accurate enough for dosimetric analysis?. <i>Acta Oncologica</i> , 2019, 58, 81-87.	0.8	18
733	The acute and late toxicity results of a randomized phase II dose-escalation trial in non-small cell lung cancer (PET-boost trial). <i>Radiotherapy and Oncology</i> , 2019, 131, 166-173.	0.3	59
734	Combination of novel systemic agents and radiotherapy for solid tumors – part I: An AIRO (Italian) Tj ETQq1 1 0.784314 rgBT /Over Reviews in <i>Oncology/Hematology</i> , 2019, 134, 87-103.	2.0	7
735	A prospective study of the feasibility of FDG-PET/CT imaging to quantify radiation-induced lung inflammation in locally advanced non-small cell lung cancer patients receiving proton or photon radiotherapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 206-216.	3.3	21
736	Association of Target Volume Margins With Locoregional Control and Acute Toxicities for Non-small cell lung cancer Treated With Concurrent Chemoradiation Therapy. <i>Practical Radiation Oncology</i> , 2019, 9, e74-e82.	1.1	9
737	Adjuvant Therapy in Patients With Completely Resected Non-small-cell Lung Cancer: Current Status and Perspectives. <i>Clinical Lung Cancer</i> , 2019, 20, 1-6.	1.1	36
738	Reasoning the effect of immunotherapy after chemoradiation in the PACIFIC trial. <i>Future Oncology</i> , 2019, 15, 81-94.	1.1	2
739	Analysis of Relapse Events After Definitive Chemoradiotherapy in Locally Advanced Non-small-Cell Lung Cancer Patients. <i>Clinical Lung Cancer</i> , 2019, 20, e1-e7.	1.1	14
740	Inhibition of NF- κ B improves sensitivity to irradiation and EGFR-TKIs and decreases irradiation-induced lung toxicity. <i>International Journal of Cancer</i> , 2019, 144, 200-209.	2.3	13

#	ARTICLE	IF	CITATIONS
741	Debulking Surgery Plus Radiation: Treatment Choice for Unresectable Stage III Thymic Carcinoma. Thoracic and Cardiovascular Surgeon, 2020, 68, 440-445.	0.4	3
742	Multidisciplinary consensus statement on the clinical management of patients with stage III non-small cell lung cancer. Clinical and Translational Oncology, 2020, 22, 21-36.	1.2	39
743	Pulmonary Complications of Anticancer Treatment. , 2020, , 715-724.e2.		1
744	Master Protocol Trial Design for Efficient and Rational Evaluation of Novel Therapeutic Oncology Devices. Journal of the National Cancer Institute, 2020, 112, 229-237.	3.0	15
745	Early Outcomes of Patients With Locally Advanced Non-small Cell Lung Cancer Treated With Intensity-Modulated Proton Therapy Versus Intensity-Modulated Radiation Therapy: The Mayo Clinic Experience. Advances in Radiation Oncology, 2020, 5, 450-458.	0.6	18
746	Radical accelerated radiotherapy for non-small cell lung cancer (NSCLC): A 5-year retrospective review of two dose fractionation schedules. Radiotherapy and Oncology, 2020, 143, 37-43.	0.3	18
747	Multifactorial risk factors for mortality after chemotherapy and radiotherapy for non-small cell lung cancer. Radiotherapy and Oncology, 2020, 152, 117-125.	0.3	19
748	Proton therapy for locally advanced non-small cell lung cancer. British Journal of Radiology, 2020, 93, 20190378.	1.0	15
749	Comparison of Hypermetabolic and Hypoxic Volumes Delineated on [18F]FDG and [18F]Fluoromisonidazole PET/CT in Non-small-cell Lung Cancer Patients. Molecular Imaging and Biology, 2020, 22, 764-771.	1.3	6
750	Differences Between the East and the West in Managing Advanced-Stage Non-small Cell Lung Cancer. Clinical Oncology, 2020, 32, e1-e9.	0.6	6
751	Pulmonary function changes following helical tomotherapy in patients with inoperable, locally advanced non-small cell lung cancer. Strahlentherapie Und Onkologie, 2020, 196, 142-150.	1.0	6
752	Cancer of the Lung. , 2020, , 1108-1158.e16.		11
753	Radioresistance of KRAS/TP53-mutated lung cancer can be overcome by radiation dose escalation or EGFR tyrosine kinase inhibition in vivo. International Journal of Cancer, 2020, 147, 472-477.	2.3	36
754	Proton vs photon: A model-based approach to patient selection for reduction of cardiac toxicity in locally advanced lung cancer. Radiotherapy and Oncology, 2020, 152, 151-162.	0.3	22
755	SBRT combined with concurrent chemoradiation in stage III NSCLC: Feasibility study of the phase I Hybrid trial. Radiotherapy and Oncology, 2020, 142, 224-229.	0.3	7
756	Chemoradiotherapy of locally-advanced non-small cell lung cancer: Analysis of radiation dose-response, chemotherapy and survival-limiting toxicity effects indicates a low $\hat{\mu}/\hat{\sigma}^2$ ratio. Radiotherapy and Oncology, 2020, 143, 58-65.	0.3	11
757	Impact of histology on patterns of failure and clinical outcomes in patients treated with definitive chemoradiotherapy for locally advanced non-small cell lung cancer. International Journal of Clinical Oncology, 2020, 25, 274-281.	1.0	7
758	Survival outcomes in patients with gastric and gastroesophageal junction adenocarcinomas treated with perioperative chemotherapy with or without preoperative radiotherapy. Cancer, 2020, 126, 37-45.	2.0	11

#	ARTICLE	IF	CITATIONS
759	Early Tumor and Nodal Response in Patients with Locally Advanced Non-Small Cell Lung Carcinoma Predict for Oncologic Outcomes in Patients Treated with Concurrent Proton Therapy and Chemotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 358-368.	0.4	6
760	Safety and efficacy of reduced dose and margins to involved lymph node metastases in locally advanced NSCLC patients. <i>Radiotherapy and Oncology</i> , 2020, 143, 66-72.	0.3	9
761	Are unsatisfactory outcomes after concurrent chemoradiotherapy for locally advanced non-small cell lung cancer due to treatment-related immunosuppression?. <i>Radiotherapy and Oncology</i> , 2020, 143, 51-57.	0.3	16
762	Isoflavone-mediated radioprotection involves regulation of early endothelial cell death and inflammatory signaling in Radiation-Induced lung injury. <i>International Journal of Radiation Biology</i> , 2020, 96, 245-256.	1.0	18
763	Comparison of the effects of radiotherapy doses of 50.4ÂGy and 60ÂGy on outcomes of chemoradiotherapy for thoracic esophageal cancer: subgroup analysis based on the Comprehensive Registry of Esophageal Cancer in Japan from 2009 to 2011 by the Japan Esophageal Society. <i>Esophagus</i> , 2020, 17, 122-126.	1.0	12
764	Phase II Study of Preoperative Chemoradiotherapy with Oxaliplatin, Infusional 5-Fluorouracil, and Cetuximab Followed by Postoperative Docetaxel and Cetuximab in Patients with Adenocarcinoma of the Esophagus: A Trial of the ECOG-ACRIN Cancer Research Group (E2205). <i>Oncologist</i> , 2020, 25, e53-e59.	1.9	6
765	High dose radiation therapy based on normal tissue constraints with concurrent chemotherapy achieves promising survival of patients with unresectable stage III non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2020, 145, 7-12.	0.3	5
766	Comparative Effectiveness of Proton vs Photon Therapy as Part of Concurrent Chemoradiotherapy for Locally Advanced Cancer. <i>JAMA Oncology</i> , 2020, 6, 237.	3.4	106
767	Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Nonâ€Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 706-714.	0.8	340
768	Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 324-343.	0.5	34
770	The impact of baseline shifts towards the heart after image guidance on survival in lung SABR patients. <i>Radiotherapy and Oncology</i> , 2020, 152, 183-188.	0.3	12
771	Cardiac toxicity of lung cancer radiotherapy. <i>Reports of Practical Oncology and Radiotherapy</i> , 2020, 25, 13-19.	0.3	17
772	Oesophageal Cancer: Conformal Radiotherapy <i>vs.</i> Hybrid-VMAT Technique With Two Different Treatment Planning Systems. <i>In Vivo</i> , 2020, 34, 331-337.	0.6	0
773	Nitroglycerin as a radiosensitizer in non-small cell lung cancer: Results of a prospective imaging-based phase II trial. <i>Clinical and Translational Radiation Oncology</i> , 2020, 21, 49-55.	0.9	11
774	Cardiac substructure segmentation with deep learning for improved cardiac sparing. <i>Medical Physics</i> , 2020, 47, 576-586.	1.6	61
775	Cardiac Dose in Locally Advanced Lung Cancer: Results From a Statewide Consortium. <i>Practical Radiation Oncology</i> , 2020, 10, e27-e36.	1.1	12
776	Acute severe radiation pneumonitis among non-small cell lung cancer (NSCLC) patients with moderate pulmonary dysfunction receiving definitive concurrent chemoradiotherapy: Impact of pre-treatment pulmonary function parameters. <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 505-514.	1.0	24
777	Treatment planning for non-small cell lung tumours: VMAT versus 3DCRT a quantitative dosimetric study. <i>Journal of Radiotherapy in Practice</i> , 2020, 19, 327-332.	0.2	0

#	ARTICLE	IF	CITATIONS
778	The evolving use of pembrolizumab in combination treatment approaches for non-small cell lung cancer. <i>Expert Review of Respiratory Medicine</i> , 2020, 14, 137-147.	1.0	6
779	Phase II study of vinorelbine plus carboplatin with concurrent radiotherapy in elderly patients with non-small cell lung cancer. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 318-324.	0.6	1
780	Lung Cancer Surveillance After Definitive Curative-Intent Therapy: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2020, 38, 753-766.	0.8	100
781	The Evolution (and Future) of Stereotactic Body Radiotherapy in the Treatment of Oligometastatic Disease. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 307-320.	0.9	11
782	“Dose of the day” based on cone beam computed tomography and deformable image registration for lung cancer radiotherapy. <i>Journal of Applied Clinical Medical Physics</i> , 2020, 21, 88-94.	0.8	16
783	Real-world incidence and cost of pneumonitis post-chemoradiotherapy for Stage III non-small-cell lung cancer. <i>Future Oncology</i> , 2020, 16, 4303-4313.	1.1	6
784	Long-Term Results from the IDEAL-CRT Phase 1/2 Trial of Isotoxically Dose-Escalated Radiation Therapy and Concurrent Chemotherapy for Stage II/III Non-small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 733-742.	0.4	14
785	Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach. <i>Clinical Lung Cancer</i> , 2020, 21, 136-144.e1.	1.1	9
786	Radiation Therapy for Thoracic Malignancies. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 109-125.	0.9	7
787	Lung organ at risk volumes: A survey of practice and the need for a consistent definition in the 4DCT era. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2020, 64, 120-126.	0.9	1
788	Utilization and factors precluding the initiation of consolidative durvalumab in unresectable stage III non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2020, 144, 101-104.	0.3	21
789	Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 248-257.	0.5	97
790	Local and regional treatment response by 18FDG-PET-CT-scans 4 weeks after concurrent hypofractionated chemoradiotherapy in locally advanced NSCLC. <i>Radiotherapy and Oncology</i> , 2020, 143, 30-36.	0.3	7
791	Image-guidance triggered adaptive replanning of radiation therapy for locally advanced lung cancer: an evaluation of cases requiring plan adaptation. <i>British Journal of Radiology</i> , 2020, 93, 20190743.	1.0	13
792	Pulmonary function decreases moderately after accelerated high-dose irradiation for stage III non-small cell lung cancer. <i>Thoracic Cancer</i> , 2020, 11, 369-378.	0.8	12
793	Cardiac radiation dose predicts survival in esophageal squamous cell carcinoma treated by definitive concurrent chemotherapy and intensity modulated radiotherapy. <i>Radiation Oncology</i> , 2020, 15, 221.	1.2	8
794	Optimal radiation dose in the neoadjuvant management of esophageal cancer. <i>Journal of Thoracic Disease</i> , 2020, 12, 4568-4570.	0.6	3
795	<i>KEAP1/NFE2L2</i> Mutations Predict Lung Cancer Radiation Resistance That Can Be Targeted by Glutaminase Inhibition. <i>Cancer Discovery</i> , 2020, 10, 1826-1841.	7.7	93

#	ARTICLE	IF	CITATIONS
796	Early response evaluation using primary tumor and nodal imaging features to predict progression-free survival of locally advanced non-small cell lung cancer. <i>Theranostics</i> , 2020, 10, 11707-11718.	4.6	32
797	Heart dose linked with cardiac events and overall survival in lung cancer radiotherapy. <i>Medicine (United States)</i> , 2020, 99, e21964.	0.4	13
798	Radiotherapy Dose and Induction Chemotherapy Cycles Are Associated With Prognosis and Toxicity Risk: A Retrospective Study of 227 Patients With Unresectable Stage III Non-Small-Cell Lung Cancer. <i>Technology in Cancer Research and Treatment</i> , 2020, 19, 153303382095180.	0.8	4
799	A phase II study of daily carboplatin plus irradiation followed by durvalumab for stage III non-small cell lung cancer patients with PS 2 up to 74 years old and patients with PS 0 or 1 from 75 years: NEJ039A 1.1 (trial in progress). <i>BMC Cancer</i> , 2020, 20, 961.		3
800	Dose surface maps of the heart can identify regions associated with worse survival for lung cancer patients treated with radiotherapy. <i>Physics and Imaging in Radiation Oncology</i> , 2020, 15, 46-51.	1.2	19
801	Impact of chemoradiotherapy on the immune-related tumour microenvironment and efficacy of anti-PD-(L)1 therapy for recurrences after chemoradiotherapy in patients with unresectable locally advanced non-small cell lung cancer. <i>European Journal of Cancer</i> , 2020, 140, 28-36.	1.3	17
802	Predictive value of vascular calcification identified in 4D planning CT of lung cancer patients treated with stereotactic body radiation therapy. <i>Physica Medica</i> , 2020, 78, 173-178.	0.4	5
804	Cancers bronchiques localement avancés ou inopérables stades III : le rôle du pneumo-oncologue. <i>Revue Des Maladies Respiratoires Actualites</i> , 2020, 12, 2S117-2S131.	0.0	0
805	PET and MRI guided adaptive radiotherapy: Rational, feasibility and benefit. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2020, 24, 635-644.	0.6	7
806	Development and application of an elastic net logistic regression model to investigate the impact of cardiac substructure dose on radiation-induced pericardial effusion in patients with NSCLC. <i>Acta Oncologica</i> , 2020, 59, 1193-1200.	0.8	6
807	Outcomes of Hypofractional Tomotherapy in Patients with Stage III Nonsmall Cell Lung Cancer Who Are Not Eligible for Surgery or Concurrent Chemoradiation. <i>BioMed Research International</i> , 2020, 2020, 1-8.	0.9	0
808	Stereotactic Body Radiation Therapy to a Splenic Metastasis in Oligoprogressive Non-small Cell Lung Cancer. <i>Advances in Radiation Oncology</i> , 2020, 5, 516-521.	0.6	0
809	Potential Functional Variants in DNA Repair Genes Are Associated with Efficacy and Toxicity of Radiotherapy in Patients with Non-Small-Cell Lung Cancer. <i>Journal of Oncology</i> , 2020, 2020, 1-7.	0.6	9
810	Neoadjuvant Four-Drug Combination Therapy for NSCLC With EGFR Mutation Avoiding Total Pneumonectomy. <i>Frontiers in Oncology</i> , 2020, 10, 1145.	1.3	0
811	Jarring Discordance Between Idealized and Real-World Management in Stage III Non-Small-Cell Lung Cancer. <i>JCO Oncology Practice</i> , 2020, 16, 628-630.	1.4	3
812	Hypofractionated Accelerated Concurrent Chemoradiotherapy in Inoperable Stage III Non-small Cell Lung Cancer: SOCCAR. A Large Single-Centre Experience. <i>Clinical Oncology</i> , 2020, 32, e211.	0.6	1
813	The changing landscape of stage III lung cancer: a literature review. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 675-686.	1.1	3
814	Host CD39 Deficiency Affects Radiation-Induced Tumor Growth Delay and Aggravates Radiation-Induced Normal Tissue Toxicity. <i>Frontiers in Oncology</i> , 2020, 10, 554883.	1.3	3

#	ARTICLE	IF	CITATIONS
815	A narrative review of toxicity of chemoradiation and immunotherapy for unresectable, locally advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2020, 9, 2040-2050.	1.3	6
816	Radiotherapy for non-small cell lung cancer in the immunotherapy era: the opportunity and challenge—a narrative review. <i>Translational Lung Cancer Research</i> , 2020, 9, 2120-2136.	1.3	16
817	Efficacy and Toxicity of Different Chemotherapy Protocols for Concurrent Chemoradiation in Non-Small Cell Lung Cancer—A Secondary Analysis of the PET Plan Trial. <i>Cancers</i> , 2020, 12, 3359.	1.7	3
818	Radiotherapy for unresectable locally advanced non-small cell lung cancer: a narrative review of the current landscape and future prospects in the era of immunotherapy. <i>Translational Lung Cancer Research</i> , 2020, 9, 2097-2112.	1.3	5
819	A narrative review of synergistic drug administration in unresectable locally advanced non-small cell lung cancer: current landscape and future prospects in the era of immunotherapy. <i>Translational Lung Cancer Research</i> , 2020, 9, 2082-2096.	1.3	4
820	Consolidation Immunotherapy After Platinum-Based Chemoradiotherapy in Patients With Unresectable Stage III Non-Small Cell Lung Cancer—Cross-Sectional Study of Eligibility and Administration Rates. <i>Frontiers in Oncology</i> , 2020, 10, 586449.	1.3	15
822	<p>Sparing Organs at Risk with Simultaneous Integrated Boost Volumetric Modulated Arc Therapy for Locally Advanced Non-Small Cell Lung Cancer: An Automatic Treatment Planning Study</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 9643-9653.	0.9	1
823	Dose-Dependent Radiation-Induced Myocardial Damage in Esophageal Cancer Treated With Chemoradiotherapy: A Prospective Cardiac Magnetic Resonance Imaging Study. <i>Advances in Radiation Oncology</i> , 2020, 5, 1170-1178.	0.6	9
825	The Promising Treatment Schedule of Concurrent Chemoradiotherapy for Stage III Non-small Cell Lung Cancer: Alternative for Conventional Fractionation Using Mathematical Analysis. <i>Anticancer Research</i> , 2020, 40, 4095-4104.	0.5	2
826	Immunoradiotherapy as an Effective Therapeutic Strategy in Lung Cancer: From Palliative Care to Curative Intent. <i>Cancers</i> , 2020, 12, 2178.	1.7	25
827	Immuno-based therapeutic strategies for initial unresectable locally advanced non-small cell lung cancer: a case report. <i>Translational Lung Cancer Research</i> , 2020, 9, 803-806.	1.3	2
828	A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN 14—179. <i>Cancer</i> , 2020, 126, 4353-4361.	2.0	100
829	Precision radiotherapy for non-small cell lung cancer. <i>Journal of Biomedical Science</i> , 2020, 27, 82.	2.6	37
830	Combinatorial drug therapy in cancer - New insights. <i>Life Sciences</i> , 2020, 258, 118134.	2.0	31
831	<p>Combined Therapeutic Effects of ¹³¹ I-Labeled and 5Fu-Loaded Multifunctional Nanoparticles in Colorectal Cancer</p>. <i>International Journal of Nanomedicine</i> , 2020, Volume 15, 2777-2787.	3.3	13
832	MED13L integrates Mediator-regulated epigenetic control into lung cancer radiosensitivity. <i>Theranostics</i> , 2020, 10, 9378-9394.	4.6	20
833	Technical Challenges of Heart Avoidance for Synchronous Breast and Lung Cancers in a Postmenopausal Female: A Planning Case Report From a Safety-Net Hospital. <i>Advances in Radiation Oncology</i> , 2020, 5, 1076-1082.	0.6	0
834	Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non-Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508). <i>Clinical Lung Cancer</i> , 2020, 21, 520-526.	1.1	8

#	ARTICLE	IF	CITATIONS
835	Re-irradiation in the thorax – An analysis of efficacy and safety based on accumulated EQD2 doses. <i>Radiotherapy and Oncology</i> , 2020, 152, 56-62.	0.3	19
836	A Prospective Study of Early Radiation Associated Cardiac Toxicity Following Neoadjuvant Chemoradiation for Distal Esophageal Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 1169.	1.3	11
837	Higher Dose Volumes May Be Better for Evaluating Radiation Pneumonitis in Lung Proton Therapy Patients Compared With Traditional Photon-Based Dose Constraints. <i>Advances in Radiation Oncology</i> , 2020, 5, 943-950.	0.6	6
838	Factors associated with treatment receipt and overall survival for patients with locally advanced large cell neuroendocrine carcinoma of the lung: A National Cancer Database analysis. <i>Lung Cancer</i> , 2020, 150, 107-113.	0.9	12
839	Intermediate Dose-Volume Parameters, Not Low-Dose Bath, Is Superior to Predict Radiation Pneumonitis for Lung Cancer Treated With Intensity-Modulated Radiotherapy. <i>Frontiers in Oncology</i> , 2020, 10, 584756.	1.3	8
840	Functional lung volume mapping with perfusion Single-Photon Emission Computed Tomography scan for radiotherapy planning in patients with locally advanced nonsmall cell lung cancer. <i>Nuclear Medicine Communications</i> , 2020, 41, 1026-1033.	0.5	0
841	Association of Planning Target Volume with Patient Outcome in Inoperable Stage III NSCLC Treated with Chemoradiotherapy: A Comprehensive Single-Center Analysis. <i>Cancers</i> , 2020, 12, 3035.	1.7	10
842	Study protocol: a multicentre, prospective, phase II trial of isotoxic hypofractionated concurrent chemoradiotherapy for non-small cell lung cancer. <i>BMJ Open</i> , 2020, 10, e036295.	0.8	2
843	¹²⁵ I Seed Brachytherapy Combined with Single-Agent Chemotherapy in the Treatment of Non-Small-Cell Lung Cancer in the Elderly: A Valuable Solution. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 10581-10591.	1.0	4
844	Multidisciplinary team discussion results in survival benefit for patients with stage III non-small-cell lung cancer. <i>PLoS ONE</i> , 2020, 15, e0236503.	1.1	25
845	European Cancer Organisation Essential Requirements for Quality Cancer Care (ERQCC): Lung cancer. <i>Lung Cancer</i> , 2020, 150, 221-239.	0.9	32
846	PET-Plan: potential for dose escalation by target volume reduction in locally advanced NSCLC. <i>Translational Lung Cancer Research</i> , 2020, 9, 1595-1598.	1.3	0
847	Contemporary Understandings of Cardiovascular Disease After Cancer Radiotherapy: a Focus on Ischemic Heart Disease. <i>Current Cardiology Reports</i> , 2020, 22, 151.	1.3	5
848	Impact of Radiation Dose on Survival for Esophageal Squamous Cell Carcinoma Treated With Neoadjuvant Chemoradiotherapy. <i>Frontiers in Oncology</i> , 2020, 10, 1431.	1.3	13
849	Efficacy and safety of immune checkpoint inhibitor consolidation after chemoradiation in patients of Asian ethnicity with unresectable stage III non-small cell lung cancer: Chinese multicenter report and literature review. <i>Thoracic Cancer</i> , 2020, 11, 2916-2923.	0.8	7
850	Efficacy and safety of recombinant human endostatin combined with radiotherapy or chemoradiotherapy in patients with locally advanced non-small cell lung cancer: a pooled analysis. <i>Radiation Oncology</i> , 2020, 15, 205.	1.2	10
851	Risk Stratification of Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with Chemo-Radiotherapy: An Institutional Analysis. <i>Cancer Management and Research</i> , 2020, Volume 12, 7165-7171.	0.9	2
852	Exploring the Relationship of Radiation Dose Exposed to the Length of Esophagus and Weight Loss in Patients with Lung Cancer. <i>Practical Radiation Oncology</i> , 2020, 10, 255-264.	1.1	6

#	ARTICLE	IF	CITATIONS
853	Simultaneous integrated boost of intensity-modulated radiation therapy to Stage II-III non-small cell lung cancer with metastatic lymph nodes. <i>Cancer Medicine</i> , 2020, 9, 8364-8372.	1.3	4
854	Paclitaxel Promotes Tumor-Infiltrating Macrophages in Breast Cancer. <i>Technology in Cancer Research and Treatment</i> , 2020, 19, 153303382094582.	0.8	4
855	Cone-Beam-CT Guided Adaptive Radiotherapy for Locally Advanced Non-small Cell Lung Cancer Enables Quality Assurance and Superior Sparing of Healthy Lung. <i>Frontiers in Oncology</i> , 2020, 10, 564857.	1.3	19
856	Rationale for concurrent chemoradiotherapy for patients with stage III non-small-cell lung cancer. <i>British Journal of Cancer</i> , 2020, 123, 10-17.	2.9	25
857	Practical implications to contemplate when considering radical therapy for stage III non-small-cell lung cancer. <i>British Journal of Cancer</i> , 2020, 123, 28-35.	2.9	8
858	Proton beam radiotherapy for esophagus cancer: state of the art. <i>Journal of Thoracic Disease</i> , 2020, 12, 7002-7010.	0.6	4
859	Beyond chemoradiotherapy: improving treatment outcomes for patients with stage III unresectable non-small-cell lung cancer through immuno-oncology and durvalumab (Imfinzi® [®] , AstraZeneca UK) Tj ETQq0 02orgBT /Owlock 10		
860	Radiomics: an overview in lung cancer management—a narrative review. <i>Annals of Translational Medicine</i> , 2020, 8, 1191-1191.	0.7	18
861	Association of Pre- and Posttreatment Neutrophil-Lymphocyte Ratio With Recurrence and Mortality in Locally Advanced Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 598873.	1.3	16
862	Is pneumonectomy justifiable for patients with a locoregional recurrence or persistent disease after curative intent chemoradiotherapy for locally advanced non-small cell lung cancer?. <i>Lung Cancer</i> , 2020, 150, 209-215.	0.9	2
863	Heart substructural dosimetric parameters and risk of cardiac events after definitive chemoradiotherapy for stage III non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2020, 152, 126-132.	0.3	14
865	Accelerated hypofractionated radiotherapy with concurrent full dose chemotherapy for locally advanced non-small cell lung cancer: A phase I/II study. <i>Radiotherapy and Oncology</i> , 2020, 148, 174-180.	0.3	18
866	Enhancing Targeted Cancer Treatment by Combining Hyperthermia and Radiotherapy Using Mn-Zn Ferrite Magnetic Nanoparticles. <i>ACS Biomaterials Science and Engineering</i> , 2020, 6, 3550-3562.	2.6	35
867	Machine learning highlights the deficiency of conventional dosimetric constraints for prevention of high-grade radiation esophagitis in non-small cell lung cancer treated with chemoradiation. <i>Clinical and Translational Radiation Oncology</i> , 2020, 22, 69-75.	0.9	9
868	Salvage surgery after chemotherapy and/or radiotherapy including SBRT and proton therapy: A consecutive analysis of 38 patients. <i>Lung Cancer</i> , 2020, 145, 105-110.	0.9	9
869	Implementation of durvalumab maintenance treatment after concurrent chemoradiotherapy in inoperable stage III non-small cell lung cancer (NSCLC)—a German radiation oncology survey. <i>Translational Lung Cancer Research</i> , 2020, 9, 288-293.	1.3	6
870	Predicting per-lesion local recurrence in locally advanced non-small cell lung cancer following definitive radiation therapy using pre- and mid-treatment metabolic tumor volume. <i>Radiation Oncology</i> , 2020, 15, 114.	1.2	4
871	FGFR Inhibition Enhances Sensitivity to Radiation in Non-Small Cell Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1255-1265.	1.9	15

#	ARTICLE	IF	CITATIONS
872	Challenges in Re-Irradiation in the Thorax: Managing Patients with Locally Recurrent Non-Small Cell Lung Cancer. <i>Seminars in Radiation Oncology</i> , 2020, 30, 223-231.	1.0	7
873	Modeling the Impact of Cardiopulmonary Irradiation on Overall Survival in NRG Oncology Trial RTOG 0617. <i>Clinical Cancer Research</i> , 2020, 26, 4643-4650.	3.2	47
874	Evaluating dosimetric constraints for carbon ion radiotherapy in the treatment of locally advanced pancreatic cancer. <i>Radiation Oncology</i> , 2020, 15, 101.	1.2	3
875	Methodological Development of Combination Drug and Radiotherapy in Basic and Clinical Research. <i>Clinical Cancer Research</i> , 2020, 26, 4723-4736.	3.2	23
876	Cardiovascular mortality and morbidity following radical radiotherapy for lung cancer: Is cardiovascular death under-reported?. <i>Lung Cancer</i> , 2020, 146, 1-5.	0.9	16
877	Impact of small residual setup errors after image guidance on heart dose and survival in non-small cell lung cancer treated with curative-intent radiotherapy. <i>Radiotherapy and Oncology</i> , 2020, 152, 177-182.	0.3	9
878	Library of deep-learning image segmentation and outcomes model-implementations. <i>Physica Medica</i> , 2020, 73, 190-196.	0.4	15
879	Central Airway Toxicity After High Dose Radiation: A Combined Analysis of Prospective Clinical Trials for Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 587-596.	0.4	8
880	Propensity score adjusted analysis of patients with isolated locoregional recurrence versus de novo locally advanced NSCLC treated with definitive therapy. <i>Lung Cancer</i> , 2020, 145, 119-125.	0.9	3
881	Can we safely reduce the radiation dose to the heart while compromising the dose to the lungs in oesophageal cancer patients?. <i>Radiotherapy and Oncology</i> , 2020, 149, 222-227.	0.3	14
882	Investigating the loco-regional control of simultaneous integrated boost intensity-modulated radiotherapy with different radiation fraction sizes for locally advanced non-small-cell lung cancer: clinical outcomes and the application of an extended LQ/TCP model. <i>Radiation Oncology</i> , 2020, 15, 124.	1.2	9
883	A review of radiation-induced lymphopenia in patients with esophageal cancer: an immunological perspective for radiotherapy. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592092682.	1.4	28
884	Pattern of Local Failure and its Risk Factors of Locally Advanced Non-small Cell Lung Cancer Treated With Concurrent Chemo-radiotherapy. <i>Anticancer Research</i> , 2020, 40, 3513-3517.	0.5	6
885	Lymphopenia and Radiation Dose to Circulating Lymphocytes With Neoadjuvant Chemoradiation in Esophageal Squamous Cell Carcinoma. <i>Advances in Radiation Oncology</i> , 2020, 5, 880-888.	0.6	35
886	Cardiac Monitoring for Thoracic Radiation Therapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 249-256.	0.6	5
887	Novel Methodology to Investigate the Effect of Radiation Dose to Heart Substructures on Overall Survival. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 1073-1081.	0.4	62
888	In response to Park, et al.. <i>Radiotherapy and Oncology</i> , 2020, 147, 245-246.	0.3	0
890	Safety and Efficacy of Carbon-ion Radiotherapy Alone for Stage III Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2020, 40, 379-386.	0.5	16

#	ARTICLE	IF	CITATIONS
891	Radiotherapy treatment for lung cancer: Current status and future directions. <i>Respirology</i> , 2020, 25, 61-71.	1.3	142
892	The emerging role of proton therapy for esophagus cancer. <i>Journal of Gastrointestinal Oncology</i> , 2020, 11, 144-156.	0.6	12
893	Predictors of chemoradiotherapy versus single modality therapy and overall survival among patients with unresectable, stage III non-small cell lung cancer. <i>PLoS ONE</i> , 2020, 15, e0230444.	1.1	4
894	The Role of Mitochondrial Dysfunction in Radiation-Induced Heart Disease: From Bench to Bedside. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 20.	1.1	41
895	Conquering lung cancer: current status and prospects for the future. <i>Pulmonology</i> , 2020, 26, 283-290.	1.0	51
896	Analysis of early respiratory-related mortality after radiation therapy of non-small-cell lung cancer: feasibility of automatic data extraction for dose-response studies. <i>Acta Oncologica</i> , 2020, 59, 628-635.	0.8	5
897	Scanning Beam Proton Therapy versus Photon IMRT for Stage III Lung Cancer: Comparison of Dosimetry, Toxicity, and Outcomes. <i>Advances in Radiation Oncology</i> , 2020, 5, 434-443.	0.6	9
898	The impact of the effective dose to immune cells on lymphopenia and survival of esophageal cancer after chemoradiotherapy. <i>Radiotherapy and Oncology</i> , 2020, 146, 180-186.	0.3	54
899	Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial. <i>Lancet Oncology</i> , The, 2020, 21, 581-592.	5.1	121
900	Less is more in radiotherapy target volume planning: lessons from the PET-plan trial. <i>Lancet Oncology</i> , The, 2020, 21, 481-483.	5.1	1
901	CT images with expert manual contours of thoracic cancer for benchmarking auto-segmentation accuracy. <i>Medical Physics</i> , 2020, 47, 3250-3255.	1.6	15
902	Chemo-radiotherapy integration in unresectable locally advanced non-small-cell lung cancer: a review. <i>Clinical and Translational Oncology</i> , 2020, 22, 1681-1686.	1.2	12
903	Locally Advanced, Unresectable Non-Small Cell Lung Cancer. <i>Current Oncology Reports</i> , 2020, 22, 31.	1.8	17
904	A Primer on Interstitial Lung Disease and Thoracic Radiation. <i>Journal of Thoracic Oncology</i> , 2020, 15, 902-913.	0.5	46
905	The use of real-world evidence to audit normal tissue complication probability models for acute esophageal toxicity in non-small cell lung cancer patients. <i>Radiotherapy and Oncology</i> , 2020, 146, 52-57.	0.3	2
906	Proton beam or photon beam radiotherapy in the treatment of non-small-cell lung cancer. <i>Lancet Oncology</i> , The, 2020, 21, 873-875.	5.1	8
907	Outcomes of concurrent radiotherapy with weekly docetaxel and platinum-based chemotherapy in stage III non-small-cell lung cancer. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2020, 24, 279-287.	0.6	6
908	Characteristics of Participation in Patient-Reported Outcomes and Electronic Data Capture Components of NRG Oncology Clinical Trials. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 950-959.	0.4	14

#	ARTICLE	IF	CITATIONS
909	Cardio-pulmonary substructure segmentation of radiotherapy computed tomography images using convolutional neural networks for clinical outcomes analysis. <i>Physics and Imaging in Radiation Oncology</i> , 2020, 14, 61-66.	1.2	38
910	Registering Study Analysis Plans (SAPs) Before Dissecting Your Data—Updating and Standardizing Outcome Modeling. <i>Frontiers in Oncology</i> , 2020, 10, 978.	1.3	4
911	Proton-Beam Therapy: At the Heart of Cardiac Dose-Sparing in Mediastinal Radiotherapy for Thymic Carcinoma. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1240-1242.	0.5	5
912	Incidence and Onset of Severe Cardiac Events After Radiotherapy for Esophageal Cancer. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1682-1690.	0.5	63
913	Cardiac MRI utilizing late gadolinium enhancement (LGE) and T1 mapping in the detection of radiation induced heart disease. <i>Cardio-Oncology</i> , 2020, 6, 6.	0.8	9
914	Relationship between radiation doses to heart substructures and radiation pneumonitis in patients with thymic epithelial tumors. <i>Scientific Reports</i> , 2020, 10, 11191.	1.6	11
916	Efficacy of oral epigallocatechin-3-gallate solution administration during radiotherapy for non-small-cell lung cancer patients: A long-term observational study. <i>Radiation Medicine and Protection</i> , 2020, 1, 94-98.	0.4	3
917	Resection following concurrent chemotherapy and high-dose radiation for stage IIIA non-small cell lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2020, 160, 1331-1345.e1.	0.4	16
918	Protecting the Heart: A Practical Approach to Account for the Full Extent of Heart Motion in Radiation Therapy Planning. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 1082-1090.	0.4	10
919	Augmenting the therapeutic window of radiotherapy: A perspective on molecularly targeted therapies and nanomaterials. <i>Radiotherapy and Oncology</i> , 2020, 150, 225-235.	0.3	12
920	Impact of Definitive Radiotherapy and Surgical Debulking on Treatment Outcome and Prognosis for Locally Advanced Masaoka-Koga stage III Thymoma. <i>Scientific Reports</i> , 2020, 10, 1735.	1.6	8
921	The UK at the Forefront of Innovative Drug—Radiotherapy Combination Clinical Trials: Introducing the CONCORDE Platform. <i>Clinical Oncology</i> , 2020, 32, 358-362.	0.6	1
922	Immune Checkpoint Inhibitors for the Treatment of Unresectable Stage III Non-Small Cell Lung Cancer: Emerging Mechanisms and Perspectives. <i>Lung Cancer: Targets and Therapy</i> , 2020, Volume 10, 161-170.	1.3	7
924	A Comparison of Radiation Techniques in Patients Treated With Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 985-992.	0.4	24
925	Where is clinical research for radiotherapy going? Cross-sectional comparison of past and contemporary phase III clinical trials. <i>Radiation Oncology</i> , 2020, 15, 36.	1.2	1
926	Different administration routes of recombinant human endostatin combined with concurrent chemoradiotherapy might lead to different efficacy and safety profile in unresectable stage III non-small cell lung cancer: Updated follow-up results from two phase II trials. <i>Thoracic Cancer</i> , 2020, 11, 898-906.	0.8	9
927	Predictive model of the first failure pattern in patients receiving definitive chemoradiotherapy for inoperable locally advanced non-small cell lung cancer (LA-NSCLC). <i>Radiation Oncology</i> , 2020, 15, 43.	1.2	6
928	Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2020, 6, 848.	3.4	89

#	ARTICLE	IF	CITATIONS
929	Mathematical oncology and its application in non melanoma skin cancer – A primer for radiation oncology professionals. <i>Oral Oncology</i> , 2020, 103, 104473.	0.8	14
931	Advances in Preclinical Research Models of Radiation-Induced Cardiac Toxicity. <i>Cancers</i> , 2020, 12, 415.	1.7	40
932	Current status and progress of concurrent chemoradiotherapy in patients with locally advanced non-small cell lung cancer prior to the approval of durvalumab. <i>Thoracic Cancer</i> , 2020, 11, 1005-1014.	0.8	10
933	Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS. <i>Annals of Oncology</i> , 2020, 31, 191-201.	0.6	70
934	Locoregional Control, Overall Survival, and Disease-Free Survival in Stage IIIA (N2) Non-Small-Cell Lung Cancer: Analysis of Resected and Unresected Patients. <i>Clinical Lung Cancer</i> , 2020, 21, e294-e301.	1.1	10
935	Blood Parameters Demonstrating a Significant Survival Impact in Patients With Locally Advanced NSCLC Undergoing Definitive Chemoradiotherapy. <i>Anticancer Research</i> , 2020, 40, 2319-2322.	0.5	4
936	Clinical outcomes, local-regional control and the role for metastasis-directed therapies in stage III non-small cell lung cancers treated with chemoradiation and durvalumab. <i>Radiotherapy and Oncology</i> , 2020, 149, 205-211.	0.3	39
937	Cardiovascular Damage Associated With Chest Irradiation. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 41.	1.1	29
938	Survival and Toxicity of Hypofractionated Intensity Modulated Radiation Therapy in 4 Gy Fractions for Unresectable Stage III Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 710-719.	0.4	14
939	Current radiotherapy techniques in NSCLC: challenges and potential solutions. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 387-402.	1.1	24
940	Radiation dose escalation with modified fractionation schedules for locally advanced NSCLC : A systematic review. <i>Thoracic Cancer</i> , 2020, 11, 1375-1385.	0.8	11
941	Hypofractionated Proton Therapy with Concurrent Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Phase 1 Trial from the University of Florida and Proton Collaborative Group. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 455-461.	0.4	21
942	Immunotherapy in Lung Cancer: From a Minor God to the Olympus. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1244, 69-92.	0.8	15
943	Challenges of radical chemoradiation planning in Stage III non-small-cell lung cancer: Can volumetric modulated arc radiotherapy overcome an unfavourable location?. <i>Physics and Imaging in Radiation Oncology</i> , 2020, 13, 50-54.	1.2	1
944	Making Checkpoint Inhibitors Part of Treatment of Patients With Locally Advanced Lung Cancers: The Time Is Now. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, e159-e170.	1.8	7
945	Efficacy and safety of concurrent chemoradiotherapy in ECOG 2 patients with locally advanced non-small-cell lung cancer: a subgroup analysis of a randomized phase III trial. <i>BMC Cancer</i> , 2020, 20, 278.	1.1	7
946	Ultra-central Thoracic Re-irradiation Using 10-fraction Stereotactic Body Radiotherapy for Recurrent Non-small-cell Lung Cancer Tumors: Preliminary Toxicity and Efficacy Outcomes. <i>Clinical Lung Cancer</i> , 2021, 22, e301-e312.	1.1	4
948	Predicting the Risk of Disease Recurrence and Death Following Curative-intent Radiotherapy for Non-small Cell Lung Cancer: The Development and Validation of Two Scoring Systems From a Large Multicentre UK Cohort. <i>Clinical Oncology</i> , 2021, 33, 145-154.	0.6	5

#	ARTICLE	IF	CITATIONS
949	Concurrent Chemo-Proton Therapy Using Adaptive Planning for Unresectable Stage 3 Non-Small Cell Lung Cancer: A Phase 2 Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 1359-1367.	0.4	13
950	Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC). <i>Lung Cancer</i> , 2021, 151, 30-38.	0.9	30
951	Personalizing Radiotherapy Prescription Dose Using Genomic Markers of Radiosensitivity and Normal Tissue Toxicity in NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 428-438.	0.5	32
952	Meaningful incorporation of artificial intelligence for personalized patient management during cancer: Quantitative imaging, risk assessment, and therapeutic outcomes. , 2021, , 339-359.		0
953	Using Auto-Segmentation to Reduce Contouring and Dose Inconsistency in Clinical Trials: The Simulated Impact on RTOG 0617. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 1619-1626.	0.4	30
954	Isotoxic Intensity Modulated Radiation Therapy in Stage III Non-Small Cell Lung Cancer: A Feasibility Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 1341-1348.	0.4	17
955	Toxicity and Survival After Intensity-Modulated Proton Therapy Versus Passive Scattering Proton Therapy for NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 269-277.	0.5	23
956	Erlotinib Versus Etoposide/Cisplatin With Radiation Therapy in Unresectable Stage III Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter, Randomized, Open-Label, Phase 2 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 1349-1358.	0.4	35
957	Radiotherapy and Immunotherapy Combinations for Lung Cancer. <i>Current Oncology Reports</i> , 2021, 23, 4.	1.8	11
958	2020 Innovation-Based Optimism for Lung Cancer Outcomes. <i>Oncologist</i> , 2021, 26, e454-e472.	1.9	17
959	Constrained by Constraints, or Manacled by Margin Mandates?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 264-266.	0.4	0
960	Analysis of Patient-Reported Outcome Utilization Within National Clinical Trials Network Cooperative Group Radiation Oncology Trials Over the Past 2 Decades. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 1151-1160.	0.4	7
961	Synergistic effect of PAF inhibition and X-ray irradiation in non-small cell lung cancer cells. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 343-352.	1.0	5
962	Optimal beam angle selection and knowledge-based planning significantly reduces radiotherapy dose to organs at risk for lung cancer patients. <i>Acta Oncol</i> , 2021, 60, 293-299.	0.8	8
963	Malignant Pericardial Mesothelioma Treated Using Volumetric Modulated Arc Therapy With a Simultaneous Integrated Boost. <i>Advances in Radiation Oncology</i> , 2021, 6, 100562.	0.6	0
964	Genomic Analyses for Predictors of Response to Chemoradiation in Stage III Non-Small Cell Lung Cancer. <i>Advances in Radiation Oncology</i> , 2021, 6, 100615.	0.6	6
965	Retrospective Planning Study of Patients with Superior Sulcus Tumours Comparing Pencil Beam Scanning Protons to Volumetric-Modulated Arc Therapy. <i>Clinical Oncology</i> , 2021, 33, e118-e131.	0.6	2
966	Effect of durvalumab on local control after concurrent chemoradiotherapy for locally advanced non-small cell lung cancer in comparison with chemoradiotherapy alone. <i>Thoracic Cancer</i> , 2021, 12, 245-250.	0.8	15

#	ARTICLE	IF	CITATIONS
967	Clinical and Dosimetric Predictors of Radiation Pneumonitis in Patients With Non-Small Cell Lung Cancer Undergoing Postoperative Radiation Therapy. <i>Practical Radiation Oncology</i> , 2021, 11, e52-e62.	1.1	18
968	Identification of the mutation signature of the cancer genome caused by irradiation. <i>Radiotherapy and Oncology</i> , 2021, 155, 10-16.	0.3	6
969	Phase II Study: The Outcome of Hypofractionated Involved-Field Radiation Therapy With Concurrent Chemotherapy for the Treatment of Locally Advanced Non-small Cell Lung Cancer. <i>Practical Radiation Oncology</i> , 2021, 11, 35-43.	1.1	2
970	Ultrasmall Gd@Cdots as a radiosensitizing agent for non-small cell lung cancer. <i>Nanoscale</i> , 2021, 13, 9252-9263.	2.8	11
971	Differences in patterns of recurrence of squamous cell carcinoma and adenocarcinoma after radiotherapy for stage III non-small cell lung cancer. <i>Japanese Journal of Radiology</i> , 2021, 39, 611-617.	1.0	8
972	Five-year survival rate analysis: the combination of fortnightly-administration of endostar and concurrent chemoradiotherapy versus concurrent chemoradiotherapy in the treatment of inoperable locally advanced non-small cell lung cancer. <i>Annals of Palliative Medicine</i> , 2021, 10, 7560-7570.	0.5	6
973	Dexrazoxane ameliorates radiation-induced heart disease in a rat model. <i>Aging</i> , 2021, 13, 3699-3711.	1.4	9
974	Treatment planning and outcomes effects of reducing the preferred mean esophagus dose for conventionally fractionated non-small cell lung cancer radiotherapy. <i>Journal of Applied Clinical Medical Physics</i> , 2021, 22, 42-48.	0.8	4
975	Radiation-induced Esophagitis in Lung Cancer—A Common Problem with Limited Therapeutic Options. <i>Oncology & Hematology Review</i> , 2021, 16, 95.	0.2	2
976	A Review of Monoclonal Antibody-Based Treatments in Non-small Cell Lung Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1286, 49-64.	0.8	8
977	Diffusion-weighted MRI improves response assessment after definitive radiotherapy in patients with NSCLC. <i>Cancer Imaging</i> , 2021, 21, 15.	1.2	10
978	Evaluating the relationship between dosimetric parameters and esophagitis in patients who experienced radiotherapy in the cervicothoracic region. <i>Journal of Cancer Research and Therapeutics</i> , 2021, ,	0.3	0
979	Durvalumab after concurrent chemotherapy and high-dose radiotherapy for locally advanced non-small cell lung cancer. <i>Oncolmmunology</i> , 2021, 10, 1959979.	2.1	23
980	Dosimetric Comparison Between Carbon-ion Radiotherapy and Photon Radiotherapy for Stage I Esophageal Cancer. <i>In Vivo</i> , 2021, 35, 447-452.	0.6	7
981	Prechemoradiotherapy Systemic Inflammation Response Index Stratifies Stage IIIB/C Non-Small-Cell Lung Cancer Patients into Three Prognostic Groups: A Propensity Score-Matching Analysis. <i>Journal of Oncology</i> , 2021, 2021, 1-9.	0.6	10
983	Introduction to the Cardiac Implications of Radiotherapy. , 2021, , 213-217.		0
984	Using Novel Statistical Techniques to Accurately Determine the Predictive Dose Range in a Study of Overall Survival after Definitive Radiotherapy for Stage III Non-Small Cell Lung Cancer in Association with Heart Dose. <i>Journal of Cancer Therapy</i> , 2021, 12, 505-529.	0.1	2
985	Dosimetric impact from cardiac motion to heart substructures in thoracic cancer patients treated with a magnetic resonance guided radiotherapy system. <i>Physics and Imaging in Radiation Oncology</i> , 2021, 17, 8-12.	1.2	1

#	ARTICLE	IF	CITATIONS
986	Experimental evaluation of four-dimensional Magnetic Resonance Imaging for radiotherapy planning of lung cancer. <i>Physics and Imaging in Radiation Oncology</i> , 2021, 17, 32-35.	1.2	4
987	Systematic review of stereotactic body radiotherapy in stage III non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 529-538.	1.3	8
988	Reinforcement Learning Applications in Health Informatics. <i>Lecture Notes in Bioengineering</i> , 2021, , 145-154.	0.3	0
989	Chemoradiotherapy in Cancer Treatment: Rationale and Clinical Applications. <i>Anticancer Research</i> , 2021, 41, 1-7.	0.5	43
990	A comparison of two methods for segmentation of functional volumes in radiotherapy planning of lung cancer patients. <i>Acta Oncol³gica</i> , 2021, 60, 353-360.	0.8	1
992	Cardiac Toxicity of Thoracic Radiotherapy: Existing Evidence and Future Directions. <i>Journal of Thoracic Oncology</i> , 2021, 16, 216-227.	0.5	117
993	Factors influencing multi-disciplinary tumor board recommendations in stage III non-small cell lung cancer. <i>Lung Cancer</i> , 2021, 152, 149-156.	0.9	11
994	Thymic malignancies treated with active scanning proton beam radiation and Monte Carlo planning: early clinical experience. <i>Acta Oncol³gica</i> , 2021, 60, 649-652.	0.8	2
995	Acquisition and Management of Data for Translational Science in Oncology. , 0, , .		1
996	Impact of EBUS-TBNA in addition to [18F]FDG-PET/CT imaging on target volume definition for radiochemotherapy in stage III NSCLC. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2894-2903.	3.3	11
997	Association of Left Anterior Descending Coronary Artery Radiation Dose With Major Adverse Cardiac Events and Mortality in Patients With Non-“Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2021, 7, 206.	3.4	101
998	Randomized phase II trial of uracil/tegafur and cisplatin versus pemetrexed and cisplatin with concurrent thoracic radiotherapy for locally advanced unresectable stage III non-squamous non-small cell lung cancer: NJLCC1001. <i>Translational Lung Cancer Research</i> , 2021, 10, 712-722.	1.3	4
1000	Radiotherapy and Immunotherapy for Head and Neck Cancer: Current Evidence and Challenges. <i>Frontiers in Oncology</i> , 2020, 10, 608772.	1.3	30
1001	Analysis of target doses on various tissues in treatment of lung cancer: a simulation study. <i>Journal of Physics: Conference Series</i> , 2021, 1825, 012091.	0.3	3
1002	A systematic review and meta-analysis of treatment-related toxicities of curative and palliative radiation therapy in non-small cell lung cancer. <i>Scientific Reports</i> , 2021, 11, 5939.	1.6	20
1003	Low cardiac dose and neutrophil-to-lymphocyte ratio predict overall survival in inoperable esophageal squamous cell cancer patients after chemoradiotherapy. <i>Scientific Reports</i> , 2021, 11, 6644.	1.6	6
1004	Radiation Modalities Used in Lung Cancer: An Overview for Thoracic Surgeons. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2021, 33, 1114-1121.	0.4	1
1005	Durvalumab after Chemoradiotherapy for PD-L1 Expressing Inoperable Stage III NSCLC Leads to Significant Improvement of Local-Regional Control and Overall Survival in the Real-World Setting. <i>Cancers</i> , 2021, 13, 1613.	1.7	18

#	ARTICLE	IF	CITATIONS
1006	The Impact of Lymphopenia and Dosimetric Parameters on Overall Survival of Esophageal Cancer Patients Treated with Definitive Radiotherapy. <i>Cancer Management and Research</i> , 2021, Volume 13, 2917-2924.	0.9	9
1007	A Pilot Study of Safer Radiation Dosage to the Heart and Its Subregions. <i>Medicina (Lithuania)</i> , 2021, 57, 320.	0.8	0
1008	Prospectively scored pulmonary toxicities in non-small cell lung cancer: Results from a randomized phase II dose escalation trial. <i>Clinical and Translational Radiation Oncology</i> , 2021, 27, 8-14.	0.9	0
1009	Concurrent paclitaxel and radiation therapy for the treatment of cutaneous angiosarcoma. <i>Clinical and Translational Radiation Oncology</i> , 2021, 27, 114-120.	0.9	9
1010	Cardiac Magnetic Resonance for Early Detection of Radiation Therapy-Induced Cardiotoxicity in a Small Animal Model. <i>JACC: CardioOncology</i> , 2021, 3, 113-130.	1.7	13
1011	Oligometastatic non-small cell lung cancer: a narrative review of stereotactic ablative radiotherapy. <i>Annals of Palliative Medicine</i> , 2021, 10, 30-30.	0.5	6
1012	Chemoradiotherapy by intensity-modulated radiation therapy with simultaneous integrated boost in locally advanced or oligometastatic non-small-cell lung cancer—two center experience. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 405-415.	1.0	2
1013	Sensible Introduction of MR-Guided Radiotherapy: A Warm Plea for the RCT. <i>Frontiers in Oncology</i> , 2021, 11, 652889.	1.3	7
1014	Dose and fractionation schedules in radiotherapy for non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 1969-1982.	1.3	11
1015	Dosimetric feasibility of stereotactic ablative radiotherapy in pulmonary vein isolation for atrial fibrillation using intensity-modulated proton therapy. <i>Journal of Applied Clinical Medical Physics</i> , 2021, 22, 79-88.	0.8	2
1016	Radiotherapy in the Era of Immunotherapy—With a Focus on Non-Small-Cell Lung Cancer: Time to Revisit Ancient Dogmas?. <i>Frontiers in Oncology</i> , 2021, 11, 662236.	1.3	19
1017	Capilliposide C from <i>Lysimachia capillipes</i> Restores Radiosensitivity in Ionizing Radiation-Resistant Lung Cancer Cells Through Regulation of ERRF1/EGFR/STAT3 Signaling Pathway. <i>Frontiers in Oncology</i> , 2021, 11, 644117.	1.3	2
1019	Improved adaptive radiotherapy to adjust for anatomical alterations during curative treatment for locally advanced lung cancer. <i>Physics and Imaging in Radiation Oncology</i> , 2021, 18, 51-54.	1.2	2
1020	Quantifying inter-fraction cardiac substructure displacement during radiotherapy via magnetic resonance imaging guidance. <i>Physics and Imaging in Radiation Oncology</i> , 2021, 18, 34-40.	1.2	4
1021	Automatic delineation of cardiac substructures using a region-based fully convolutional network. <i>Medical Physics</i> , 2021, 48, 2867-2876.	1.6	20
1022	Concurrent chemoradiotherapy for stage III non-small-cell lung cancer: recent progress and future perspectives (a narrative review). <i>Translational Lung Cancer Research</i> , 2021, 10, 2018-2031.	1.3	9
1023	Combining radiotherapy with targeted therapies in non-small cell lung cancer: focus on anti-EGFR, anti-ALK and anti-angiogenic agents. <i>Translational Lung Cancer Research</i> , 2021, 10, 2032-2047.	1.3	12
1024	iRGD Co-Administration with Paclitaxel-Loaded PLGA Nanoparticles Enhance Targeting and Antitumor Effect in Colorectal Cancer Treatment. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2021, 21, 910-918.	0.9	5

#	ARTICLE	IF	CITATIONS
1025	Treatment Intensification in Locally Advanced/Unresectable NSCLC Through Combined Modality Treatment and Precision Dose Escalation. <i>Seminars in Radiation Oncology</i> , 2021, 31, 105-111.	1.0	3
1026	Evolving target volume concepts in locally advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 1999-2010.	1.3	8
1027	The Impact of Radiation to Epicardial Adipose Tissue on Prognosis of Esophageal Squamous Cell Carcinoma Receiving Neoadjuvant Chemoradiotherapy and Esophagectomy. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 4023.	1.3	2
1028	Radiation Treatment of Non-Small Cell Lung Cancer. <i>Seminars in Radiation Oncology</i> , 2021, 31, 95-96.	1.0	0
1029	Dosimetric Comparison of Radiation Therapy Using Hybrid-VMAT Technique for Stage I Esophageal Cancer. <i>Anticancer Research</i> , 2021, 41, 1951-1958.	0.5	4
1030	Evolution of systemic therapy for stages I-III non-metastatic non-small-cell lung cancer. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 547-557.	12.5	152
1031	An overview of the published and running randomized phase 3 clinical results of radiotherapy in combination with immunotherapy. <i>Translational Lung Cancer Research</i> , 2021, 10, 2048-2058.	1.3	11
1032	Prognostic Value of Postinduction Chemotherapy Volumetric PET/CT Parameters for Stage IIIA or IIIB Non-Small Cell Lung Cancer Patients Receiving Definitive Chemoradiotherapy. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1684-1691.	2.8	5
1033	Adaptive intensity-modulated radiotherapy with simultaneous integrated boost for stage III non-small cell lung cancer: Is a routine adaptation beneficial?. <i>Radiotherapy and Oncology</i> , 2021, 158, 118-124.	0.3	13
1034	Developments in radiation techniques for thoracic malignancies. <i>European Respiratory Review</i> , 2021, 30, 200224.	3.0	6
1035	Role of Consolidation Durvalumab in Patients With EGFR- and HER2-Mutant Unresectable Stage III NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 868-872.	0.5	42
1036	Beyond PACIFIC: Uncharted Waters. <i>Journal of Thoracic Oncology</i> , 2021, 16, 715-718.	0.5	0
1037	Combined Radiochemotherapy: Metalloproteinases Revisited. <i>Frontiers in Oncology</i> , 2021, 11, 676583.	1.3	7
1038	The utilization of immunotherapy with radiation therapy in lung cancer: a narrative review. <i>Translational Cancer Research</i> , 2021, 10, 2596-2608.	0.4	8
1039	Radiotherapy and Receptor Tyrosine Kinase Inhibition for Solid Cancers (ROCKIT): A Meta-Analysis of 13 Studies. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab050.	1.4	14
1040	Letter Response. <i>Journal of Thoracic Oncology</i> , 2021, 16, e28-e29.	0.5	0
1041	Prognostic value of low skeletal muscle mass in patient treated by exclusive curative radiochemotherapy for a NSCLC. <i>Scientific Reports</i> , 2021, 11, 10628.	1.6	9
1042	Effects of peripherally inserted central catheter on dosimetry of the blood vessel region in volumetric modulated arc therapy planning for lung cancer. <i>Precision Radiation Oncology</i> , 2021, 5, 93-99.	0.4	0

#	ARTICLE	IF	CITATIONS
1043	Phase I trial of the MEK inhibitor selumetinib in combination with thoracic radiotherapy in non-small cell lung cancer. <i>Clinical and Translational Radiation Oncology</i> , 2021, 28, 24-31.	0.9	4
1044	Dose escalation guided by 18F-FDG PET/CT for esophageal cancer. <i>Radiation Medicine and Protection</i> , 2021, 2, 55-60.	0.4	3
1045	Metabolic reprogramming of antioxidant defense: a precision medicine perspective for radiotherapy of lung cancer?. <i>Biochemical Society Transactions</i> , 2021, 49, 1265-1277.	1.6	4
1046	Intensity-modulated radiotherapy combined with intensity-modulated radiotherapy CT-guided iodine 125 seed brachytherapy for non-small cell lung cancer: A case report. <i>Precision Radiation Oncology</i> , 2021, 5, 106-109.	0.4	0
1048	Assessment of a Contralateral Esophagus-Sparing Technique in Locally Advanced Lung Cancer Treated With High-Dose Chemoradiation. <i>JAMA Oncology</i> , 2021, 7, 910.	3.4	16
1049	Cardiac-sparing radiotherapy for locally advanced non-small cell lung cancer. <i>Radiation Oncology</i> , 2021, 16, 95.	1.2	5
1050	Identification and characterization of effusion tumor cells (ETCs) from remnant pleural effusion specimens. <i>Cancer Cytopathology</i> , 2021, 129, 893-906.	1.4	6
1051	Is a higher estimated dose of radiation to immune cells predictive of survival in patients with locally advanced non-small cell lung cancer treated with thoracic radiotherapy?. <i>Radiotherapy and Oncology</i> , 2021, 159, 218-223.	0.3	2
1052	Phase II Trial of Flaxseed to Prevent Acute Complications After Chemoradiation for Lung Cancer. <i>Journal of Alternative and Complementary Medicine</i> , 2021, 27, 824-831.	2.1	3
1053	Systemic immune-inflammation index changes predict outcome in stage III non-small-cell lung cancer patients treated with concurrent chemoradiotherapy. <i>Future Oncology</i> , 2021, 17, 2141-2149.	1.1	6
1054	Definitive Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer: Current Status and Future Perspectives. , 0, , .		0
1055	Prognostic index for estimating the survival benefit of postoperative radiotherapy in pathologic N2 non-small cell lung cancer: A real-world validation study. <i>Lung Cancer</i> , 2021, 156, 100-108.	0.9	6
1057	Prevention and management of acute esophageal toxicity during concomitant chemoradiotherapy for locally advanced lung cancer. <i>Tumori</i> , 2022, 108, 470-476.	0.6	2
1058	The possibilities of combination immunotherapy with radiation therapy for the treatment of patients with inoperable locally advanced non-small cell lung cancer. <i>IssledovaniĀ I Praktika V Medicine</i> , 2021, 8, 109-123.	0.1	0
1059	Reliability of Quantitative 18F-FDG PET/CT Imaging Biomarkers for Classifying Early Response to Chemoradiotherapy in Patients With Locally Advanced Non-Small Cell Lung Cancer. <i>Clinical Nuclear Medicine</i> , 2021, 46, 861-871.	0.7	9
1060	Radiation Therapy in Non-Small-Cell Lung Cancer. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2021, 11, a037713.	2.9	8
1061	Complete pathological response in locally advanced non-small-cell lung cancer patient: A case report. <i>World Journal of Clinical Cases</i> , 2021, 9, 5540-5546.	0.3	1
1062	A Multicenter Retrospective Study on the Prognosis of Stage III Unresectable Mutant Non-Small Cell Lung Cancer With Tyrosine Kinase Inhibitors Therapy. <i>Frontiers in Oncology</i> , 2021, 11, 692703.	1.3	7

#	ARTICLE	IF	CITATIONS
1063	Salvage lung surgery in long-term survivors after biological and immunotherapeutic treatments. Shanghai Chest, 0, 5, 24-24.	0.3	0
1064	Integrating Multiomics Information in Deep Learning Architectures for Joint Actuarial Outcome Prediction in Non-Small Cell Lung Cancer Patients After Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2021, 110, 893-904.	0.4	31
1065	Concurrent Chemoradiation Therapy With or Without Nimotuzumab in Locally Advanced Squamous Cell Lung Cancer: A Phase 2 Randomized Trial. International Journal of Radiation Oncology Biology Physics, 2021, 111, 917-925.	0.4	7
1066	Who Will Benefit from Charged-Particle Therapy?. Cancer Research and Treatment, 2021, 53, 621-634.	1.3	5
1067	Intensity-modulated radiation therapy with concurrent chemotherapy followed by durvalumab for stage III non-small cell lung cancer: A multi-center retrospective study. Radiotherapy and Oncology, 2021, 160, 266-272.	0.3	24
1068	A Dose-finding Study Followed by a Phase II Randomized, Placebo-controlled Trial of Chemoradiotherapy With or Without Veliparib in Stage III Non-small-cell Lung Cancer: SWOG 1206 (8811). Clinical Lung Cancer, 2021, 22, 313-323.e1.	1.1	11
1069	Implementation of the Australian Computer-Assisted Theragnostics (AusCAT) network for radiation oncology data extraction, reporting and distributed learning. Journal of Medical Imaging and Radiation Oncology, 2021, 65, 627-636.	0.9	11
1070	12 Gy stereotactic radiotherapy for lung tumors. Is there a difference in response between lung metastases and primary bronchial carcinoma?. Strahlentherapie Und Onkologie, 2021, , 1.	1.0	1
1071	Probing thoracic dose patterns associated to pericardial effusion and mortality in patients treated with photons and protons for locally advanced non-small-cell lung cancer. Radiotherapy and Oncology, 2021, 160, 148-158.	0.3	12
1072	Feasibility of intensity modulated radiotherapy with involved field radiotherapy for Japanese patients with locally advanced non-small cell lung cancer. Journal of Radiation Research, 2021, 62, 894-900.	0.8	6
1073	Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFR Mutation Positive Stage III Non-small-cell Lung Cancer: LAURA Trial in Progress. Clinical Lung Cancer, 2021, 22, 371-375.	1.1	44
1074	Outcomes of curative-intent radiotherapy in non-small cell lung cancer (NSCLC) patients with chronic obstructive pulmonary disease (COPD) and interstitial lung disease (ILD). Radiotherapy and Oncology, 2021, 160, 78-81.	0.3	9
1075	Radiogenomic Analysis of Locally Advanced Lung Cancer Based on CT Imaging and Intratreatment Changes in Cell-Free DNA. Radiology Imaging Cancer, 2021, 3, e200157.	0.7	26
1076	Radiation Therapy Planning of Thoracic Tumors: A Review of Challenges Associated With Lung Toxicities and Potential Perspectives of Gallium-68 Lung PET/CT Imaging. Frontiers in Medicine, 2021, 8, 723748.	1.2	12
1077	Lung cancer. Lancet, The, 2021, 398, 535-554.	6.3	896
1078	Symptoms Related to Brachial Plexus Neuropathy After Supraclavicular Irradiation and Boost in Breast Cancer. Practical Radiation Oncology, 2021, , .	1.1	3
1079	A Critical Review of Radiation Therapy: From Particle Beam Therapy (Proton, Carbon, and BNCT) to Beyond. Journal of Personalized Medicine, 2021, 11, 825.	1.1	37
1080	A data mining based clinical decision support system for survival in lung cancer. Reports of Practical Oncology and Radiotherapy, 2021, 26, 839-848.	0.3	2

#	ARTICLE	IF	CITATIONS
1081	Improving Early Identification of Significant Weight Loss Using Clinical Decision Support System in Lung Cancer Radiation Therapy. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 944-952.	1.0	2
1082	Optimal surgical timing and radiotherapy dose for trimodality therapy in locally advanced non-small cell lung cancer. <i>Cancer Medicine</i> , 2021, 10, 5794-5808.	1.3	2
1083	Real-World Incidence of Pneumonitis in Patients Receiving Durvalumab. <i>Clinical Lung Cancer</i> , 2022, 23, 34-42.	1.1	18
1084	Accelerated Hypofractionated Image-Guided vs Conventional Radiotherapy for Patients With Stage II/III Non-Small Cell Lung Cancer and Poor Performance Status. <i>JAMA Oncology</i> , 2021, 7, 1497.	3.4	45
1085	Treatment outcomes of passive scattering proton beam therapy for stage I non-small cell lung cancer. <i>Radiation Oncology</i> , 2021, 16, 155.	1.2	4
1086	The Impact of Durvalumab on Local-Regional Control in Stage III NSCLCs Treated With Chemoradiation and on KEAP1-NFE2L2-Mutant Tumors. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1392-1402.	0.5	12
1087	Planning target volume as a predictor of disease progression in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy and concurrent and/or sequential immune checkpoint inhibition. <i>Investigational New Drugs</i> , 2021, , 1.	1.2	5
1088	Short term clinical outcomes of accelerated hypofractionated radiotherapy in inoperable non-small cell lung cancer patients. <i>Reports of Practical Oncology and Radiotherapy</i> , 2021, 26, 747-755.	0.3	0
1089	Coronary Artery Calcifications and Cardiac Risk After Radiation Therapy for Stage III Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 188-196.	0.4	12
1090	Forging a Path for Metformin Use in Inoperable Locally Advanced Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2021, 7, 1341.	3.4	6
1091	Locally advanced lung cancer. <i>Ca-A Cancer Journal for Clinicians</i> , 2021, 71, 461-465.	157.7	4
1092	Duration of acute esophageal toxicity in concomitant radio-chemotherapy for non-small cell lung cancer with different fractionation schedules. <i>British Journal of Radiology</i> , 2021, 94, 20210776.	1.0	0
1093	Hypofractionated Intensity Modulated Radiation Therapy With Concurrent Chemotherapy in Locally Advanced Non-Small Cell Lung Cancer: A Phase II Prospective Clinical Trial (GASTO1011). <i>Practical Radiation Oncology</i> , 2021, 11, 374-383.	1.1	15
1094	Statin Use, Heart Radiation Dose, and Survival in Locally Advanced Lung Cancer. <i>Practical Radiation Oncology</i> , 2021, 11, e459-e467.	1.1	16
1095	Prognostic Value of Computed Tomography and/or 18F-Fluorodeoxyglucose Positron Emission Tomography Radiomics Features in Locally Advanced Non-small Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2021, 22, 461-468.	1.1	4
1096	Immunoradiotherapy goes club(bing). <i>Nature Cancer</i> , 2021, 2, 871-872.	5.7	2
1097	Mean heart dose-based normal tissue complication probability model for pericardial effusion: a study in oesophageal cancer patients. <i>Scientific Reports</i> , 2021, 11, 18166.	1.6	2
1098	Predicting muscle loss during lung cancer treatment (PREDICT): protocol for a mixed methods prospective study. <i>BMJ Open</i> , 2021, 11, e051665.	0.8	0

#	ARTICLE	IF	CITATIONS
1099	Estimating the modulating effect of lung tissue in particle therapy using a clinical CT voxel histogram analysis. <i>Physics in Medicine and Biology</i> , 2021, 66, 185002.	1.6	2
1100	A Comparison of Isotoxic Dose-escalated Radiotherapy in Lung Cancer with Moderate Deep Inspiration Breath Hold, Mid-ventilation and Internal Target Volume Techniques. <i>Clinical Oncology</i> , 2022, 34, 151-159.	0.6	1
1101	Cardiovascular Manifestations From Therapeutic Radiation. <i>JACC: CardioOncology</i> , 2021, 3, 360-380.	1.7	81
1102	Pan-cancer prediction of radiotherapy benefit using genomic-adjusted radiation dose (GARD): a cohort-based pooled analysis. <i>Lancet Oncology</i> , The, 2021, 22, 1221-1229.	5.1	76
1103	Veliparib in combination with carboplatin/paclitaxel-based chemoradiotherapy in patients with stage III non-small cell lung cancer. <i>Lung Cancer</i> , 2021, 159, 56-65.	0.9	7
1104	Metformin in Combination With Chemoradiotherapy in Locally Advanced Nonâ€“Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2021, 7, 1333.	3.4	59
1105	Addition of Metformin to Concurrent Chemoradiation in Patients With Locally Advanced Nonâ€“Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2021, 7, 1324.	3.4	53
1106	Dosimetric Validation of a System to Treat Moving Tumors Using Scanned Ion Beams That Are Synchronized With Anatomical Motion. <i>Frontiers in Oncology</i> , 2021, 11, 712126.	1.3	5
1107	Predictors of In-Hospital Death in Patients with Lung Cancer Admitted for Acute Radiation Pneumonitis: A Healthcare Cost and Utilization Project (HCUP) Analysis. <i>Clinical Lung Cancer</i> , 2021, 22, e716-e722.	1.1	5
1108	Past, Present, and Future of Radiation-Induced Cardiotoxicity: Refinements in Targeting, Surveillance, and Risk Stratification. <i>JACC: CardioOncology</i> , 2021, 3, 343-359.	1.7	76
1109	A Comprehensive Review of Current Perspectives on Novel Drug Delivery Systems and Approaches for Lung Cancer Management. <i>Journal of Pharmaceutical Innovation</i> , 2022, 17, 1530-1553.	1.1	4
1110	Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Nonâ€“Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2021, 7, 1351.	3.4	113
1111	Repurposing Proton Beam Therapy through Novel Insights into Tumour Radioresistance. <i>Clinical Oncology</i> , 2021, 33, e469-e481.	0.6	2
1112	Clinical Outcomes After Proton Beam Therapy for Locally Advanced Non-Small Cell Lung Cancer: Analysis of a Multi-institutional Prospective Registry. <i>Advances in Radiation Oncology</i> , 2021, 7, 100767.	0.6	2
1113	Dosimetry, Efficacy, Safety, and Cost-Effectiveness of Proton Therapy for Non-Small Cell Lung Cancer. <i>Cancers</i> , 2021, 13, 4545.	1.7	3
1114	Real-World Treatment Patterns and Clinical Outcomes in Patients With Stage III NSCLC: Results of KINDLE, a Multicountry Observational Study. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1733-1744.	0.5	26
1115	Increased biologically effective dose (BED) to the primary tumor is associated with improved survival in patients with oligometastatic NSCLC. <i>Radiotherapy and Oncology</i> , 2021, 163, 114-118.	0.3	12
1116	Post-operative radiation therapy for non-small cell lung cancer: A comparison of radiation therapy techniques. <i>Lung Cancer</i> , 2021, 161, 171-179.	0.9	2

#	ARTICLE	IF	CITATIONS
1117	The role of surgery in the treatment of oligoprogression after systemic treatment for advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2021, 161, 141-151.	0.9	5
1118	Implementation of a Knowledge-Based Treatment Planning Model for Cardiac-Sparing Lung Radiation Therapy. <i>Advances in Radiation Oncology</i> , 2021, 6, 100745.	0.6	4
1119	Management of Locally Advanced Non-Small Cell Lung Cancer. , 2022, , 810-824.		1
1121	Palliative Thoracic Radiotherapy for Non-small Cell Lung Cancer: Is There any Impact of Target Volume Size on Survival?. <i>Anticancer Research</i> , 2021, 41, 355-358.	0.5	4
1122	Potential benefits of volumetric modulated arc therapy to reduce the incidence of grade 2 radiation pneumonitis in radiotherapy for locally advanced non-small cell lung cancer patients. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 1729-1735.	0.6	5
1124	Deriving Lung Perfusion Directly from CT Image Using Deep Convolutional Neural Network: A Preliminary Study. <i>Lecture Notes in Computer Science</i> , 2019, , 102-109.	1.0	5
1125	Advances in the Treatment of Stage III Non-Small Cell Lung Cancer. <i>Clinics in Chest Medicine</i> , 2020, 41, 211-222.	0.8	18
1126	Combining Immunotherapy with Radiation Therapy in Non-Small Cell Lung Cancer. <i>Thoracic Surgery Clinics</i> , 2020, 30, 221-239.	0.4	25
1127	Pro-con of proton: Dosimetric advantages of intensity-modulation over passive scatter for thoracic malignancies. <i>Technical Innovations and Patient Support in Radiation Oncology</i> , 2020, 15, 37-46.	0.6	7
1128	Investigation of the Bragg peak degradation caused by homogeneous and heterogeneous lung tissue substitutes: proton beam experiments and comparison to current clinical dose calculation. <i>Physics in Medicine and Biology</i> , 2020, 65, 245036.	1.6	6
1130	Single-arm prospective interventional study assessing feasibility of using gallium-68 ventilation and perfusion PET/CT to avoid functional lung in patients with stage III non-small cell lung cancer. <i>BMJ Open</i> , 2020, 10, e042465.	0.8	15
1131	Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 1256-1266.	3.2	20
1132	Increased Biological Effective Dose of Radiation Correlates with Prolonged Survival of Patients with Limited-Stage Small Cell Lung Cancer: A Systematic Review. <i>PLoS ONE</i> , 2016, 11, e0156494.	1.1	10
1133	Early Change in Metabolic Tumor Heterogeneity during Chemoradiotherapy and Its Prognostic Value for Patients with Locally Advanced Non-Small Cell Lung Cancer. <i>PLoS ONE</i> , 2016, 11, e0157836.	1.1	53
1134	Trends and Outcomes of Proton Radiation Therapy Use for Non-Small Cell Lung Cancer. <i>International Journal of Particle Therapy</i> , 2018, 5, 18-27.	0.9	2
1135	Cardiovascular Toxicities of Radiation Therapy. <i>Methodist DeBakey Cardiovascular Journal</i> , 2021, 15, 274.	0.5	21
1136	A phase II open-label multicenter study of gefitinib in combination with irradiation followed by chemotherapy in patients with inoperable stage III non-small cell lung cancer. <i>Oncotarget</i> , 2017, 8, 15924-15933.	0.8	16
1137	Quantitative assessment of Zirconium-89 labeled cetuximab using PET/CT imaging in patients with advanced head and neck cancer: a theragnostic approach. <i>Oncotarget</i> , 2017, 8, 3870-3880.	0.8	48

#	ARTICLE	IF	CITATIONS
1138	Poly (ADP-ribose) polymerase inhibitor, an effective radiosensitizer in lung and pancreatic cancers. <i>Oncotarget</i> , 2017, 8, 26344-26355.	0.8	16
1139	Prognostic value of tumor mutations in radically treated locally advanced non-small cell lung cancer patients. <i>Oncotarget</i> , 2017, 8, 25189-25199.	0.8	12
1140	Individual isotoxic radiation dose escalation based on V20 and advanced technologies benefits unresectable stage III non-small cell lung cancer patients treated with concurrent chemoradiotherapy: long term follow-up. <i>Oncotarget</i> , 2017, 8, 51848-51858.	0.8	9
1141	Definitive radiochemotherapy <i>versus</i> surgery within multimodality treatment in stage III non-small cell lung cancer (NSCLC) - a cumulative meta-analysis of the randomized evidence. <i>Oncotarget</i> , 2017, 8, 41670-41678.	0.8	60
1142	Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced non-small cell lung cancer in Chinese population: A retrospective study. <i>Oncotarget</i> , 2017, 8, 49084-49092.	0.8	9
1143	Polymorphisms in BMP2/BMP4, with estimates of mean lung dose, predict radiation pneumonitis among patients receiving definitive radiotherapy for non-small cell lung cancer. <i>Oncotarget</i> , 2017, 8, 43080-43090.	0.8	9
1144	A retrospective study of shrinking field radiation therapy during chemoradiotherapy in stage III non-small cell lung cancer. <i>Oncotarget</i> , 2018, 9, 12443-12451.	0.8	5
1145	Practical and theoretical implications of weight gain in advanced non-small cell lung cancer patients. <i>Annals of Translational Medicine</i> , 2017, 5, 152-152.	0.7	6
1146	Clinical significance of pretreatment tumor growth rate for locally advanced non-small cell lung cancer. <i>Annals of Translational Medicine</i> , 2019, 7, 95-95.	0.7	4
1147	Implications of pneumonitis after chemoradiation and durvalumab for locally advanced non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2020, 12, 6690-6700.	0.6	25
1148	Smooth sailing for immunotherapy for unresectable stage III non-small cell lung cancer: the PACIFIC study. <i>Translational Cancer Research</i> , 2018, 7, S16-S20.	0.4	4
1149	A case report of exceptional clinical response to chemoradiotherapy and tyrosine kinase inhibitors in a patient with EML4-ALK fusion variant 1 non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2020, 9, 2500-2507.	1.3	3
1150	Plasma Metabolites and Risk of Radiation-induced Esophagitis: A Secondary Analysis from a Prospective Study. <i>Anticancer Research</i> , 2017, 37, 719-726.	0.5	2
1151	A Phase I Study of Hypofractionated Carbon-ion Radiotherapy for Stage III Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2018, 38, 885-891.	0.5	17
1152	Neoadjuvant Tyrosine Kinase Inhibition in Locally-advanced Non-small Cell Lung Cancer: Two Cases and a Brief Literature Review. <i>Anticancer Research</i> , 2019, 39, 897-902.	0.5	10
1153	Prognostic Factors in Stage III Non-Small-Cell Lung Cancer Patients. <i>Asian Pacific Journal of Cancer Prevention</i> , 2016, 17, 4693-4697.	0.5	18
1154	Image-guided adaptive radiotherapy in patients with locally advanced non-small cell lung cancer: the art of PET. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 62, 369-384.	0.4	6
1155	Long-term survival of locally advanced stage III non-small cell lung cancer patients treated with chemoradiotherapy and perspectives for the treatment with immunotherapy. <i>Radiology and Oncology</i> , 2018, 52, 281-288.	0.6	22

#	ARTICLE	IF	CITATIONS
1156	A current review of dose-escalated radiotherapy in locally advanced non-small cell lung cancer. <i>Radiology and Oncology</i> , 2019, 53, 6-14.	0.6	32
1157	Particle Beam Therapy. <i>Japanese Journal of Lung Cancer</i> , 2015, 55, 924-931.	0.0	1
1158	Perspectives on Treatment Advances for Stage III Locally Advanced Unresectable Non-Small-Cell Lung Cancer. <i>Current Oncology</i> , 2019, 26, 37-42.	0.9	56
1159	Multidisciplinary team approach for the management of patients with locally advanced non-small cell lung cancer: searching the evidence to guide the decision. <i>Radiation Oncology Journal</i> , 2017, 35, 16-24.	0.7	16
1160	Efficacy and safety of CT-guided 125I brachytherapy in elderly patients with non-small cell lung cancer. <i>Oncology Letters</i> , 2020, 20, 183-192.	0.8	3
1161	Novel radiotherapy approaches for lung cancer: combining radiation therapy with targeted and immunotherapies. <i>Translational Lung Cancer Research</i> , 2015, 4, 545-52.	1.3	70
1162	Dose escalation for unresectable locally advanced non-small cell lung cancer: end of the line?. <i>Translational Lung Cancer Research</i> , 2016, 5, 126-33.	1.3	10
1163	Continuous hyperfractionated accelerated radiotherapy using modern radiotherapy techniques for nonsmall cell lung cancer patients unsuitable for chemoradiation. <i>Indian Journal of Cancer</i> , 2017, 54, 120.	0.2	1
1164	Radical radiotherapy or chemoradiotherapy for inoperable, locally advanced, non-small cell lung cancer: Analysis of patient profile, treatment approaches, and outcomes for 213 patients at a tertiary cancer center. <i>Indian Journal of Cancer</i> , 2018, 55, 125.	0.2	6
1165	Induction chemotherapy for unresectable Stage III non-small-cell lung cancer may improve survival of induction chemotherapy responders as predicted by elevated levels of carcinoembryonic antigen and cytokeratin fragment 19 and classification as stage N3 cancer. <i>Journal of Cancer Research and Therapeutics</i> , 2020, 16, 222.	0.3	2
1166	Dose-Response Relationship between Radiation Dose and Loco-regional Control in Patients with Stage II-III Esophageal Cancer Treated with Definitive Chemoradiotherapy. <i>Cancer Research and Treatment</i> , 2017, 49, 669-677.	1.3	44
1167	EGFR Mutation Is Associated with Short Progression-Free Survival in Patients with Stage III Non-squamous Cell Lung Cancer Treated with Concurrent Chemoradiotherapy. <i>Cancer Research and Treatment</i> , 2019, 51, 493-501.	1.3	30
1168	Salvage Concurrent Chemo-radiation Therapy for Loco-regional Recurrence Following Curative Surgery of Non-small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2019, 51, 769-776.	1.3	9
1169	Deep diving in the PACIFIC: Practical issues in stage III non-small cell lung cancer to avoid shipwreck. <i>World Journal of Clinical Oncology</i> , 2020, 11, 898-917.	0.9	4
1170	GSH-responsive curcumin/doxorubicin encapsulated Bactrian camel serum albumin nanocomposites with synergistic effect against lung cancer cells. <i>Journal of Biomedical Research</i> , 2020, 34, 54.	0.7	10
1171	Review of the Terminology Describing Ionizing Radiation-Induced Skin Injury: A Case for Standardization. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 153303382110396.	0.8	6
1172	Moving Beyond the Standard of Care: Accelerate Testing of Radiation-Drug Combinations. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 1131-1139.	0.4	5
1173	Cancers bronchiques de stade III : r�le de lâ€™onco-radioth�rapeute. <i>Revue Des Maladies Respiratoires Actualites</i> , 2021, 13, 2S97-2S108.	0.0	0

#	ARTICLE	IF	CITATIONS
1174	Deep learning model for automatic contouring of cardiovascular substructures on radiotherapy planning CT images: Dosimetric validation and reader study based clinical acceptability testing. <i>Radiotherapy and Oncology</i> , 2021, 165, 52-59.	0.3	14
1175	Clinical and Preclinical Outcomes of Combining Targeted Therapy With Radiotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 749496.	1.3	13
1176	Prognostic impact of immune inflammation biomarkers in predicting survival and radiosensitivity in patients with non-small cell lung cancer treated with chemoradiotherapy. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2022, 66, 146-157.	0.9	7
1177	Low activity 125I implantation into VX2 tumor rabbits and quantitative evaluation of the precise therapeutic effect. <i>Experimental and Therapeutic Medicine</i> , 2021, 22, 1438.	0.8	0
1178	Modified VMAT Plans for Locally Advanced Centrally Located Non-Small Cell Lung Cancer (NSCLC). <i>Life</i> , 2021, 11, 1085.	1.1	1
1179	Clinically validated model predicts the effect of intratumoral heterogeneity on overall survival for non-small cell lung cancer (NSCLC) patients. <i>Computer Methods and Programs in Biomedicine</i> , 2021, 212, 106455.	2.6	4
1180	Learning healthcare systems and rapid learning in radiation oncology: Where are we and where are we going?. <i>Radiotherapy and Oncology</i> , 2021, 164, 183-195.	0.3	9
1181	Non-small cell lung cancer: Emerging molecular targeted and immunotherapeutic agents. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1876, 188636.	3.3	27
1182	Three-dimensional Conformal Radiotherapy and Dose-fractionation for Non-small-cell Lung Cancer. <i>Japanese Journal of Lung Cancer</i> , 2015, 55, 913-917.	0.0	1
1183	Treatment with Intensity-Modulated Radiation Therapy (IMRT) and Chemotherapy in Advanced Inoperable Non-Small Cell Lung Cancer (NSCLC): Toxicity, Survival and Patterns of Failure in Relation to Treatment with High and Low Radiation Dose. <i>Journal of Cancer Therapy</i> , 2015, 06, 943-953.	0.1	0
1184	<i>Thoracic Cancers.</i> , 2016, , 79-91.		0
1185	<i>Radiation-Induced Toxicities and Management Strategies in Thoracic Malignancies.</i> , 2016, , 483-505.		0
1186	è,ç™CEã«ã-3/4ã™ã,ç²'âç.šæ²»ç™,. <i>Japanese Journal of Lung Cancer</i> , 2016, 56, 948-951.	0.0	0
1187	<i>Adapting Therapy Based on Tumor Response.</i> , 2016, , 195-224.		0
1188	Definitive Upfront Stereotactic Ablative Radiotherapy Combined with Image-Guided, Intensity Modulated Radiotherapy (IG-IMRT) or IG-IMRT Alone for Locally Advanced Non-Small Cell Lung Cancer. <i>PLoS ONE</i> , 2016, 11, e0162453.	1.1	1
1189	History and Future of Multimodality Treatment for N2 NSCLC. <i>Japanese Journal of Lung Cancer</i> , 2017, 57, 167-174.	0.0	0
1190	Complete Resection Following Alectinib Administration for Stage IIIA-N2 ALK-translocated Non-small Cell Lung Cancer. <i>Japanese Journal of Lung Cancer</i> , 2017, 57, 752-757.	0.0	1
1191	<i>Locally Advanced Non-small Cell Lung Cancer and Targeted Therapy.</i> , 2017, , 155-165.		0

#	ARTICLE	IF	CITATIONS
1192	Proton radiotherapy for treating the most common carcinomas. <i>Nowotwory</i> , 2017, 66, 396-402.	0.1	0
1193	Multimodale und palliative Therapie des Lungenkarzinoms. , 2018, , 205-211.		0
1194	Radiation-Related Heart Disease: Up-to-Date Developments. , 0, , .		0
1195	Adaptive radiation therapy for lung cancer. <i>Imaging in Medical Diagnosis and Therapy</i> , 2017, , 351-368.	0.0	0
1196	Hybrid Arc Could Combine the Benefits of IMRT and VMAT to Deliver a Fast, Conformal, Homogeneous Treatment in Non-Small Cell Lung Cancer without Limitations of Low Dose Bath: A Planning Study. <i>UHOD - Uluslararası Hematoloji-Onkoloji Dergisi</i> , 2017, 27, 161-170.	0.1	1
1197	MRI-based IGRT for lung cancer. <i>Imaging in Medical Diagnosis and Therapy</i> , 2017, , 369-384.	0.0	0
1198	Lung Cancer in Older Adults: Local Treatment. , 2018, , 1-14.		0
1199	Proton therapy in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2018, 7, 103-105.	1.3	0
1200	How Histopathologic Tumor Extent and Patterns of Recurrence Data Inform the Development of Radiation Therapy Treatment Volumes in Solid Malignancies. <i>Seminars in Radiation Oncology</i> , 2018, 28, 218-237.	1.0	1
1201	Advances in radiation therapy for thoracic malignancies. <i>Journal of Thoracic Disease</i> , 2018, 10, S2431-S2436.	0.6	0
1202	Advances in radiotherapy for lung cancer. <i>Onkologie (Czech Republic)</i> , 2018, 12, 155-160.	0.0	2
1203	æ”³/4â° „ç-šæ²»ç™,ã®update. <i>Japanese Journal of Lung Cancer</i> , 2018, 58, 940-943.	0.0	0
1204	RESECTION OF TRACHEAL BIFURCATION IN TREATMENT OF NON-SMALL CELL LUNG CANCER (LITERATURE) Tj ETQg0,0 0 rgBJ /Overlock 0,1 5		
1205	Multimodality Therapy for Locally Advanced Non-Small Cell Lung Cancer and the Associated Problems. <i>Journal of the Nihon University Medical Association</i> , 2018, 77, 359-364.	0.0	0
1206	Non-small Cell Lung Cancer. , 2019, , 143-192.		0
1207	Radiation Therapy in Non-small-Cell Lung Cancer. , 2019, , 1-55.		0
1208	Landmark Trials in Lung Cancer. , 2019, , 41-74.		0
1209	Radiotherapy for lung cancer. , 2019, , 481-489.		0

#	ARTICLE	IF	CITATIONS
1210	Current Progress and a New Era in Chemoradiotherapy for Stage III NSCLC. Japanese Journal of Lung Cancer, 2019, 59, 117-122.	0.0	0
1211	Updates on Radiotherapy for Lung Cancer. Japanese Journal of Lung Cancer, 2019, 59, 1104-1106.	0.0	0
1212	Principles of Radiation Therapy. , 2020, , 199-220.		0
1213	Surgical Treatment for N2 Non-small Cell Lung Cancer. Japanese Journal of Lung Cancer, 2019, 59, 1129-1133.	0.0	0
1214	Oesophageal Cancer: Conformal Radiotherapy vs. Hybrid-VMAT Technique With Two Different Treatment Planning Systems. In Vivo, 2020, 34, 331-337.	0.6	1
1215	Literature Review of Clinical Usefulness of Heavy Ion Particle as an New Advanced Cancer Therapy. Bangsaseon Gisul Gwahak, 2019, 42, 413-422.	0.1	3
1217	Acute Esophageal Damage in Patients with Inoperable Non-small Cell Lung Cancer Treated with Concurrent and Sequential Chemoradiotherapy. Open Access Macedonian Journal of Medical Sciences, 2020, 8, 307-311.	0.1	0
1218	Torasik Ā-zofagus Karsinomunda 3D-CRT, IMRT, IMAT ve Helical Tomoterapinin Dozimetrik KarĀĀ±laĀĀ±rmasĀ±. SDU Journal of Science, 0, , 130-139.	0.1	0
1219	Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent lung cancer. Clinical and Translational Radiation Oncology, 2020, 22, 76-82.	0.9	10
1220	IMMUNOTERAPĀ° VE RADYOTERAPĀ° KOMBĀ°NASYONU. UludaĀĀ±niversitesi TĀ±p FakĀĀ±ltesi Dergisi, 0, , .	0.2	1
1221	Associations between cardiac irradiation and survival in patients with non-small cell lung cancer: Validation and new discoveries in an independent dataset. Radiotherapy and Oncology, 2021, 165, 119-125.	0.3	5
1222	Non-Small-Cell Lung Cancer Patients with a High Predicted Risk of Irradical Resection: Can Chemoradiotherapy Offer Similar Survival?. Annals of Surgical Oncology, 2022, 29, 1807-1814.	0.7	1
1224	Proposal for Establishing a New Radiotherapy Facility. , 2022, , 41-55.		0
1225	Retrospective Treatment Outcomes of Concurrent Chemoradiotherapy in Patients with Stage III Non-small Cell Lung Cancer at a Single Institution: The Pre-PACIFIC Era. Japanese Journal of Lung Cancer, 2021, 61, 383-388.	0.0	0
1226	Current and future strategies in radiotherapy for small-cell lung cancer. Journal of Clinical and Translational Research, 0, , .	0.3	3
1227	Elective Nodal Irradiation for Non-small Cell Lung Cancer Complicated With Chronic Obstructive Pulmonary Disease Affects Immunotherapy ĩfter Definitive Chemoradiotherapy. Anticancer Research, 2020, 40, 6957-6970.	0.5	7
1228	Bronchoplastic Procedure Versus Pneumonectomy After High-dose Radiation for Non-small Cell Lung Cancer. Annals of Thoracic Surgery, 2021, 112, 1832-1840.	0.7	5
1230	Toxicity Management for Thorax Tumors in Radiation Oncology. , 2020, , 107-169.		0

#	ARTICLE	IF	CITATIONS
1231	Current status and future directions in unresectable stage III non-small cell lung cancer. <i>Journal of Clinical and Translational Research</i> , 0, , .	0.3	3
1232	Lung Cancer in Older Adults: Local Treatment. , 2020, , 785-797.		0
1233	Targeting lung cancer using advanced drug delivery systems. , 2020, , 493-516.		4
1234	Translating Targeted Radiosensitizers into the Clinic. <i>Cancer Drug Discovery and Development</i> , 2020, , 17-33.	0.2	0
1235	Real-World Treatment Patterns of Lung Cancer in a Resource-Restricted Country: the Experience of Georgia. <i>Health Services Insights</i> , 2021, 14, 117863292110552.	0.6	0
1236	Results of a Multi-Institutional Phase 2 Clinical Trial for 4DCT-Ventilation Functional Avoidance Thoracic Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 986-995.	0.4	19
1237	Adding Base-Excision Repair Inhibitor TRC102 to Standard Pemetrexed+Platinum+Radiation in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer: Results of a Phase I Trial. <i>Clinical Cancer Research</i> , 2022, 28, 646-652.	3.2	3
1238	Analysis of Outcomes With Addition of Immunotherapy to Chemoradiation Therapy for Non-Small Cell Lung Cancer—Reply. <i>JAMA Oncology</i> , 2022, 8, 168.	3.4	2
1239	Preliminary tests of dosimetric quality and projected therapeutic outcomes of multi-phase 4D radiotherapy with proton and carbon ion beams. <i>Physics in Medicine and Biology</i> , 2021, 66, 235004.	1.6	3
1240	Treatment strategies for unresectable locally advanced non-small cell lung cancer in the real-life ESME cohort. <i>Lung Cancer</i> , 2021, 162, 119-127.	0.9	3
1241	Radiation Pneumonitis After Volumetric Modulated Arc Therapy for Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2021, 41, 5793-5802.	0.5	9
1242	Proton therapy needs further technological development to fulfill the promise of becoming a superior treatment modality (compared to photon therapy). <i>Journal of Applied Clinical Medical Physics</i> , 2021, 22, 4-11.	0.8	3
1243	Conservative treatment of stage III lung cancer using chemoradiotherapy in hypofractionation mode, case report. <i>Meditinskiy Sovet</i> , 2020, , 271-276.	0.1	0
1244	Approaches in patients with locally advanced NSCLC: a radiation oncologist's perspective. , 0, , 178-185.		0
1245	Long-term survival of locally advanced stage III non-small cell lung cancer patients treated with chemoradiotherapy and perspectives for the treatment with immunotherapy. <i>Radiology and Oncology</i> , 2018, .	0.6	0
1246	Immunotherapy for Lung Cancer—Improving Outcomes in Patients With Locally Advanced Non-Small Cell Lung Cancer With Immunotherapy. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 548-554.	1.0	2
1247	Radiotherapy for lung cancer: State of the art. <i>Japanese Journal of Lung Cancer</i> , 2020, 60, 902-905.	0.0	0
1248	(18)F-FDG avid volumes on pre-radiotherapy FDG PET as boost target delineation in non-small cell lung cancer. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 7561-8.	1.3	4

#	ARTICLE	IF	CITATIONS
1249	Proliferation PET image to characterize pathological spatial features in patients with non-small cell lung cancer: a pilot study. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 9758-64.	1.3	4
1250	Molecular targeted therapy to improve radiotherapeutic outcomes for non-small cell lung carcinoma. <i>Annals of Translational Medicine</i> , 2016, 4, 50.	0.7	8
1251	Immunotherapy in locally-advanced non-small cell lung cancer: releasing the brakes on consolidation?. <i>Translational Lung Cancer Research</i> , 2016, 5, 138-42.	1.3	14
1252	Phase I study of concurrent and consolidation cisplatin and docetaxel chemotherapy with thoracic radiotherapy in non-small cell lung cancer. <i>Current Oncology</i> , 2018, 25, 22-31.	0.9	0
1257	Association between IDO activity and prognosis in patients with non-small cell lung cancer after radiotherapy. <i>Annals of Translational Medicine</i> , 2020, 8, 1169.	0.7	2
1258	Current status and future directions in unresectable stage III non-small cell lung cancer. <i>Journal of Clinical and Translational Research</i> , 2020, 6, 109-120.	0.3	3
1259	Current and future strategies in radiotherapy for small-cell lung cancer. <i>Journal of Clinical and Translational Research</i> , 2020, 6, 97-108.	0.3	5
1260	Hypofractionation and Stereotactic Body Radiation Therapy in Inoperable Locally Advanced Non-small Cell Lung Cancer. <i>Journal of Clinical and Translational Research</i> , 2021, 7, 199-208.	0.3	1
1261	Advances in multimodal treatment for stage IIIA-N2 non-small cell lung cancer. <i>Journal of Clinical and Translational Research</i> , 2021, 7, 185-198.	0.3	1
1262	Radiotherapy Patterns of Care for Locally-advanced Non-small Cell Lung Cancer in the Pre- and Post-durvalumab Era: A Region-wide Survey in a Japanese Prefecture. <i>Journal of Radiation Research</i> , 2022, 63, 264-271.	0.8	3
1263	Proton Image-guided Radiation Assignment for Therapeutic Escalation via Selection of locally advanced head and neck cancer patients [PIRATES]: A Phase I safety and feasibility trial of MRI-guided adaptive particle radiotherapy. <i>Clinical and Translational Radiation Oncology</i> , 2022, 32, 35-40.	0.9	3
1264	Dosimetric Planning Tradeoffs to Reduce Heart Dose Using Machine Learning-Guided Decision Support Software in Patients with Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 996-1003.	0.4	4
1265	Exercise Enhanced Cardiac Function in Mice With Radiation-Induced Heart Disease via the FND5/Irisin-Dependent Mitochondrial Turnover Pathway. <i>Frontiers in Physiology</i> , 2021, 12, 739485.	1.3	7
1266	Deregulation of AKT-mTOR Signaling Contributes to Chemoradiation Resistance in Lung Squamous Cell Carcinoma. <i>Molecular Cancer Research</i> , 2022, 20, 425-433.	1.5	3
1267	Enhancing Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer Patients with iCE, a Novel System for Automated Multi-Criterial Treatment Planning Including Beam Angle Optimization. <i>Cancers</i> , 2021, 13, 5683.	1.7	8
1268	Malignant neoplasm of the bronchi and lung: Russian clinical guidelines. <i>Journal of Modern Oncology</i> , 2021, 23, 369-402.	0.1	5
1270	Outcomes of Image-Guided Moderately Hypofractionated Radiotherapy for Stage III Non-Small-Cell Lung Cancer. <i>Journal of Oncology</i> , 2021, 2021, 1-9.	0.6	4
1271	Prognostic value of early FDG PET response imaging and peripheral immunologic biomarkers: sub-study of a phase II trial of risk-adaptive chemoradiation for unresectable non-small cell lung cancer. <i>Advances in Radiation Oncology</i> , 2021, 7, 100857.	0.6	0

#	ARTICLE	IF	CITATIONS
1272	In Reply to Yavas et al.. International Journal of Radiation Oncology Biology Physics, 2021, 111, 1323.	0.4	0
1273	In Regard to de Groot et al.. International Journal of Radiation Oncology Biology Physics, 2021, 111, 1322.	0.4	1
1274	Current and Future Technologies of the CNAO Dose Delivery System. IEEE Instrumentation and Measurement Magazine, 2021, 24, 61-69.	1.2	1
1275	The impact of the radiotherapy technique in sparing the heart substructures in central tumor irradiation in lung cancer. Journal of Radiotherapy in Practice, 0, , 1-6.	0.2	0
1276	Targeting PARP for Chemoradiosensitization: Opportunities, Challenges, and the Road Ahead. International Journal of Radiation Oncology Biology Physics, 2022, 112, 265-270.	0.4	1
1277	Association between IDO activity and prognosis in patients with non-small cell lung cancer after radiotherapy. Annals of Translational Medicine, 2020, 8, 1169-1169.	0.7	6
1278	Radiation Time, Dose, and Fractionation in the Treatment of Lung Cancer. Medical Radiology, 2021, , .	0.0	0
1279	Combined Radiation Therapy and Chemotherapy as an Exclusive Treatment Option in Locally Advanced Inoperable Non-small Cell Lung Cancer. Medical Radiology, 2021, , .	0.0	1
1280	Risk factors for radiation pneumonitis after rotating gantry intensity-modulated radiation therapy for lung cancer. Scientific Reports, 2022, 12, 590.	1.6	8
1281	Dose-escalation by hypofractionated simultaneous integrated boost IMRT in unresectable stage III non-small-cell lung cancer. BMC Cancer, 2022, 22, 96.	1.1	2
1282	Differentiation between immune checkpoint inhibitor-related and radiation pneumonitis in lung cancer by CT radiomics and machine learning. Medical Physics, 2022, 49, 1547-1558.	1.6	28
1283	Improving Outcomes in NSCLC: Optimum Dose Fractionation in Radical Radiotherapy Matters. Journal of Thoracic Oncology, 2022, 17, 532-543.	0.5	16
1285	Radiomic Phenotypes for Improving Early Prediction of Survival in Stage III Non-Small Cell Lung Cancer Adenocarcinoma after Chemoradiation. Cancers, 2022, 14, 700.	1.7	7
1286	Phase I Study of Accelerated Hypofractionated Proton Therapy and Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2022, 113, 742-748.	0.4	8
1287	Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer. Radiation Oncology, 2022, 17, 7.	1.2	20
1288	Systemic and Radiation Therapy Approaches for Locally Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 2022, 40, 576-585.	0.8	20
1289	Radiation and Systemic Therapy for Limited-Stage Small-Cell Lung Cancer. Journal of Clinical Oncology, 2022, 40, 661-670.	0.8	38
1290	Survival benefits for non-small cell lung cancer patients treated with adaptive radiotherapy. Radiotherapy and Oncology, 2022, 168, 234-240.	0.3	10

#	ARTICLE	IF	CITATIONS
1291	Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 1301-1311.	0.8	445
1292	Postoperative radiotherapy for patients with completely resected stage III non-small cell lung cancer: in or out. <i>Thoracic Cancer</i> , 2022, 13, 659-663.	0.8	3
1293	Real-world Treatment Patterns and Outcomes in Stage III Non-small Cell Lung Cancer: Middle East and Africa – KINDLE Study. <i>Clinical Lung Cancer</i> , 2022, 23, 364-373.	1.1	3
1294	The role of thoracic radiotherapy dosing in the treatment of limited-stage small cell lung cancer: A study based on the National Cancer Database. <i>Advances in Radiation Oncology</i> , 2022, 7, 100907.	0.6	0
1295	PET/CT-based adaptive radiotherapy of locally advanced non-small cell lung cancer in multicenter yDEGRO ARO 2017-01 cohort study. <i>Radiation Oncology</i> , 2022, 17, 29.	1.2	3
1296	Stereotactic Body Radiotherapy and Systemic Dose Chemotherapy for Locally Advanced Lung Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2022, 45, 129-133.	0.6	7
1297	Paclitaxel Drug Delivery Systems: Focus on Nanocrystals™ Surface Modifications. <i>Polymers</i> , 2022, 14, 658.	2.0	23
1298	Radiotherapy for primary lung cancer. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2022, 26, 231-243.	0.6	8
1299	Increased cardiac uptake of (18F)-fluorodeoxyglucose incidentally detected on positron emission tomography after left breast irradiation: How to interpret?. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2022, 26, 724-729.	0.6	2
1300	Controversies in lung cancer: heterogeneity in treatment recommendations for stage III NSCLC according to disease burden and oncogenic driver alterations. <i>Clinical Lung Cancer</i> , 2022, , .	1.1	1
1301	Is Thoracic Radiotherapy an Absolute Contraindication for Treatment of Lung Cancer Patients With Interstitial Lung Disease? A Systematic Review. <i>Clinical Oncology</i> , 2022, 34, e493-e504.	0.6	8
1302	Long-Term Cardiac Damage Associated With Abdominal Irradiation in Mice. <i>Frontiers in Pharmacology</i> , 2022, 13, 850735.	1.6	2
1303	Prediction of cardiac events following concurrent chemoradiation therapy for non-small-cell lung cancer using FDG PET. <i>Annals of Nuclear Medicine</i> , 2022, 36, 439-449.	1.2	3
1304	Research Progress of Heavy Ion Radiotherapy for Non-Small-Cell Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2316.	1.8	3
1305	Tumor Coverage vs Healthy Tissue Sparing – What Is the Balance When Palliation Is the Goal?. <i>JAMA Oncology</i> , 2022, 8, 569.	3.4	1
1306	NVP-AUY922 alleviates radiation-induced lung injury via inhibition of autophagy-dependent ferroptosis. <i>Cell Death Discovery</i> , 2022, 8, 86.	2.0	15
1307	Multi-institutional feasibility study of intensity-modulated radiotherapy with chemotherapy for locally advanced non-small cell lung cancer. <i>International Journal of Clinical Oncology</i> , 2022, 27, 1025-1033.	1.0	2
1308	Final results of the IFCT-0803 study, a phase II study of cetuximab, pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non-squamous, non-small-cell lung cancer. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2022, 26, 670-677.	0.6	1

#	ARTICLE	IF	CITATIONS
1309	Quantitative analysis of dose-averaged linear energy transfer (LET d) robustness in pencil beam scanning proton lung plans. <i>Medical Physics</i> , 2022, , .	1.6	2
1310	The Impact of Radiation Dose to Heart Substructures on Major Coronary Events and Patient Survival after Chemoradiation Therapy for Esophageal Cancer. <i>Cancers</i> , 2022, 14, 1304.	1.7	17
1311	Chemoradiation with Hypofractionated Proton Therapy in Stage II-III Non-Small Cell Lung Cancer: A Proton Collaborative Group Phase 2 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 732-741.	0.4	5
1312	Lung cancer: progress with prognosis and the changing state of play. <i>Medical Journal of Australia</i> , 2022, 216, 334-336.	0.8	2
1313	Durvalumab Induces Sustained Survival Benefit After Concurrent Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 1271-1274.	0.8	8
1314	Is Hypofractionation a Good Idea in Radiotherapy for Locally Advanced NSCLC?. <i>Journal of Thoracic Oncology</i> , 2022, 17, 487-488.	0.5	0
1315	Deep learning driven predictive treatment planning for adaptive radiotherapy of lung cancer. <i>Radiotherapy and Oncology</i> , 2022, 169, 57-63.	0.3	4
1316	Durvalumab after chemoradiotherapy for locally advanced non-small cell lung cancer prolonged distant metastasis-free survival, progression-free survival and overall survival in clinical practice. <i>BMC Cancer</i> , 2022, 22, 364.	1.1	9
1317	Fast and Furious: New Data Examining Accelerated Radiation Therapy for Limited-Stage Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 1067-1070.	0.4	0
1318	Major adverse cardiac event risk prediction model incorporating baseline Cardiac disease, Hypertension, and Logarithmic Left anterior descending coronary artery radiation dose in lung cancer (CHyLL). <i>Radiotherapy and Oncology</i> , 2022, 169, 105-113.	0.3	9
1319	Higher Radiation Dose to the Immune Cells Correlates with Worse Tumor Control and Overall Survival in Patients with Stage III NSCLC: A Secondary Analysis of RTOG0617. <i>Cancers</i> , 2021, 13, 6193.	1.7	39
1320	Relationship between biodosimetric parameters and treatment volumes in three types of prostate radiotherapy. <i>Scientific Reports</i> , 2021, 11, 24406.	1.6	0
1321	Limited-Stage Small-Cell Lung Cancer: Current Progress and the Next Frontier. <i>Radiation</i> , 2021, 1, 317-333.	0.6	0
1322	Analysis of the planned, delivered dose distributions and quality assurance for helical tomotherapy and volumetric modulated arc therapy in locally advanced non-small cell lung cancer. <i>Reports of Practical Oncology and Radiotherapy</i> , 2021, 26, 939-947.	0.3	3
1323	Multicellular Effects of STAT3 in Non-small Cell Lung Cancer: Mechanistic Insights and Therapeutic Opportunities. <i>Cancers</i> , 2021, 13, 6228.	1.7	33
1324	Quantum deep reinforcement learning for clinical decision support in oncology: application to adaptive radiotherapy. <i>Scientific Reports</i> , 2021, 11, 23545.	1.6	13
1325	Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2022, 40, 1356-1384.	0.8	104
1326	Consolidation treatments after chemoradiotherapy in patients with locally advanced inoperable non-small cell lung cancer: a systematic review and network meta-analysis protocol. <i>BMJ Open</i> , 2022, 12, e060900.	0.8	0

#	ARTICLE	IF	CITATIONS
1327	Thorough design and pre-trial quality assurance (QA) decrease dosimetric impact of delineation and dose planning variability in the STRICTLUNG and STARLUNG trials for stereotactic body radiotherapy (SBRT) of central and ultra-central lung tumours. <i>Radiotherapy and Oncology</i> , 2022, 171, 53-61.	0.3	8
1328	SCOPE 2 at Still Answering the Unanswered Questions in Oesophageal Radiotherapy? SCOPE 2: a Randomised Phase II/III Trial to Study Radiotherapy Dose Escalation in Patients with Oesophageal Cancer Treated with Definitive Chemoradiation with an Embedded Phase II Trial for Patients with a Poor Early Response using Positron Emission Tomography/Computed Tomography. <i>Clinical Oncology</i> , 2022, 34, e269-e280.	0.6	9
1335	Open issues in the therapeutic management of unresectable stage III NSCLC in the immunotherapy era. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 174, 103684.	2.0	2
1336	Unmet needs in the management of unresectable stage III non-small cell lung cancer: a review after the "radio talk"™ webinars. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 549-559.	1.1	1
1337	Mutual enhancing learning-based automatic segmentation of CT cardiac substructure. <i>Physics in Medicine and Biology</i> , 2022, 67, 105008.	1.6	9
1345	Chemoradiotherapy for stage III non-small cell lung cancer: have we reached the limit?. <i>Chinese Clinical Oncology</i> , 2015, 4, 45.	0.4	6
1347	GOECP/SEOR radiotherapy guidelines for non-small-cell lung cancer. <i>World Journal of Clinical Oncology</i> , 2022, 13, 237-266.	0.9	6
1348	Development and Validation of a Radiomics Nomogram Using Computed Tomography for Differentiating Immune Checkpoint Inhibitor-Related Pneumonitis From Radiation Pneumonitis for Patients With Non-Small Cell Lung Cancer. <i>Frontiers in Immunology</i> , 2022, 13, 870842.	2.2	13
1349	The Diverse Analysis Identifies Mutated KRAS Associated With Radioresistance in Non-Small Cell Lung Cancer. <i>World Journal of Oncology</i> , 2022, 13, 84-95.	0.6	4
1350	Exposure of the heart in lung cancer radiation therapy: A systematic review of heart doses published during 2013 to 2020. <i>Radiotherapy and Oncology</i> , 2022, 172, 118-125.	0.3	12
1351	Chemoradiation followed by adjuvant durvalumab in stage III non-small cell lung cancer: Real-world comparison of treatment outcomes to historical controls treated with chemoradiation alone. <i>Thoracic Cancer</i> , 2022, 13, 1763-1771.	0.8	8
1352	Real-World Treatment Patterns and Clinical Outcomes in Patients With Stage III Non-Small-Cell Lung Cancer: Results of KINDLE-Vietnam Cohort. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	2
1354	Avoiding Toxicity With Lung Radiation Therapy: An IASLC Perspective. <i>Journal of Thoracic Oncology</i> , 2022, 17, 961-973.	0.5	9
1355	Radiation dose on oesophagus predicts OS in SCLC patients treated with chemoradiotherapy. , 0, , .		0
1357	Clinical outcomes and immune phenotypes associated with STK11 co-occurring mutations in non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2022, 14, 1772-1783.	0.6	6
1358	Voxel-Level BED Corrected Dosimetric and Radiobiological Assessment of 2 Kinds of Hybrid Radiotherapy Planning Methods for Stage III NSCLC. <i>Technology in Cancer Research and Treatment</i> , 2022, 21, 153303382211079.	0.8	0
1359	Radioresistance of Non-Small Cell Lung Cancers and Therapeutic Perspectives. <i>Cancers</i> , 2022, 14, 2829.	1.7	13
1360	Chemoradiation-induced pneumonitis in patients with unresectable stage III non-small cell lung cancer: A systematic literature review and meta-analysis. <i>Lung Cancer</i> , 2022, 174, 174-185.	0.9	9

#	ARTICLE	IF	CITATIONS
1361	Optimizing Lung Cancer Radiotherapy Treatments Using Personalized Dose-Response Curves. <i>Medical Radiology</i> , 2022, , .	0.0	0
1362	Patient-Reported Outcomes in Lung Cancer. <i>Medical Radiology</i> , 2022, , .	0.0	0
1363	Therapeutic Strategies for Resectable Stage-III A N2 Non-â€œSmall Cell Lung Cancer Patients: A Network Meta-Analysis. <i>Clinical Medicine Insights: Oncology</i> , 2022, 16, 117955492211094.	0.6	0
1365	A Review of Concurrent Chemo/Radiation, Immunotherapy, Radiation Planning, and Biomarkers for Locally Advanced Non-small Cell Lung Cancer and Their Role in the Development of ECOG-ACRIN EA5181. <i>Clinical Lung Cancer</i> , 2022, 23, 547-560.	1.1	2
1366	PET/CT for Target Delineation of Lung Cancer Before Radiation Therapy. <i>Seminars in Nuclear Medicine</i> , 2022, , .	2.5	3
1367	Durvalumab after Sequential High Dose Chemoradiotherapy versus Standard of Care (SoC) for Stage III NSCLC: A Bi-Centric Retrospective Comparison Focusing on Pulmonary Toxicity. <i>Cancers</i> , 2022, 14, 3226.	1.7	3
1368	Redefine the Role of Proton Beam Therapy for the Locally-Advanced Non-Small Cell Lung Cancer Assisting the Reduction of Acute Hematologic Toxicity. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
1369	Locally Advanced Non-Small Cell Lung Cancer: Clinical Outcome, Toxicity and Predictive Factors in Patients Treated with Hypofractionated Sequential or Exclusive Radiotherapy. <i>Current Oncology</i> , 2022, 29, 4893-4901.	0.9	0
1370	The Clinical Efficacy and Economic Benefits of Recombinant Human Thrombopoietin for the Treatment of Chemotherapy or Chemoradiotherapy-Induced Thrombocytopenia. <i>Contrast Media and Molecular Imaging</i> , 2022, 2022, 1-7.	0.4	3
1371	Effectiveness of durvalumab consolidation in stage III non-small-cell lung cancer: focus on treatment selection and prognostic factors. <i>Immunotherapy</i> , 2022, 14, 927-944.	1.0	7
1372	Circulating T Cell Activation and Exhaustion Markers Are Associated With Radiation Pneumonitis and Poor Survival in Non-Small-Cell Lung Cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
1373	Locally advanced NSCLC: a plea for sparing the ipsilateral normal lungâ€œ” prospective, clinical trial with DART-bid (dose-differentiated accelerated radiation therapy, 1.8AGy twice daily) by VMAT. <i>Radiation Oncology</i> , 2022, 17, .	1.2	2
1374	Isolated Nodal Recurrence After Definitive Stereotactic Ablative Radiation Therapy for Non-Small Cell Lung Cancer. <i>Practical Radiation Oncology</i> , 2023, 13, e35-e44.	1.1	1
1375	Cardiovascular Disease in Adult Cancer Survivors: a Review of Current Evidence, Strategies for Prevention and Management, and Future Directions for Cardio-oncology. <i>Current Oncology Reports</i> , 2022, 24, 1579-1592.	1.8	11
1376	Excessive esophageal toxicity in patients with locally advanced non-small cell lung cancer treated with concurrent hypofractionated chemoradiotherapy and 3-weekly platinum doublet chemotherapy. <i>Clinical and Translational Radiation Oncology</i> , 2022, 36, 70-76.	0.9	0
1377	Systemic Therapy and Radiation Therapy in Lung Cancer. , 2023, , 23-33.		0
1378	Erring Characteristics of Deformable Image Registration-Based Auto-Propagation for Internal Target Volume in Radiotherapy of Locally Advanced Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
1379	Effect of 3-Dimensional Interstitial High-Dose-Rate Brachytherapy With Regional Metastatic Lymph Node Intensity-Modulated Radiation Therapy in Locally Advanced Peripheral Non-Small Cell Lung Cancer: 5-Year Follow-up of a Phase 2 Clinical Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2023, 115, 347-355.	0.4	3

#	ARTICLE	IF	CITATIONS
1380	Impact of Blood Parameters and Normal Tissue Dose on Treatment Outcome in Esophageal Cancer Patients Undergoing Neoadjuvant Radiochemotherapy. <i>Cancers</i> , 2022, 14, 3504.	1.7	1
1381	Dosimetric comparison of different intensity-modulated radiotherapy techniques for whole-breast irradiation of right-breast cancer. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2022, , .	0.6	0
1382	Role of Real-World Data in Assessing Cardiac Toxicity After Lung Cancer Radiotherapy. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
1383	Therapeutic revolution for inoperable stage III non-small cell lung cancer in the immune era. <i>Cancer Biology and Medicine</i> , 2022, 19, 569-572.	1.4	1
1384	Measuring Indirect Radiation-Induced Perfusion Change in Fed Vasculature Using Dynamic Contrast CT. <i>Journal of Personalized Medicine</i> , 2022, 12, 1254.	1.1	6
1385	Dose-volume-based evaluation of convolutional neural network-based auto-segmentation of thoracic organs at risk. <i>Physics and Imaging in Radiation Oncology</i> , 2022, 23, 109-117.	1.2	6
1386	The efficacy and safety of Zengxiao Jiandu decoction combined with definitive concurrent chemoradiotherapy for unresectable locally advanced non-small cell lung cancer: a randomized, double-blind, placebo-controlled clinical trial. <i>Annals of Translational Medicine</i> , 2022, 10, 800-800.	0.7	3
1387	Gut Microbiome Is Associated With the Response to Chemoradiotherapy in Patients With Non-small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2023, 115, 407-418.	0.4	4
1388	Treatment patterns and prognosis of patients with inoperable stage III NSCLC after completion of concurrent chemoradiotherapy±immune checkpoint inhibition: a decade-long single-center historical analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	1
1389	Cardiopulmonary Toxicity Following Intensity-Modulated Proton Therapy (IMPT) Versus Intensity-Modulated Radiation Therapy (IMRT) for Stage III Non-Small Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2022, 23, e526-e535.	1.1	8
1390	Direct incorporation of patient-specific efficacy and toxicity estimates in radiation therapy plan optimization. <i>Medical Physics</i> , 0, , .	1.6	2
1391	Dynamic change of IDO1 activity predicts survival in patients with unresectable stage III NSCLC and chemoradiotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
1392	Personalized mid-course FDG-PET based adaptive treatment planning for non-small cell lung cancer using machine learning and optimization. <i>Physics in Medicine and Biology</i> , 0, , .	1.6	4
1393	Efficacy and safety of EGFR inhibitors and radiotherapy in locally advanced non-small-cell lung cancer: a meta-analysis. <i>Future Oncology</i> , 0, , .	1.1	1
1394	Analysis of prognosis and treatment decisions for patients with second primary lung cancer following esophageal cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
1395	Case Report: Resolution of radiation pneumonitis with androgens and growth hormone. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
1396	Primary site as a novel prognostic factor for cardiovascular mortality post-radiotherapy in limited-stage small cell lung cancer: A large population-based study. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	2
1397	Xenon-Enhanced Ventilation Computed Tomography for Functional Lung Avoidance Radiation Therapy in Patients With Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2023, 115, 356-365.	0.4	1

#	ARTICLE	IF	CITATIONS
1398	Clinical validation of deep learning algorithms for radiotherapy targeting of non-small-cell lung cancer: an observational study. <i>The Lancet Digital Health</i> , 2022, 4, e657-e666.	5.9	24
1399	If at First You Don't Succeedâ€”Stereotactic Body Radiation Therapy for Recurrent Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 114, 5-9.	0.4	0
1400	The efficacy profiles of concurrent chemoradiotherapy with intensity-modulated radiotherapy followed by durvalumab in patients with unresectable stage III nonâ€“small cell lung cancer: A multicenter retrospective cohort study. <i>Clinical and Translational Radiation Oncology</i> , 2022, 37, 57-63.	0.9	1
1401	Tailoring radiotherapies and nanotechnology for targeted treatment of solid tumors. <i>Coordination Chemistry Reviews</i> , 2022, 472, 214757.	9.5	14
1403	Heavy Particles in Non-small Cell Lung Cancer: Protons. <i>Medical Radiology</i> , 2022, , .	0.0	0
1404	Radiation Therapy-Induced Lung and Heart Toxicity. <i>Medical Radiology</i> , 2022, , .	0.0	0
1405	Combined Radiotherapy and Chemotherapy: Theoretical Considerations and Biological Premises. <i>Medical Radiology</i> , 2022, , .	0.0	1
1406	Target Volume Delineation in Non-small Cell Lung Cancer. <i>Medical Radiology</i> , 2022, , .	0.0	0
1407	Translational Research in Lung Cancer. <i>Medical Radiology</i> , 2022, , .	0.0	0
1408	Remote Symptom Monitoring of Patients With Cancer Undergoing Radiation Therapy. <i>Cureus</i> , 2022, , .	0.2	0
1409	Clinical target volume automatic segmentation based on lymph node stations for lung cancer with bulky lump lymph nodes. <i>Thoracic Cancer</i> , 2022, 13, 2897-2903.	0.8	5
1410	Anti-EGF nanobodies enhance the antitumoral effect of osimertinib and overcome resistance in non-small cell lung cancer (NSCLC) cellular models. , 2022, 39, .		3
1411	Cardiac Function Modifies the Impact of Heart Base Dose on Survival: A Voxel-Wise Analysis of Patients With Lung Cancer From the PET-Plan Trial. <i>Journal of Thoracic Oncology</i> , 2023, 18, 57-66.	0.5	14
1412	Four-Phase, Definitive Chemoradiation for a Real-World (Poor Risk and/or Elderly) Patient Population With Locally Advanced Non-small Cell Lung Cancer. <i>Cureus</i> , 2022, , .	0.2	0
1413	Prehabilitation and Rehabilitation for Patients with Lung Cancer: A Review of Where we are Today. <i>Clinical Oncology</i> , 2022, 34, 724-732.	0.6	7
1414	Realâ€“world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage <sc>III</sc> nonâ€“small cell lung cancer. <i>Thoracic Cancer</i> , 2022, 13, 3152-3161.	0.8	11
1415	Treatment-related pulmonary adverse events induced by chemoradiation and Durvalumab affect survival in locally advanced non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2022, 176, 149-156.	0.3	10
1416	The critical components for effective adaptive radiotherapy in patients with unresectable non-small-cell lung cancer: who, when and how. <i>Future Oncology</i> , 2022, 18, 3551-3562.	1.1	1

#	ARTICLE	IF	CITATIONS
1417	Bayesian methods provide a practical real-world evidence framework for evaluating the impact of changes in radiotherapy. <i>Radiotherapy and Oncology</i> , 2022, 176, 53-58.	0.3	0
1418	Dosimetric robustness of lung tumor photon radiotherapy evaluated from multiple event CT imaging. <i>Physica Medica</i> , 2022, 103, 1-10.	0.4	2
1419	Concurrent Chemoradiation Therapy for Soft Tissue Sarcoma. <i>Practical Guides in Radiation Oncology</i> , 2022, , 139-153.	0.0	1
1420	Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study. <i>Journal of Thoracic Oncology</i> , 2023, 18, 181-193.	0.5	66
1422	Feasibility of radical cardiac-sparing, treatment planning strategies for patients with locally advanced, non-small cell lung cancer. <i>Journal of Applied Clinical Medical Physics</i> , 0, , .	0.8	2
1424	On the feasibility of cardiac substructure sparing in magnetic resonance imaging guided stereotactic lung radiotherapy. <i>Medical Physics</i> , 0, , .	1.6	2
1425	Stereotactic Ablative RadioTherapy in NEWly Diagnosed and Recurrent Locally Advanced Non-Small Cell Lung Cancer Patients Unfit for Concurrent RAdio-Chemotherapy: Early Analysis of the START-NEW-ERA Non-Randomised Phase II Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2023, 115, 886-896.	0.4	5
1426	Consolidation Systemic Therapy in Locally Advanced, Inoperable Nonsmall Cell Lung Cancer—How to Identify Patients Which Can Benefit from It?. <i>Current Oncology</i> , 2022, 29, 8316-8329.	0.9	1
1427	Heart dose and cardiac comorbidities influence death with a cardiac cause following hypofractionated radiotherapy for lung cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
1428	Dose-Response Analysis Describes Particularly Rapid Repopulation of Non-Small Cell Lung Cancer during Concurrent Chemoradiotherapy. <i>Cancers</i> , 2022, 14, 4869.	1.7	0
1429	Integrating Novel Cancer Therapies with Radiation — Illuminating the Tunnel. <i>Clinical Oncology</i> , 2022, , .	0.6	0
1430	The treatment in patients with unresectable locally advanced non-small cell lung cancer: Explorations on hot issues. <i>Cancer Letters</i> , 2022, 551, 215947.	3.2	1
1431	Dose escalation in the treatment of NSCLC with proton radiotherapy. <i>Onkologie (Czech Republic)</i> , 2022, 16, 246-249.	0.0	0
1432	Research landscape and trends of lung cancer radiotherapy: A bibliometric analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
1433	Case 35-2022: A 60-Year-Old Man with Progressive Dyspnea, Neck Swelling, and a Lung Mass. <i>New England Journal of Medicine</i> , 2022, 387, 1889-1896.	13.9	1
1434	Radiosensitization-Related Cuproptosis LncRNA Signature in Non-Small Cell Lung Cancer. <i>Genes</i> , 2022, 13, 2080.	1.0	6
1435	Stereotactic Radiotherapy in the Management of Ventricular Tachycardias. <i>Cardiac Electrophysiology Clinics</i> , 2022, 14, 779-792.	0.7	0
1436	Intensity-Modulated Radiation Therapy and Volumetric Modulated Arc Therapy for Lung Cancer. <i>Medical Radiology</i> , 2022, , .	0.0	0

#	ARTICLE	IF	CITATIONS
1437	The Interaction of Preexisting Cardiac Dysfunction and Heart Dose From Radical Radiotherapy on All-Cause Mortality in Locally Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2023, 18, 14-16.	0.5	1
1438	Association between radiotherapy protocol variations and outcome in the CONVERT trial. <i>Clinical and Translational Radiation Oncology</i> , 2023, 39, 100560.	0.9	0
1439	High-Risk Non-Small Cell Lung Cancer Treated With Active Scanning Proton Beam Radiation Therapy and Immunotherapy. <i>Advances in Radiation Oncology</i> , 2023, 8, 101125.	0.6	3
1440	Contralateral esophageal sparing technique in definitive radiotherapy for non-small cell lung cancer: dosimetric parameters and normal tissue complication probability modeling. <i>Reports of Practical Oncology and Radiotherapy</i> , 2022, 27, 933-942.	0.3	1
1441	Left Anterior Descending Coronary Artery Radiation Dose Association With All-Cause Mortality in NRG Oncology Trial RTOG 0617. <i>International Journal of Radiation Oncology Biology Physics</i> , 2023, 115, 1138-1143.	0.4	8
1442	Impact of Systemic Autoimmune Diseases on Treatment Outcomes and Radiation Toxicities in Patients with Stage I Non-Small Cell Lung Cancer Receiving Stereotactic Body Radiation Therapy: A Matched Case-Control Analysis. <i>Cancers</i> , 2022, 14, 5915.	1.7	0
1443	Characterizing Pulmonary Function Test Changes for Patients With Lung Cancer Treated on a 2-Institution, 4-Dimensional Computed Tomography-Ventilation Functional Avoidance Prospective Clinical Trial. <i>Advances in Radiation Oncology</i> , 2023, 8, 101133.	0.6	4
1444	Malignant neoplasm of the bronchi and lung: Russian clinical guidelines. <i>Journal of Modern Oncology</i> , 2022, 24, 269-304.	0.1	2
1445	The Multidisciplinary Approach in Stage III Non-Small Cell Lung Cancer over Ten Years: From Radiation Therapy Optimisation to Innovative Systemic Treatments. <i>Cancers</i> , 2022, 14, 5700.	1.7	6
1446	Four-Dimensional Computed Tomography Ventilation Image-Guided Lung Functional Avoidance Radiation Therapy: A Single-Arm Prospective Pilot Clinical Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2023, 115, 1144-1154.	0.4	2
1447	Enhanced cardiac substructure sparing through knowledge-based treatment planning for non-small cell lung cancer radiotherapy. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
1448	Presurgical radiation and chemotherapy in preparation for thoracic tumor resection. <i>Current Opinion in Anaesthesiology</i> , 2023, 36, 74-82.	0.9	0
1449	Radiotherapie von Lungenkarzinomen: L"angere A"oerberlebenszeit "cave kardiale Toxizit"at. , 0, , .		0
1450	Experimental Validation of a Real-Time Adaptive 4D-Optimized Particle Radiotherapy Approach to Treat Irregularly Moving Tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2023, 115, 1257-1268.	0.4	2
1451	Cardiac Morbidity Following Chemoradiation in Stage III Non-small Cell Lung Cancer Patients: A Population-Based Cohort Study. <i>Clinical Oncology</i> , 2023, 35, e182-e188.	0.6	2
1452	Myocardial Contractility Pattern Characterization in Radiation-Induced Cardiotoxicity Using Magnetic Resonance Imaging: A Pilot Study with ContractiX. <i>Tomography</i> , 2023, 9, 36-49.	0.8	1
1453	Association of cardiac calcium burden with overall survival after radiotherapy for non-small cell lung cancer. <i>Physics and Imaging in Radiation Oncology</i> , 2023, 25, 100410.	1.2	0
1454	Machine-learning-based prediction of the effectiveness of the delivered dose by exhale-gated radiotherapy for locally advanced lung cancer: The additional value of geometric over dosimetric parameters alone. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3

#	ARTICLE	IF	CITATIONS
1456	Induction Immune Checkpoint Inhibitors and Chemotherapy Before Definitive Chemoradiation Therapy for Patients With Bulky Unresectable Stage III Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2023, 116, 590-600.	0.4	10
1457	Definitive intensity modulated proton re-irradiation for lung cancer in the immunotherapy era. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
1458	High-Dose Once-Daily Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: CALGB 30610 (Alliance)/RTOG 0538. <i>Journal of Clinical Oncology</i> , 2023, 41, 2394-2402.	0.8	16
1459	High-risk patients with locally advanced non-small cell lung cancer treated with stereotactic body radiation therapy to the peripheral primary combined with conventionally fractionated volumetric arc therapy to the mediastinal lymph nodes. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
1460	Dose Limiting Pulmonary Toxicity in a Phase I/II Study of Radiation and Chemotherapy with Ipilimumab followed by Nivolumab for Patients with Stage III Unresectable Non-small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2023, , .	0.4	3
1461	Death without progression as an endpoint to describe cardiac radiation effects in locally advanced non-small cell lung cancer. <i>Clinical and Translational Radiation Oncology</i> , 2023, 39, 100581.	0.9	1
1462	Poly-Lactide-Co-Glycolide-Polyethylene Glycol-Ginsenoside Rg3-Ag Exerts a Radio-Sensitization Effect in Non-Small Cell Lung Cancer. <i>Journal of Biomedical Nanotechnology</i> , 2022, 18, 2001-2009.	0.5	2
1463	Clinical significance of mean corpuscular volume as a prognostic indicator of radiotherapy for locally advanced lung cancer: a retrospective cohort study. <i>Journal of Thoracic Disease</i> , 2022, 14, 4916-4924.	0.6	1
1464	Preoperative immunochemotherapy for locally advanced non-small cell lung cancer: an analysis of the clinical outcomes, optimal number of cycles, and peripheral immune markers. <i>Translational Lung Cancer Research</i> , 2022, 11, 2364-2381.	1.3	5
1465	Tumor regression during radiotherapy as a predictor of response in locally advanced nonsmall cell carcinoma. <i>Journal of Cancer Research and Therapeutics</i> , 2022, 18, 964.	0.3	0
1466	Cardiotoxicity of Anti-Cancer Radiation Therapy: a Focus on Heart Failure. <i>Current Heart Failure Reports</i> , 2023, 20, 44-55.	1.3	1
1467	Segmentectomy preserves better immune-nutritional status than lobectomy in patients with early-stage lung cancer. <i>European Journal of Cardio-thoracic Surgery</i> , 2023, 63, .	0.6	4
1468	Comparison of Recurrence Patterns between Adenocarcinoma and Squamous Cell Carcinoma after Stereotactic Body Radiotherapy for Early-Stage Lung Cancer. <i>Cancers</i> , 2023, 15, 887.	1.7	4
1469	Dosimetric benefits of adaptive radiation therapy for patients with stage III non-small cell lung cancer. <i>Radiation Oncology</i> , 2023, 18, .	1.2	2
1470	¹⁸ F-FDG-PET guided vs whole tumour radiotherapy dose escalation in patients with locally advanced non-small cell lung cancer (PET-Boost): Results from a randomised clinical trial. <i>Radiotherapy and Oncology</i> , 2023, 181, 109492.	0.3	10
1471	Metrics of dose to highly ventilated lung are predictive of radiation-induced pneumonitis in lung cancer patients. <i>Radiotherapy and Oncology</i> , 2023, 182, 109553.	0.3	2
1472	Computed tomography and radiation dose images-based deep-learning model for predicting radiation pneumonitis in lung cancer patients after radiation therapy. <i>Radiotherapy and Oncology</i> , 2023, 182, 109581.	0.3	1
1473	Multi-omics to predict acute radiation esophagitis in patients with lung cancer treated with intensity-modulated radiation therapy. <i>European Journal of Medical Research</i> , 2023, 28, .	0.9	10

#	ARTICLE	IF	CITATIONS
1474	Higher Lung and Heart Doses Decrease Early and Long-Term Survival, Respectively, in Patients With Non-Small Cell Lung Cancer Undergoing Postoperative Radiation. <i>Advances in Radiation Oncology</i> , 2023, 8, 101213.	0.6	1
1475	Dosimetric effects of the custom dose iteration times on stereotactic radiotherapy for lung cancer. <i>Radiation Physics and Chemistry</i> , 2023, 208, 110882.	1.4	0
1476	An Integrated Physical Optimization Framework for Proton Stereotactic Body Radiation Therapy FLASH Treatment Planning Allows Dose, Dose Rate, and Linear Energy Transfer Optimization Using Patient-Specific Ridge Filters. <i>International Journal of Radiation Oncology Biology Physics</i> , 2023, 116, 949-959.	0.4	13
1477	Demystifying the Results of RTOG 0617: Identification of Dose Sensitive Cardiac Subregions Associated With Overall Survival. <i>Journal of Thoracic Oncology</i> , 2023, 18, 599-607.	0.5	14
1478	A narrative review of genetic biomarkers in non-small cell lung cancer: an update and future perspectives. <i>AME Medical Journal</i> , 0, 8, 6-6.	0.4	1
1479	Immunotherapy progress and clinical strategy of unresectable locally advanced non-small cell lung cancer. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	2
1480	Feasibility of omitting the clinical target volume under PET-CT guidance in unresectable stage III non-small-cell lung cancer: A phase II clinical trial. <i>Radiotherapy and Oncology</i> , 2023, 181, 109505.	0.3	2
1481	Beta Blockers with Statins May Decrease All-Cause Mortality in Patients with Cardiovascular Diseases and Locally Advanced Unresectable Non-Small-Cell Lung Cancer after Chemoradiotherapy. <i>Cancers</i> , 2023, 15, 1277.	1.7	3
1482	Cardiovascular Toxicity and Risk Mitigation with Lung Cancer Treatment. <i>Current Oncology Reports</i> , 2023, 25, 433-444.	1.8	4
1483	Waiting for Big Changes in Limited-Stage Small-Cell Lung Cancer: For Now, More of the Same. <i>Journal of Clinical Oncology</i> , 2023, 41, 2326-2330.	0.8	1
1484	Inhalable Biomaterialized Liposomes for Cyclic Ca ²⁺ -Burst-Centered Endoplasmic Reticulum Stress Enhanced Lung Cancer Ferroptosis Therapy. <i>ACS Nano</i> , 2023, 17, 5486-5502.	7.3	24
1485	Stage III Non-Small-Cell Lung Cancer: An Overview of Treatment Options. <i>Current Oncology</i> , 2023, 30, 3160-3175.	0.9	8
1488	Safety and efficacy of radiotherapy/chemoradiotherapy combined with immune checkpoint inhibitors for non-small cell lung cancer: A systematic review and meta-analysis. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	3
1489	Non-Small Cell Lung Cancer Treatment with Molecularly Targeted Therapy and Concurrent Radiotherapy—A Review. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5858.	1.8	4
1490	Advances in Surgical Techniques for Lung Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2023, , .	0.9	1
1491	Factorial design. , 2023, , 315-320.		0
1492	Differences in radiation-induced heart dysfunction in male versus female rats. <i>International Journal of Radiation Biology</i> , 2023, 99, 1096-1108.	1.0	3
1493	Chemo-Radio-Immunotherapy for NSCLC III: ESR/ATS Thresholds for DLCO Correlate with Radiation Dosimetry and Pneumonitis Rate. <i>Cancers</i> , 2023, 15, 1966.	1.7	0

#	ARTICLE	IF	CITATIONS
1494	Biology-Guided Radiation Therapy. <i>Surgical Oncology Clinics of North America</i> , 2023, 32, 553-568.	0.6	1
1495	Utilization and Factors Precluding Receipt of Checkpoint Inhibitor Consolidation for Stage III NSCLC in a Large US Academic Health System. <i>Clinical Lung Cancer</i> , 2023, 24, 474-482.	1.1	3
1496	Cardiovascular Substructure Dose and Cardiac Events following Proton- and Photon-Based Chemoradiotherapy for Non-Small Cell Lung Cancer. <i>Advances in Radiation Oncology</i> , 2023, 8, 101235.	0.6	0
1497	Study of radiation-induced pneumonitis after arc and static irradiation in lungs of rats. <i>Sibirskij Å¾urnal Kliničeskoj I Å¾sperimental'noj Mediciny</i> , 2023, 38, 118-125.	0.1	0
1498	Radiation Therapy-Related Toxicity: Esophagus. <i>Medical Radiology</i> , 2023, , .	0.0	0
1499	Respiration-controlled radiotherapy in lung cancer: Systematic evaluation of the optimal application practice. <i>Clinical and Translational Radiation Oncology</i> , 2023, 40, 100628.	0.9	1
1544	Treatment planning and doses analysis in the case of stage IIIB Non-Small Cell Lung Cancer (NSCLC). <i>AIP Conference Proceedings</i> , 2023, , .	0.3	0
1545	Evaluation of radiotherapy planning based on the value of target doses on tissues in the treatment of lung cancer stage II using 3D Slicer-SliceRT. <i>AIP Conference Proceedings</i> , 2023, , .	0.3	0
1557	Radiation Therapy for Lung Tumors. , 2023, , 1-21.		0
1558	Early-Stage Lung Cancer in the Era of Precision Oncology: From Immunotherapy to Targeted Therapy. , 2023, , 1-17.		0
1561	Dynamic treatment regimens and biomarker-driven strategies: Bridging the two worlds. , 2024, , 283-292.		0
1568	Locally advanced non-â€“small cell lung cancer. , 2024, , 155-174.		0
1570	Treatment of Stage III Non-small Cell Lung Cancer. <i>Respiratory Medicine</i> , 2023, , 147-163.	0.1	0
1581	Creation, evolution, and future challenges of ion beam therapy from a medical physicistâ€™s viewpoint (Part 3): Chapter 3. Clinical research, Chapter 4. Future challenges, Chapter 5. Discussion, and Conclusion. <i>Radiological Physics and Technology</i> , 2023, 16, 443-470.	1.0	0